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Abstract 
HIV-1 Nef is a key pathogenic protein, allowing HIV-1 to evade the host immune 
system by downregulating MHC-I and CD4. Furthermore, it was recently discovered 
that Nef counteracts the host factor SERINC5 to increase HIV-1 infectivity, but the 
mechanistic details of the Nef:SERINC5 interaction still need to be explored. 
Throughout this dissertation, I will explore the hypothesis that the genetic diversity 
that defines HIV-1 has a pronounced effect on the HIV-1 protein Nef, altering its 
function between and within group M subtypes. To address this hypothesis I 
investigated how MHC-I and CD4 downregulation differ among all non-recombinant 
group M subtypes. These studies revealed subtype-specific differences in Nef 
function that were associated with differences in Nef expression between subtypes. 
Further investigation revealed unique subcellular distribution of Nef within the rarely 
studied subtypes G and H. A low expressing Nef isolate of the globally predominant 
subtype C was then analyzed using mutational and stability studies, identifying a 
previously undefined region in an alpha helix of Nef that is essential for protein 
expression and function. Moreover, the molecular details of the recently defined Nef-
mediated SERINC5 downregulation are elucidated. The microscopy technique of 
bimolecular fluorescence complementation was used to demonstrate an in 
cellulo Nef:SERINC5 interaction, implicating key Nef protein interaction motifs. The 
Nef:SERINC5 complex was then mapped throughout the cell, highlighting the ability 
of Nef to hijack protein trafficking machinery, shuttling SERINC5 to degradative 
compartments to favour HIV-1 replication. Mutational analysis of SERINC5 shed 
light on the genetic determinants of the anti-infectivity of this poorly understood HIV-
1 restriction factor. From there, these findings were placed in the context of the HIV-
1 epidemic, investigating the conservation and variation in SERINC5 downregulation 
among Nef isolates from subtype C and A endemic regions. 
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Chapter 1  
1 Introduction 
1.1 Viruses; masters of adaptation 
Across all domains of life, there are countless examples of life forms that are 
exquisitely adapted to their environment, thriving in niches upon their emergence. 
Indeed, the ability to adapt is often included in the definition of life itself (1). 
However, some of the most remarkable examples of adaptation come from 
viruses, that segment of biology that is often left out of the conversation of life (2). 
While there is no universal definition of life, viruses meet many of the commonly 
cited requirements for something to be considered living (3). Namely, they are 
able to utilize energy to adapt and respond to stimuli in their environment. 
However, viruses lack a cellular architecture and depend on other forms of life to 
replicate their genetic material (2, 4). This dependence on cellular life 
necessitates that viruses be able to rapidly adapt to new environments.  
The functional capability of viruses varies dramatically, but a defining feature of 
all viruses is their inability to generate energy or produce proteins on their own, 
preventing their replication outside of cellular hosts (5, 6). The largest known 
viruses encode more proteins than some bacteria and are even able to repair 
DNA damage (7-9). Some of the smallest known viruses encode only four 
proteins, just enough to replicate their RNA genomes and form a capsid (10). 
The functional limitations of these small viruses are due to their restricted 
  
2 
genomes, which are free of much of the redundancy that usually protects cellular 
life.  
Bacteria, archaea, and eukarya all require genetic mutations to adapt to 
changing environments, but their complicated genomic architecture is vulnerable 
to high mutation rates (11-13). Disruption of the structure or function of key 
metabolic proteins can prove fatal, which has led to the evolution of high fidelity 
DNA repair mechanisms and duplication or convergent evolution of proteins 
serving similar functions (14, 15). Viruses hijack these highly conserved 
metabolic pathways, pairing them with their genetic plasticity to rapidly evolve 
and establish themselves across the three domains of life. 
Although viruses are not included in the classical three domains of life, the 
importance of these obligate intracellular symbionts cannot be understated. 
Viruses are ubiquitous in nature (16) and when their symbiotic relationship is 
parasitic, infected species evolve to control or eliminate the virus from the 
population (17, 18). Furthermore, the ability of viruses to move within and 
between species provides a form of gene transfer as viral particles incorporate 
genetic material from their hosts and carry it within virions to new hosts (19, 20). 
This allows viruses to act as both an impetus for, and mechanism of natural 
selection. 
1.2 Retroviruses and their influence on human life 
The ubiquity of viruses is exemplified by estimates that up to 8% of the human 
genome is composed of viral remnants, genome fragments from viruses that had 
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infected and integrated into germline cells of distant human ancestors (21, 22). 
These fragments are termed human endogenous retroviruses (HERVs) and the 
vast majority have been mutated extensively since their chromosomal 
integration, losing the ability to produce functional proteins (23, 24). However, 
certain endogenous retrovirus (ERV) sequences are highly conserved over the 
millions of years since they first integrated into ancient primate chromosomes 
and may still encode functional proteins (25-27). Syncytin is an example of a 
protein derived from a retrovirus that infected ancient primate germline cells. 
Specifically, syncytin is a viral envelope surface protein that enabled these 
retroviruses to attach and infect permissive host cells (27). Interestingly, cells 
expressing syncytin from HERV gene remnants in humans and other mammalian 
species have acquired the ability to attach to and fuse with cells that express the 
cognate syncytin receptor (27-29). This observation suggests that these proteins, 
introduced into the human genome by viral infection of ancient primate germline 
cells millions of years ago, have retained their function. Furthermore, it is 
hypothesized that this acquired function plays a fundamental role in placentation 
in mammals (27). Indeed, syncytin expression in trophoblasts during fetal 
development allows for cell-to-cell fusion that is essential for proper development 
of the maternal-fetal interface in utero (27-29). If this hypothesis is correct, it is 
yet another example of the complicated and serendipitous methods by which 
evolution produces novel phenotypes and underscores the role viruses have 
played in shaping human biology.  
  
4 
1.3 Human Immunodeficiency Virus type-1  
Prior to their integration into ancient primate genomes, the HERVs responsible 
for syncytin protein production were freely circulating retroviruses, closely related 
to present gammaretroviruses from the Retroviridae family (24, 30).  These 
viruses are referred to as retroviruses because following infection they generate 
a DNA copy of their RNA genome using an enzyme known as reverse 
transcriptase, thereby reversing the linear “DNA to RNA dogma” long held in 
molecular biology. The independent discovery of reverse transcriptase in the 
1970s by David Baltimore and Howard Temin expanded our understanding of 
how genetic information could be transmitted (31, 32). The research that led to 
these discoveries was conducted with Rous sarcoma virus, a retrovirus that 
causes cancer in chickens; however, retroviruses have also had a dramatic 
impact on humans, revealing once again our vulnerability as a species.  
The identification of human immunodeficiency virus (HIV) in 1983 began what 
has been a long and painful struggle, with close to 40 million deaths globally 
since its discovery and countless more prior (33-35). HIV is an enveloped, single-
stranded positive-sense RNA virus in the genus Lentiviridae and the Retroviridae 
family (36). The HIV RNA genome is just over 9.7 kb and encodes 15 proteins 
flanked by two long terminal repeats (LTR). Nine of these proteins are derived 
from the 3 polyproteins encoded by the gag, pol and env genes, and the 
remaining six proteins, Vif, Vpu, Vpr, Rev, Tat and Nef, are encoded by individual 
genes (Figure 1.1). We now know that there are two types of HIV, HIV type 1 
(HIV-1) and type 2 (HIV-2), which originated from zoonotic transmissions from 
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distinct primate species in central Africa (37). It has been reported that HIV-1 
began as a zoonotic transmission from chimpanzees (Pan troglodytes) (38, 39) 
or gorillas (Gorilla gorilla) (40) infected with simian immunodeficiency virus (SIV) 
in central Africa, whereas HIV-2 was due to zoonotic transmission from sooty 
mangabeys (Cercocebus atys) (41, 42). Despite similar origins, HIV-1 and HIV-2 
vary greatly in prevalence and pathogenesis. HIV-1 has infected tens of millions 
more humans than HIV-2 and results in an accelerated pathogenesis compared 
to HIV-2 (35, 43, 44). As a result, the vast majority of HIV biomedical research 
has focused on HIV-1.  
  
6 
Figure 1.1 Genomic Structure of Human Immunodeficiency Virus type 1 
(HIV-1).  
(A) HIV-1 is an enveloped, single-stranded positive-sense RNA virus from the 
genus Lentivirdae and family Retroviridae. (B) The RNA genome is 
approximately 9.7 kb and encodes 15 proteins on 3 reading frames flanked by 5’ 
and 3’ long terminal repeats (LTR). The genes gag, pol and env encode 
polyproteins that are post-translationally cleaved and responsible for the 
structural (gag and env) and enzymatic (pol) functions of HIV-1. HIV-1 also 
encodes a set of accessory proteins (green; Vif, Vpr, Tat, Rev, Vpu and Nef) that 
are required for optimal in vivo replication. (C) The HIV-1 accessory protein Nef 
is encoded by an open reading frame at the 3’ end of the HIV-1 RNA genome. 
Nef is a small (~27 kDa) non-enzymatic and non-structural protein that is 
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expressed early in HIV-1 infection and packaged in HIV-1 virions. The N-
terminus of Nef is co-translationally modified through the attachment of a 
myristoyl lipid moiety (light blue).   
Although discovered in 1983, HIV-1 is believed to have been circulating in human 
populations on the African continent since the early 1900s (45, 46). However, it 
was not until the second half of the century that HIV-1 reached the pandemic 
proportions we now experience (47-49). We may never get a completely 
accurate picture on the natural history of the virus, but multiple factors are 
thought to have promoted the spread of HIV-1 within and out of central Africa. 
These include the socio-political state of the world during the emergence of HIV-
1 (50) and specific virus characteristics and functions (51). As with many human 
pathologies, the extent of the spread and control of HIV-1 has been greatly 
influenced by human behaviour. The pandemic nature of HIV-1, and most other 
infectious diseases, is only possible in the current interconnected world enabled 
by intra- and intercontinental travel, which has drastically modified the global 
transmission patterns of many viruses (52-54). Furthermore, when one looks at 
the epidemiology of HIV-1 in the 21st century, it is impossible to ignore the fact 
that the populations most heavily affected by HIV-1 are marginalized, 
impoverished and underserved (35). Years of colonialism and resource 
extraction left central Africa with a fractured society unable to adequately monitor 
and respond to an emerging epidemic (55-57). Moreover, the stigmatization of 
homosexuality delayed and diminished the initial response to HIV-1 once the 
virus reached high-income nations. Indeed, when the clinical manifestations of 
HIV-1 infection were first seen in the United States, patients were diagnosed with 
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gay related immune deficiency (GRID) as many erroneously believed the 
infection was restricted to men having sex with men (MSM) (58). Furthermore, 
generations of institutionalized racism have left populations across the world 
more susceptible to infection and less likely to receive effective antiretroviral 
treatment. Accordingly, HIV-1 rates in the African American and indigenous 
populations in the United States and Canada, respectively, are among the 
highest (59-62) in those countries. Finally, stigma towards those affected by 
addiction currently risks our ability to control new outbreaks as people who inject 
drugs currently represent the populations with the greatest increase in incidence 
rates (35, 62). Thus, as its name suggests, HIV-1 is very much a human disease, 
unquestionably shaped by our anthropology and precisely adapted to our 
biology.  
The devastating impact HIV-1 has had on the human species is due to the ability 
of the virus to deplete certain aspects of the immune system. As an obligate 
intracellular parasite, HIV-1 must find a way into its target cells. The primary 
receptor that HIV-1 uses to infect cells is the cell surface protein cluster of 
differentiation 4 (CD4) (63, 64). CD4 is a marker for a subset of immune cells, 
CD4+ T helper cells, among other CD4+ cells such as monocytes, macrophages, 
dendritic cells and natural killer T cells (65). All these additional cell types can be 
infected with HIV-1, however the extent to which they are involved in HIV-1 
pathogenicity is not fully understood. CD4+ T helper cells play a key role in 
orchestrating adaptive immune responses (66). As a result, as HIV-1 replicates 
and spreads within its host, it targets and kills these immune cells that are 
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essential for eliminating the virus (67). This depletion of CD4+ T cells is why HIV-
1 infection progresses to acquired immunodeficiency syndrome (AIDS), a 
weakened immune state in which CD4+ T helper cells drop to levels so low that 
the immune system is overcome by otherwise well-controlled infections (68). 
Indeed, unexplained infections of patients with the fungus Pneumocystis jirovecii 
(69) and the rarely seen human herpesvirus 8 (70) were what prompted the initial 
investigations that led to the discovery of HIV-1. These immune system-altering 
characteristics help explain the lethal consequences of an untreated HIV-1 
infection and why the development of a cure or vaccine is so important. 
Historically, when scientists have sought protective measures against infectious 
diseases, they have attempted to induce or mimic the natural immune response 
that is mounted against the pathogen. However, as HIV-1 selectively targets and 
depletes key immune cells, there are no known effective responses to replicate 
or mimic for HIV-1. This characteristic changes the methods required to target 
this devastating virus. In addition, as a retrovirus, HIV-1 integrates its genome 
into the genome of the cells it infects. As a result, once HIV-1 establishes an 
infection in a host organism, the host is infected for life (71). Furthermore, the 
reverse transcriptase that HIV-1 encodes and uses to transcribe its RNA genome 
into a DNA template is a low fidelity enzyme that lacks any proofreading 
capability (72, 73). Thus, this error-prone reverse transcription results in a 
mutation rate that far exceeds what would be viable in cellular life and increases 
the pace at which HIV-1 can evolve (74). Ultimately, this results in infected hosts 
being infected with not a single HIV-1 virus, but a quasispecies composed of 
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millions of unique viruses, upon which the forces of natural selection can act (75, 
76). 
1.4 Genetic diversity is a defining characteristic of HIV-1 
As a consequence of the high mutation rate engendered by its reverse 
transcriptase, HIV-1 has developed a vast degree of genetic diversity (77). In an 
attempt to understand the evolution of HIV-1, the virus has been categorized into 
4 groups: Group M or the Major group, group N for non-M or O, group O for 
outlier and group P, named so to conform with previous nomenclature (36, 37). 
Each group is believed to represent a distinct zoonotic transmission event of SIV 
into humans, with groups M and N originating from SIV-infected chimpanzees 
(Pan troglodytes) (38, 39) and groups O and P originating from SIV-infected 
gorillas (Gorilla gorilla) (40). For reasons that are not entirely understood, group 
M is the only group to have spread widely out of central Africa and is responsible 
for over 95% of the infections globally, representing roughly 34 million infections 
(77, 78). Group M is further divided into a number of subtypes labeled A through 
K (with the exceptions of E and I), some of which can be divided further into sub-
subtypes (36, 37). Subtypes are designated based on genetic similarity, with 
inter-subtype diversity of up to 30% and intra-subtype diversity of up to 12% (77) 
(Figure 1.2A and B). 
In addition to these subtypes, which are believed to have diverged from a 
common zoonotic transmission event, HIV-1 also has the ability to genetically 
recombine, introducing even more genetic diversity (79). The recombination 
ability of HIV-1 is due to the fact that as HIV-1 virions assemble in infected cells, 
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2 copies of the RNA genome are packaged into the viral capsid (80, 81). 
Interestingly, in regions endemic for more than one subtype of HIV-1, individuals 
can be infected with multiple subtypes. In this situation, the same cell can be 
infected and express the viral genomes of two subtypes, thereby resulting in 
virions that have packaged one RNA genome from each subtype. Consequently, 
when these virions infect cells and undergo reverse transcription, the polymerase 
can jump from one genome to another producing recombinant viruses (80). If 
these viruses are viable and spread to new hosts, they are termed circulating 
recombinant forms (CRFs); however, if these recombinants are only isolated 
from a single individual they are known as unique recombinant forms (URFs) 
(Figure 1.2B). There are currently over 96 CRFs that have been classified and 
this number is expected to increase (37). Global migration continues to introduce 
new subtypes into diverse populations and changing transmission patterns are 
connecting previously isolated populations. Importantly, recombination allows for 
a rapid exchange of large amounts of genetic information (82). The potential for 
genetic exchange may pose a threat to controlling drug resistance in the age of 
widespread anti-retroviral therapy (83, 84). Indeed, if drug resistant viruses co-
infect HIV-1 positive individuals, there may be selective pressure for 
recombination events to transfer drug-resistant mutations, generating novel 
recombinant viruses.  
1.5 Pandemic spread of HIV-1 
In addition to the genetic diversity described above, HIV-1 Group M also displays 
a great deal of geographic diversity. As expected, central Africa, the region of the 
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original zoonotic transmission from chimpanzees to humans, has the greatest 
diversity of infecting subtypes (78) (Figure 1.3C). The spread of HIV-1 outside of 
central Africa is hypothesized to have been shaped by the founder effect (85-87). 
This phenomena is common in evolution and occurs when a relatively small 
group of organisms is introduced into a region they previously did not inhabit and 
subsequently shape the genetic characteristics of all following generations (88). 
As an aside, a similar phenomenon occurs with each new HIV-1 infection. 
Indeed, the quasispecies that is established in HIV-1 positive individuals is 
largely determined by a relatively small number of transmitted founder viruses 
(89, 90).  
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Figure 1.2 Extensive genetic and geographic diversity of HIV-1. 
(A) Phylogenic tree showing the distinct genetic clustering of HIV-1 groups M, N, 
O and P with different SIV strain from chimpanzees (SIVcpz) or gorillas (SIVgor). 
(B) Taxonomic structure and nomenclature of HIV. (C) Global map illustrating the 
geographic diversity of HIV-1 group M infections. Regions of the world are 
coloured based on the predominant infecting subtype or recombinant. Size of pie 
charts corresponds to the number of infections. (A modified from (77), B created 
using information from (91), and C modified from (78)). CRFs; circulating 
recombinant forms, URFs; unique recombinant forms.  
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Up until recently, HIV-1 infections in North America were almost exclusively due 
to subtype B viruses. Interestingly, subtype B is found at low frequencies in 
regions outside of the Americas and Western Europe that otherwise have high 
HIV-1 prevalence (78) (Figure 1.3C). In the United States, this is believed to be 
due to the initial introduction, via Haiti, of a subtype B virus into the MSM 
population early in the epidemic (85). As the HIV-1 epidemic grew in the United 
States, it is thought to have seeded epidemics throughout the Americas and 
Western Europe (92-94). This original subtype distribution has been changing 
over time, as immigration from HIV-1 endemic countries has introduced a 
diversity of subtypes (78, 95). Indeed, as of 2011, these immigrant populations 
make up over 20% of new HIV-1 infections in Ontario and close to 17% of new 
infections in Canada as a whole (62) (Figure 1.3B). In contrast to subtype B, HIV-
1 subtype C, which occurs at low rates in North America, is the predominant 
subtype found in southern Africa and India, regions with very high incidence rates 
and large populations, respectively. As a result, HIV-1 subtype C is responsible 
for just under half of all HIV-1 infections globally (77, 78). A similar geographic 
discrepancy with respect to subtypes is observed in Southeast Asia where the 
circulating recombinant form 01_AE (CRF01_AE) makes up the vast majority of 
HIV-1 infections and has significantly contributed to the increasing proportion of 
global HIV-1 infections due to CRFs (78) (Figure 1.3C). 
The geographic distribution of subtypes is highly influenced by the route of HIV-1 
transmission. Within a given population, there may be separate subpopulations 
that are at higher risk for HIV-1 infection, but these subpopulations can exist 
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largely independent of each other. For example, in South Africa, there is a high 
rate of heterosexual HIV-1 transmission that has largely consisted of subtype C 
infections. Indeed, the near ubiquitous nature of subtype C infections in South 
Africa (98% of HIV-1 infections in South Africa in 2007 were subtype C) has led 
to it being the most prevalent subtype globally (78). However, within the MSM 
population in South Africa and in particular the white MSM population, a 
disproportionate number of infections are due to subtype B (96, 97). These 
differences reflect the epidemiological and social separation of these populations 
and further highlight the complicated evolutionary history of HIV-1. Although 
these independent epidemics are becoming more integrated over time, they 
illustrate the dramatic diversity of HIV-1 between and within nations (Figure 1.3). 
Knowledge of these intricate differences in subtype distribution is critical for 
monitoring outbreaks of HIV-1 and enables officials to track and predict future 
infections, a mainstay in the control of infectious diseases.  
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Figure 1.3 Breakdown of new HIV-1 infections in key populations. 
The percentage of new HIV-1 infections in different subsets of the population 
from selected WHO geographic regions (A) or provinces in Canada (B). Regions 
and provinces were chosen to demonstrate the differences in the populations 
that HIV-1 infects in different geographic regions. (A modified from (35) and (98), 
B modified from (62)) 
In addition to being valuable for epidemiological monitoring of HIV-1, subtypes 
may impact how individual patients experience an HIV-1 infection. Following the 
initial infection, HIV-1 replicates unchecked by the adaptive immune response. 
This results in a period known as peak viremia, where viral loads in the blood are 
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elevated. As a consequence, there is a transient drop in CD4+ T cells and the 
patient experiences flu-like symptoms, typically 2-4 weeks following infection. 
Once the adaptive immune system can mount a response, viremia is controlled 
to a viral set-point, and CD4+ T cells rebound close to pre-infection levels (99-
101). However, HIV-1 is still actively replicating in the body, just at low levels. 
This period is known as the asymptomatic phase and varies between individuals, 
generally lasting 8-10 years (102, 103). Throughout this phase, the low level of 
HIV-1 replication in CD4+ T cells leads to their slow decline. Eventually, this 
decline in CD4+ T cells compromises the immune system to a point where it can 
no longer function adequately. At this state, individuals are diagnosed with AIDS 
(104). At the AIDS stage, HIV-1 replication is no longer controlled, viral loads 
increase and the body is susceptible to a number of opportunistic infections that 
would otherwise be cleared by a healthy immune system (68). It is these 
opportunistic infections that result in death in HIV-1 infected patients, not the 
virus itself, but the debilitating effect the virus has on the body’s immune system. 
As a result, if HIV-1 infected individuals do not receive treatment, they can 
present with serious complications from infections with Pneumocystis jirovecii, 
Candida and human herpesvirus 8, which are usually not observed in non-
immune compromised individuals. In addition, AIDS results in an increased risk 
of developing multiple forms of cancers and increases the risk of serious 
complications from microorganisms that otherwise cause mild symptoms (68, 
104) (Figure 1.4).     
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Figure 1.4 The clinical course of HIV-1 from primary infection to death.  
The clinical course of HIV-1 is most commonly described based on CD4+ 
lymphocyte levels (blue, left axis) and viral load (red, right axis). Following 
primary infection, HIV-1 viral loads peak, corresponding with a transient drop in 
CD4+ lymphocytes. This initial phase represents acute HIV-1 infection and is 
associated with flu-like symptoms. As CD4+ lymphocytes rebound, viral load 
reaches a nadir, known as the viral set-point and symptoms resolve, signifying 
the beginning of the asymptomatic phase. Throughout the asymptomatic phase, 
viral load increases and CD4+ lymphocytes decline. The rate of these changes 
varies from patient to patient based on viral and host characteristics, lasting a 
median of 8-10 years. Patients are diagnosed with acquired immunodeficiency 
syndrome (AIDS) once CD4+ lymphocytes drop below 200 cells/mm3 and/or they 
develop one of many AIDS-defining conditions. In the absence of treatment, 
patients succumb to opportunistic infections or another AIDS-defining condition. 
(Figure modified from (105)). 
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1.6 HIV-1 disease progression 
The rate at which CD4+ T cells decline throughout an HIV-1 infection is one 
measure that is often used to categorize HIV-1 disease progression (105). In an 
effort to determine how disease progression can be halted or reversed, there is 
much interest in understanding what is responsible for the differences observed 
in disease progression. The progression of HIV-1 infection to AIDS is influenced 
by host and viral factors, as well as the complex interactions between the virus 
and the host. Some of the most studied host factors affecting HIV-1 disease 
progression are human leukocyte antigen (HLA) alleles (106-109). Certain HLA 
alleles have been repeatedly shown to be associated with decreased HIV-1 
disease progression or decreased susceptibility to HIV-1 infection (107, 108, 110, 
111). Furthermore, studies have linked these associations with a more efficient 
adaptive immune response. Many other naturally occurring polymorphisms have 
been suggested to play a role in HIV-1 diseases progression. Not surprisingly, 
these polymorphisms are often located in genes for immune-related proteins. 
These include host restriction factors that have been shown to have anti-HIV 
activity, but are counteracted by HIV-1 proteins (112), cytokines that regulate the 
adaptive immune response (113, 114) and pattern recognition receptors (PRRs) 
of the innate arm of immunity (115). However, these findings have not been fully 
substantiated and large genome-wide association studies have failed to identify a 
correlation between many of these polymorphisms and HIV-1 disease 
progression (116). That being said, a study of 2554 HIV-1-infected Caucasians 
did find that mutations in the chemokine receptors CCR5 and CCR2 had 
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protective effects on HIV-1 disease progression (117). These findings are in line 
with the role of CCR5 and CCR2 as main and minor co-receptors for HIV-1, 
respectively (118, 119). Studies such as this do not exclude the possibility of 
other polymorphisms affecting HIV-1 disease progression, but rather underscore 
the complex interplay between host genomic factors and the difficulty in isolating 
the effect of a single genetic mutation at the population level. Taken together, 
these findings suggest that there may be a HIV-1 protective immune phenotype 
that may prevent infection or decrease the rate of HIV-1 disease progression.  
Given the differences in subtype distribution across nations and populations, 
there have also been attempts to determine if the infecting subtype plays a role in 
HIV-1 disease progression. These studies are difficult to conduct, as they require 
demographically similar populations where two or more subtypes are endemic. 
However, despite the difficulty in setting up these studies, evidence suggests that 
the infecting subtype does influence disease progression. Multiple studies have 
been conducted in cohorts of HIV-1-infected individuals in eastern Africa where 
subtypes D and A both circulate. These cohorts are composed of pregnant 
women, sex workers, or members of the adult population that do not identify to 
these to groups. The cohorts have ranged in size from 145 to 1045 individuals. 
All these studies have shown that individuals infected with subtype D viruses 
progress more rapidly to AIDS compared to those infected with subtype A viruses 
(120-122). Studies have also demonstrated that there is a higher risk of dying 
from AIDS in patients infected with subtype D (123, 124). 
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Interestingly, a recent analysis of 303 HIV-1-infected women from Uganda and 
Zimbabwe infected with subtypes A, C or D confirmed the findings of the studies 
mentioned above, but also demonstrated that patients infected with subtype C 
viruses progress more slowly to AIDS (125). These findings may have 
implications for control of the global epidemic and suggest a possible explanation 
behind the high global prevalence of subtype C, as a subtype with a slower 
progressing disease provides more opportunity for transmission.  
The aforementioned studies have all been conducted in sub-Saharan Africa 
where there is a high prevalence of multiple HIV-1 group M subtypes in close 
geographic and epidemiologic proximity. As discussed earlier, the spread of HIV-
1 outside of central Africa resulted in distinct viral populations emerging 
throughout the world (78). Due to these relatively more heterogeneous 
populations, studies investigating differences in disease progression between 
subtypes outside of Africa have been difficult. In particular, comparing subtype B 
disease progression to other subtypes is difficult due to the isolated nature of 
subtype B infections in higher-income countries (126-128). This renders it hard to 
control for confounding factors such as income and access to healthcare when 
comparing to subtypes found predominantly in middle to low-income countries.  
Overall, the mechanisms governing the above differences in disease progression 
are poorly understood. This is partly due to the fact that much of the research 
that has been conducted on the molecular mechanisms of the viral-host 
interactions that occur during an HIV-1 infection have been studied in the context 
of a subtype B infection (129). In the years that followed the recognition of AIDS 
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as a clinical entity, there was intense research into determining the causative 
agent. HIV-1 was identified as the virus responsible for AIDS when researchers 
isolated full-length molecular clones from AIDS patients (33, 34). The original 
HIV-1 molecular clone was known as IIIB/LAI (formerly known as BRU) and was 
isolated in 1983 in France (130). This clone gave rise to the molecular clone 
HXB2, which is still widely used, but has been altered through laboratory 
adaptations. In addition, IIIB/LAI was intentionally recombined with another HIV-1 
isolate, NY5, to generate the laboratory clone pNL4-3 (131). Laboratories in the 
United States also isolated HIV-1 molecular clones, notably the clone SF2, which 
is widely used in HIV-1 research (132). These isolated viruses, among a handful 
of others, became the clones used by thousands of researchers in the following 
decades. Importantly, as this pioneering research was conducted in France and 
the United States, the AIDS patients these clones were isolated from were 
infected with HIV-1 subtype B.  As a result, despite almost 90% of global HIV-1 
infections being non-subtype B, our understanding of how HIV-1 affects the 
molecular processes of the cells it infects is from research predominantly using 
subtype B viruses. This same discrepancy is true for the research on the drugs 
that have been developed to treat HIV-1 (133, 134). The long-term impact of this 
disconnect between research and reality, and its effect on our ability to control 
HIV-1 globally is yet to be determined. 
1.7 HIV-1 Nef: a key pathogenic factor 
Evidence for one of the most compelling viral factors shown to influence disease 
progression comes from the clinical observation of an Australian cohort of eight 
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patients that were infected with HIV-1 after receiving a contaminated blood 
transfusion. Known as the Sydney Blood Bank Cohort, these eight individuals 
were transfused with blood or blood products from an HIV-1-infected donor 
between 1980 and 1984. The recipients ranged in age from 18 to 71 and varied 
in their indications for transfusion. Three of the recipients died of non-HIV-1 
related causes, while the remaining five recipients, as well as the original donor, 
survived without antiretroviral therapy for 14-18 years post-infection (135-137). 
The donor eventually commenced antiretroviral therapy, but significantly later 
than the 8-10 years seen in normal HIV-1 infections. Two of the recipients also 
commenced antiretroviral therapy, but passed away from non-HIV-1 related 
causes shortly thereafter. Strikingly, three of the HIV-1 infected recipients have 
continued to have undetectable viral loads over 25 years since infection and do 
not show clinical signs of HIV-1 infection (138). Upon the isolation and 
sequencing of the HIV-1 viruses from the patients of the Sydney Blood Bank 
Cohort, it was found that the viral genome contained a large deletion in the HIV-1 
nef gene that resulted in a non-functional Nef protein (139, 140). A small non-
enzymatic and non-structural protein, Nef has subsequently been shown to be 
essential to HIV-1 pathogenesis. Studies in both transgenic mouse models (141) 
and SIV-infected macaques (140) have clearly demonstrated the requirement of 
Nef for CD4 decline and the progression to AIDS.  
Initially thought to decrease the infectivity of HIV-1 virions, this 27-35 kDa protein 
was originally termed a negative factor, from which the name Nef is derived (142, 
143). However, it was quickly shown that Nef in fact increases infectivity of 
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virions (144-146) along with a number of other functions, just a few of which will 
be expanded on below.  
As it is not required for in vitro HIV-1 replication, Nef, along with a number of 
other proteins encoded by HIV-1, is termed an accessory protein. To 
compensate for its lack of enzymatic or structural properties, Nef interacts with a 
plethora of host proteins to carry out the functions that make it necessary for in 
vivo replication (145, 147-150). Through these interactions, Nef hijacks the host 
cell trafficking machinery and alters the molecular architecture of infected cells 
(151-153). The effect of Nef on the organization of infected cells is most apparent 
when looking at how the composition of cell surface proteins changes in its 
presence or absence. The degree to which Nef is able to alter the levels of cell 
surface proteins is astounding, with reports demonstrating that Nef increases or 
decreases the cell surface levels of at least 37 proteins (154). These 
downregulated proteins include key proteins involved in cytokine signaling, T cell 
maturation and immune regulation. The impact of this large-scale reorganization 
is not completely understood, but there are a handful of well-studied Nef-
mediated modifications in infected cells that can help explain its essential role in 
HIV-1 pathogenesis. 
1.8 The multiple functions of HIV-1 Nef 
One of the first described effects of Nef expression was its ability to 
downregulate CD4 from the surface of infected cells (155). This finding was of 
particular significance for HIV-1 infection, as CD4 is the main receptor used by 
HIV-1 to enter host cells (119). Indeed, CD4 is one of the main co-receptors for 
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the T cell receptor (TCR) and is involved in stabilizing the interaction of the TCR 
with major histocompatibility complex class II (MHC-II) (66). As Nef-mediated 
CD4 downregulation was further explored, it was also shown to involve key host-
virus protein interactions with the intracellular trafficking machinery. These 
interactions result in CD4 molecules from the cell surface being shuttled into a 
retrograde transport pathway. The culmination of this Nef-mediated 
downregulation is the trafficking of CD4 molecules to a lysosomal compartment 
where CD4 is degraded. Specifically, Nef functions to facilitate the internalization 
of CD4 through interactions with adaptor protein 2 (AP-2) (151, 156, 157) and 
then targets CD4 containing endosomes to lysosomes through interaction with 
the beta subunit of the coatomer COPI (158, 159). In addition to identifying the 
host proteins involved, the specific residues within Nef that mediate the 
interactions required for CD4 downregulation have been described and will be 
elaborated on later in this chapter. Interestingly, the ability of Nef to downregulate 
CD4 is conserved across HIV-1 subtypes with over 80 Nef proteins from each of 
subtypes A, B, C and D all showing robust downregulation, albeit with subtype C 
showing a slightly decreased ability compared to subtype B (160). In addition to 
Nef, the HIV-1 proteins Env (161, 162) and Vpu (163) also contribute to 
decreasing cell surface levels of CD4 on infected cells.  
The conservation and redundancy of this Nef function suggests it provides a 
replication advantage for HIV-1. Indeed, as mentioned above, CD4 is the primary 
receptor used by HIV-1 to enter cells. Once a cell becomes infected, it is 
beneficial for HIV-1 to remove the remaining CD4 from the cell surface to prevent 
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reinfection with additional virions (164, 165). This repeated infection, known as 
superinfection, can overwhelm the infected cell leading to apoptosis, preventing 
any new HIV-1 virions from being released. Removal of CD4 from the cell 
surface also increases the dissemination of HIV-1 virions by preventing newly 
released virions from reinfecting the host cell from which they just budded. In 
addition, it has been demonstrated that circulating antibodies can bind HIV-1 Env 
proteins on the surface of infected cells more efficiently when those Env proteins 
are interacting with CD4 molecules on the cell surface. The Env:CD4 interaction 
leads to conformational changes in Env, revealing epitopes that antibodies can 
recognize (166). These antibodies can then act as ligands for receptors on 
natural killer (NK) cells, a subset of immune cells that can induce lysis of the 
infected cells via the release of effector proteins that is initiated by the 
antibody:receptor interaction (167). By decreasing cell surface levels of CD4, 
HIV-1 Nef prevents this innate and adaptive immune process known as antibody-
dependent cell-mediated cytotoxicity (ADCC) (168) (Figure 1.5). As expected, the 
ability of HIV-1 Vpu to downregulate CD4 also plays a role in limiting ADCC, 
highlighting the complementary functionality of the HIV-1 accessory proteins 
(169). 
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Figure 1.5 CD4 downregulation by HIV-1 Nef protects infected cells from 
ADCC and superinfection. 
In the absence of Nef (Nef -), HIV-1 infected cells have increased CD4 levels on 
the cell surface. Binding of CD4 with HIV-1 Env increases the binding affinity of 
anti-Env antibodies and sensitizes infected cells to recognition by CD16 
expressing NK cells and subsequent NK killing by antibody-dependent cell-
mediated cytotoxicity (ADCC). Increased CD4 levels on the cell surface also 
allows for superinfection of CD4+ T lymphoctyes with multiple strains of HIV-1, as 
represented by different coloured virions. In the presence of HIV-1 Nef (Nef +), 
CD4 is more efficiently removed from the cell surface and shuttled to lysosomes 
for degradation, as represented by fragmented CD4 in gradient shaded vesicle.     
Preventing ADCC is not the only method by which Nef allows HIV-1 to evade the 
host immune system. Nef is also able to downregulate major histocompatibility 
complex class I (MHC-I) (170, 171). MHC-I is an immune receptor expressed 
ubiquitously on all nucleated cells in the body. It functions in immune surveillance 
by continuously expressing protein fragments generated from the cellular 
proteasomal degradation pathway. In healthy cells, these protein fragments 
originate from the natural turnover of proteins and are recognized by cytotoxic T 
lymphocytes (CTLs) as self peptides (172). In the context of infection, viral 
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proteins are translated in the cytoplasm and following their proteasomal 
degradation are loaded onto MHC-I molecules in the endoplasmic reticulum (ER) 
and trafficked to the cell surface. Once at the cell surface, these MHC-I 
molecules displaying viral peptides are recognized as non-self by CTLs, which 
then induce apoptosis in infected cells (173). Nef is able to remove MHC-I from 
the cell surface, preventing infected cells from signaling to CTLs, and thereby 
allowing HIV-1 infected cells to go undetected (174) (Figure 1.6). In order to 
remove MHC-I from the cell surface, Nef utilizes a separate intracellular 
trafficking pathway from the one used to downregulate CD4 (175, 176). Nef 
requires interaction with the trafficking protein phosphofurin acidic cluster sorting 
protein-2 (PACS-2) to localize to the trans-Golgi network (TGN) and initiate a 
signaling cascade through the activation of a Src family kinase (SFK) (170, 177, 
178). The result of this signaling cascade is the clathrin-independent endocytosis 
of MHC-I, mediated by the small GTPases ADP-ribosylation factor 1 and 6 
(ARF1 and ARF6) (179). Nef will subsequently interact with the trafficking 
proteins adaptor protein -1 (AP-1) and PACS-1 to shuttle MHC-I containing 
endosomes back to the TGN where it is sequestered (170, 175, 180).  
The key role MHC-I plays in immune surveillance has led to the convergent 
evolution of viral strategies to alter its surface expression. Indeed, both herpes 
simplex virus (HSV) and human papillomavirus (HPV) modulate the levels of 
MHC-I on the cell surface. HSV interferes with peptide loading of MHC-I 
molecules (181), whereas HPV decreases MHC-I expression at the 
transcriptional level (182). These are just two of many viruses that target MHC-I 
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(183-185). However, the human immune system has evolved a method to 
counter the actions of these viruses. Circulating NK cells detect the absence of 
MHC-I molecules from the surface of cells and induce apoptosis (186). 
Interestingly, HIV-1 Nef specifically targets the MHC-I molecules HLA-A and B 
and to some extant HLA-C while leaving most HLA-C as well as HLA-G and E on 
the surface. This selective downregulation prevents recognition by NK cells, 
allowing HIV-1 infected cells to evade both CTL and NK killing (187).  
 
Figure 1.6 Evasion of CD8+ T lymphocyte by Nef-mediated MHC-I 
downregulation. 
In the absence of Nef (Nef -), peptides from HIV-1 proteins (yellow circles) are 
loaded onto MHC-I complexes and presented at the surface of infected cells. 
Upon recognition of the viral peptide:MHC-I complex, circulating CD8+ T 
lymphocytes are activated and stimulated through TCR and co-stimulatory 
(B7:CD28) signaling. Once activated, CD8+ T lymphocytes induce apoptosis of 
infected cells, limiting viral spread. In the presence of Nef (Nef +), MHC-I is 
removed from the surface of HIV-1 infected cells and the virus is able to replicate 
and disseminate. 
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1.9 SERINC5: a novel HIV-1 restriction factor 
As mentioned above, the initial identification and functional description of Nef in 
1985 and 1986 determined this accessory protein to have a negative regulatory 
effect on HIV-1 viral replication (142, 143). However, before the end of the 
decade, there were conflicting reports, suggesting that Nef did not impair 
replication (144). In the following eight years, the negative regulatory effects of 
Nef were largely refuted and it was established that this protein was actually 
required for optimal in vivo infectivity (145, 146). The original studies 
demonstrating the role of Nef in infectivity were published in the early to mid 
1990s, but the mechanism by which Nef increased infectivity remained poorly 
understood for more than twenty years. It was not until 2015 that Nef was once 
again demonstrated to downregulate a host protein from the cell surface to exert 
its effects. Two simultaneous reports identified the host proteins serine 
incorporator 3 and 5 (SERINC3 and SERINC5) as HIV-1 restriction factors that 
Nef counteracts to optimize viral infectivity (188, 189). In both reports SERINC5 
was shown to be the more potent restriction factor, and subsequent studies have 
focused on SERINC5, with SERINC3 thought to play a minimal role in anti-HIV-1 
activity.  
The identification of SERINC5 as an intrinsic restriction factor counteracted by an 
accessory protein is familiar in the HIV-1 field (190). Vif and Vpu, two other 
accessory proteins, counteract the host proteins APOBEC3G (191) and tetherin 
(192), respectively. HIV-1 replication and spread is greatly impaired by these 
restriction factors unless the HIV-1 accessory proteins are present. A similar 
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phenomenon occurs with Nef and SERINC5. In the absence of Nef, cell surface 
SERINC5 is incorporated into budding virions. Once in virions, SERINC5 has an 
inhibitory effect on the fusion of virions with target cells and by doing so it acts as 
a viral restriction factor. However, when Nef is expressed in infected cells, it 
downregulates SERINC5, reducing the amount of SERINC5 at the cell surface 
and therefore the amount of SERINC5 in budding virions (188, 189, 193).  
The exact mechanism by which SERINC5 impairs the fusion of HIV-1 virions with 
target cells is not known, partially because the physiological function of SERINC5 
in uninfected cells has not been thoroughly studied. Prior to its discovery as an 
HIV-1 restriction factor, there had been very few studies on the function of 
SERINC5, which has also been called C5orf12 and TPO1. The original articles 
describing SERINC5 focused on the transcriptional profile of the rat orthologue 
TPO1, which was highly expressed in oligodendrocytes in the rat brain (194). 
Even with the discovery of the human orthologue, many of the subsequent 
articles only identified SERINC5 as part of large-scale screens. The few studies 
that have tried to assess the function of SERINC5 have outlined a potential role 
for SERINC5 in membrane lipid biosynthesis (195, 196). Specifically, SERINC5 
is thought to act as a scaffold for key enzymes involved in serine biosynthesis 
and its subsequent incorporation into phosphatidylserine and sphingolipids (197). 
However, with its discovery as a restriction factor, there has been a flurry of 
research into SERINC5, which has increased our understanding of this protein, 
but also left many questions unanswered. The study of Nef proteins from a 
number of primate lentiviruses has suggested the anti-SERINC5 ability of Nef as 
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one of the determinants of transmission between species (198). Mutational 
analysis has revealed motifs required for Nef to counteract SERINC5 (193). A 
biochemical examination showed that the lipid composition of HIV-1 virions is not 
altered by SERINC5 (199). The most highly expressed and functionally active 
splicing isoform of SERINC5 has been identified (200). Domain swapping studies 
have implicated certain regions of SERINC5 in its anti-infectivity function (201). In 
addition, HIV-1 Env has also been demonstrated to have anti-SERINC5 activity, 
but at a different stage in the HIV-1 infection cycle (202). The evolution of two 
viral proteins to counteract SERINC5 suggests a strong selection pressure to 
overcome the anti-infectivity function of this newly identified restriction factor. 
1.10 The structure-function relationship of Nef 
The ability of Nef to downregulate CD4, MHC-I and SERINC5 highlights the 
multifunctional nature of Nef. Indeed, this multifunctionality is quite astounding, 
but also a necessity for a virus such as HIV-1, whose genome is only 9 kb and 
encodes 15 proteins (33, 34). With this limited coding capacity, HIV-1 has 
evolved proteins that are able to carry out multiple functions in order to 
successfully infect and replicate in host cells. The structure of Nef provides some 
insight into how this small protein can have such a dramatic effect on a cell. HIV-
1 Nef consists of two structured globular domains connected with a flexible loop 
region and unstructured tails at both the amino and carboxy-termini (147, 203-
205). Upon the discovery of Nef, even before its function was determined, 
researchers noted an N-terminal glycine at position 2, which undergoes a co-
translational modification known as myristoylation (206). This modification adds a 
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myristoyl group, a fatty acid derivative, to the amino-terminus of Nef, which 
subsequently acts to localize it to lipid membranes. This membrane localization is 
required for Nef to carry out essentially all its functions. As such, a Nef G2A 
mutant is often used as a negative control in studies of Nef function (207, 208). 
Furthermore, a glycine at position 2 is highly conserved across all HIV-1 groups 
(91, 209). Molecular pathways that rely on the assembly of multi-protein 
complexes often use lipid membranes as an anchor or scaffold, from which they 
can initiate downstream signaling cascades (210). This is exemplified by 
signaling through the ubiquitous G-coupled protein receptors (211) or through T 
cell receptor (212, 213). The N-myristoylation of Nef facilitates its interaction with 
host proteins at the cell surface and allows Nef to subvert their function to favour 
HIV-1 replication.  
Throughout its structure, Nef has binding motifs it uses to interact with a variety 
of host proteins that play key roles in intracellular trafficking and signaling. These 
host proteins have a large number of interaction partners, amplifying the host 
pathways that Nef can subvert. One such example is the PxxP75 motif in the 
central globular domain of Nef that interacts with the SRC homology 3 (SH3) 
domain found in the RT loop of SFKs (205, 214). The interaction of Nef with the 
SFK Hck leads to its activation and has been implicated in viral replication. 
Indeed, suppression of Hck activation through the use of antagonists or dominant 
negative mutants decreases HIV-1 replication (215-218).  The ability of Nef to 
downregulate such a large number of cell surface proteins can also be attributed 
to specific motifs. As mentioned earlier in this chapter, Nef is able to interact with 
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the cell sorting proteins PACS-1 and -2, thereby shuttling MHC-I away from the 
cell surface (177, 219). An acidic cluster motif from position 62 to 65, EEEE65 
mediates this interaction. Mutation of this acidic cluster (E4A) impairs the 
Nef:PACS interaction and significantly decreases the ability of Nef to remove 
MHC-I from the cell surface (170, 177, 179, 219). Distinct motifs have also been 
implicated in the ability of Nef to interact directly with the cytoplasmic tail of CD4 
(WL58) (220), hijack the membrane trafficking proteins AP-1 and -2 (LL165) (221, 
222), and activate the serine/threonine-protein kinase Pak2 (RR106) (223). The 
extensive network of interaction motifs on this 206 amino acid protein helps 
explain the multitude of functions that have been ascribed to Nef (147). 
The motifs above have been identified through mutational analysis to elucidate 
their roles in the functions carried out by Nef. Given the genetic instability of the 
HIV-1 genome explored earlier in this chapter, the conservation of these binding 
motifs across the epidemic suggests the interactions they mediate play a vital 
role in HIV-1 replication. The identification of these highly conserved protein 
sequences may be valuable given the propensity of HIV-1 to mutate to escape 
detection by the immune system (111, 224). Despite the fact that the adaptive 
immune response is eventually overcome by HIV-1 with the development of 
AIDS, it is continuously attempting to target and eliminate HIV-1 infected cells. As 
mentioned above, HIV-1, and Nef in particular, has evolved mechanisms to 
evade some of these adaptive immune responses. Potentially the most effective 
method by which HIV-1 avoids detection and elimination by the immune system 
is by the inherent genetic flexibility that leads to the high degree of HIV-1 genetic 
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diversity (74). By mutating so frequently and with such ease, HIV-1 is a 
constantly moving target. T cell-mediated adaptive immune responses largely 
evolved to target specific peptide sequences from foreign organisms. This 
specificity is one of the reasons why normal tissues do not normally sustain 
collateral damage during an adaptive immune response (173, 225). However, 
this defining characteristic also means it is inadequately prepared to clear 
infections like HIV-1. By the time the body is able to activate and mature immune 
cells, the peptides for which they have specificity may no longer exist in the pool 
of viruses now circulating.  
The changes in protein sequences that allow HIV-1 to continue to replicate are 
known as escape mutations. Although these mutations may allow infected cells 
to evade MHC-I meditated detection, they can have a fitness cost to the virus 
(74). As such, the evolution of HIV-1 viral proteins is a balance between avoiding 
clearance by CTLs, while maintaining the functional capacity to replicate (226, 
227). These evolutionary forces are particularly strong in the HIV-1 proteins Gag, 
Pol and Nef, which appear to be the most immunogenic viral proteins, that is, 
peptides expressed on MHC-I molecules are most frequently derived from these 
three HIV-1 proteins (228). This process may contribute to the protective effects 
seen in individuals with specific HLA alleles described earlier in this chapter. For 
example, the presence of the HLA-B*13 allele has been linked to decreased HIV-
1 viral loads. Indeed, the escape mutations that emerge in Gag and Nef in 
individuals who carry the HLA-B*13 allele have been shown to result in impaired 
function of both viral proteins (229). Different HLA alleles have different potential 
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binding grooves meaning they show preference for certain viral epitopes. If the 
epitopes that are displayed by the HLA molecules are derived from highly 
conserved regions of their native viral protein, escape mutations are more likely 
to have fitness costs to the virus. This results in a situation where mutations will 
decrease pathogenesis. Conversely, a lack of mutations in these regions allows 
for better control of the virus. Combined, the mutation, or not, of these epitopes 
results in decreased disease progression (74, 226, 227). The ability to identify 
highly immunogenic epitopes with limited mutational flexibility may be useful in 
future vaccination attempts as eliciting CTL responses to these epitopes may 
provide more broad and sustained protection against HIV-1 (230-232). Indeed, a 
similar approach is being used to target the stalk region of influenza A and B 
viruses, in hopes of developing a “universal” influenza vaccine (233, 234).  
1.11 Treatment and control of HIV-1 
As with all infectious diseases, there is great interest in generating a vaccine that 
induces protection against HIV-1. Although there have been numerous clinical 
trials of potential HIV-1 vaccines using a variety of different strategies, there is no 
HIV-1 vaccine presently available (235). While none of the tested vaccines have 
been clinically successful, these attempts have enhanced our understanding of 
the correlates of immune protection. The only vaccine to demonstrate significant 
protection was the RV144 vaccine trial, which displayed 31.2% efficacy at two 
years (236). The results of this trial have been extensively analyzed since they 
were reported in 2009. It is believed that the protection seen in the RV144 trial 
was due to a combination of non-neutralizing Env targeting antibodies (236-238), 
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HLA A*02 restricted epitopes (239) and ADCC from vaccine-induced antibodies 
(238, 240, 241). There are numerous vaccine trials currently underway, at 
various clinical phases. The furthest along is the HVTN702 trial, which is at 
phase IIb/III. Based on the promise of the RV144 trial, the vaccine trial HVTN702 
is being conducted in South Africa using a modified version of the vaccine used 
in RV144. Upon its completion in 2021, HVTN702 will be the largest HIV-1 
vaccine trial ever and offers hope for improved efficacy (235).  
The value of an effective HIV-1 vaccine is increased by the fact that there is 
currently no mechanism to cure an HIV-1 infection, as present treatment requires 
life-long pharmacotherapy (242). If HIV-1 positive individuals have access to 
current antiretrovirals, they can expect to have a normal life span (102). As a 
result, HIV-1 has effectively become a chronic disease that is medically managed 
throughout a patient’s life, more akin to diabetes or hypertension when compared 
to other viral infections. Current HIV-1 therapy is a combination of three 
antiretrovirals that are usually taken orally once a day. In total, there are twenty-
eight United States Food and Drug Administration (USFDA)-approved 
antiretrovirals from seven drug classes, which are differentiated by their 
mechanism of action. That being said, clinical treatment of HIV-1 largely uses 
drugs from just four classes. Two classes target reverse transcription, the 
nucleoside analogues nucleoside reverse transcriptase inhibitors (NRTIs) and 
the allosterically binding non-nucleoside reverse transcriptase inhibitors 
(NNRTIs). The other two classes are protease inhibitors (PIs), which block the 
proteolytic cleavage of viral proteins that is required for viral maturation and 
  
38 
integrase inhibitors (INIs), which prevent the integration of viral DNA into the host 
chromosome (242). As of 2016, the preferred first-line regimen according to the 
World Health Organization (WHO) consists of a backbone of two NRTIs and an 
additional NNRTI or INI with a PI used in special circumstances (243).  
In addition to these commonly used antiretrovirals, there are also three classes of 
drugs that target the entry of the virus into cells (242). These three classes are 
fusion inhibitors, co-receptor antagonists and CD4 attachment inhibitors, each 
with only one USFDA-approved drug. The fusion inhibitor enfuvirtide binds the 
viral envelope protein gp41, preventing fusion of the viral and host membranes, 
however, enfuvirtide has a low potency and short half-life and is rarely used 
clinically (244). The co-receptor antagonist maraviroc binds the HIV-1 co-
receptor CCR5, inducing a conformational change that prevents binding of the 
viral envelope protein (245). The recently approved monoclonal antibody 
ibalizumab is a CD4 attachment inhibitor and is the first biologic approved for the 
treatment of HIV-1. It binds to CD4, preventing HIV-1 entry, but does not alter the 
immunological function of CD4 (246). Both maraviroc and ibalizumab are used as 
salvage treatment, with ibalizumab just being approved for use in patients with 
multi-drug resistant HIV-1 in 2018. Thus, although patients cannot be cured at 
this point, the vast array of drugs is a testament to the past three decades of 
basic and clinical HIV-1 research.  
As is the case with the management of all chronic diseases, optimal outcomes 
only occur with consistent access to health care resources and high levels of 
adherence to treatment regimens. The benchmark used for antiretroviral 
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treatment is an adherence level of 95%, measured using self-reported data or 
data from drug dispensing records. Results from studies of drug adherence are 
highly variable and generally range from around 20% to close to 90% depending 
on population demographics and location (247-250). A systematic review from 
2006 made a pooled estimate that adequate adherence was only achieved in 
55% of patients in North America (data from 17 573 patients) and 77% in Sub-
Saharan Africa (data from 12 116) (251), while a 2018 study of adherence in 8 
501 patients in Korea observed an adherence rate of 70% (252). In many of the 
high-risk HIV-1 positive populations, there are a number of barriers to achieving 
95% adherence. Homelessness, daily alcohol or illicit drug use, and less than a 
high school education have all been independently shown to negatively correlate 
with medication adherence (251, 253, 254). Qualitative research has also 
demonstrated that HIV-1 stigma, medication cost and a desire to be “drug free” 
are commonly cited as reasons why patients stop taking antiretrovirals (250, 255, 
256). Addressing these barriers will be essential as we attempt control of the 
HIV/AIDS pandemic.   
The long-term use of antiretrovirals raises additional concerns. We are entering 
an unknown territory with patients expected to take daily treatment for up to 50 
years, but we are just beginning to investigate the health impacts of long-term 
antiretroviral therapy. The epidemiological studies on the complications of 
chronic antiretroviral exposure are mixed, but systematic reviews have 
suggested that antiretroviral use is correlated with diabetes, chronic kidney 
disease and cardiovascular disease (257-264). These studies in no way 
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undermine the success of antiretroviral treatments, but rather highlight the 
complexities involved in the long-term care of HIV-1-infected patients. 
Although managed like other chronic diseases, the infectious nature of HIV-1 
makes the risk of resistance to current treatments a serious concern. The same 
genetic instability that allows HIV-1 to evade immune responses can result in 
mutations that impair or eliminate the binding of drugs used to treat HIV-1. The 
history of antiretroviral drug development is shaped by drug-resistant mutations. 
From 1986 to 1996 antiretroviral therapy consisted of mono or dual therapy. 
These treatments significantly decreased viral loads, but this viral suppression 
was short-lived as viruses evolved mutations that rendered them resistant to 
binding by the drugs. It was not until patients were treated with three drugs that 
they achieved sustained viral suppression. The use of triple therapy dramatically 
reduced the chances that a virus will evolve resistant mutations to all three drugs 
(242). This remains true, but many people who fail antiretroviral treatment do so 
because of acquired or transmitted drug-resistant mutations. Acquired drug 
resistance refers to de novo mutations that evolve throughout antiretroviral 
treatment and are a major cause of increased viral loads in patients on treatment, 
known as virological failure (247, 265-267). Patients with elevated viral loads are 
more likely to transmit these drug-resistant viruses to other individuals. The 
presence of antiretroviral-resistant mutations in newly infected, treatment-naive 
patients is known as transmitted drug resistance and is a major public health 
concern (268). Transmitted drug resistance is most prevalent in regions of the 
world that have had access to antiretrovirals for the longest period of time. As a 
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result, the prevalence of transmitted drug resistance is around 12% in North 
America and 10% in Europe, whereas prevalence in sub-Saharan Africa and 
Southeast Asia is closer to 3% (269-272). It is possible to overcome this 
resistance by using drugs that target a different mechanism of HIV-1 replication. 
However, resistance is of particular concern in low- and middle-income countries 
(LMICs) where access to these second and third-line antiretroviral treatments 
can be limited, drug supplies can be interrupted more frequently and there are 
decreased resources for pre-treatment screening to identify resistance mutations 
(271). Current guidelines in high-income nations are to screen patients at 
diagnosis in order to guide treatment (273, 274), however, in LMICs screening is 
prohibitively expensive and resource-intensive (272, 275, 276). Even patients in 
LMICs who fail first-line treatment are not routinely screened for drug-resistant 
mutations and instead are treated empirically with a second-line therapy (272). 
Antiretroviral resistance increases the risk of HIV-1-related morbidity and 
mortality, increases the cost of future treatment and increases the risk of further 
transmission of HIV-1 (277-279). Transmitted drug resistance to NNRTIs is of 
particular concern as it is the first-line treatment for prevention of mother-to-child 
transmission (243, 272).  
Both vaccine and cure approaches to controlling HIV-1 have their obstacles. For 
cure approaches, these include achieving complete eradication of HIV-1 infected 
cells from the body (280). As of yet this has not been feasible due to what is 
known as the viral reservoir. During the acute phase of HIV-1 infection, the virus 
predominantly infects effector CD4+ T cells. Following the acute phase, most of 
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these virally infected cells die off either from the cytopathic effects of HIV-1 
infection or by the antiviral immune response (105, 281). However, a minority of 
these cells transition into CD4+ memory T cells and form a long-lived population 
of cells that contain integrated HIV-1 genomes (281). These cells are referred to 
as latently infected as they are not actively replicating and producing a large 
number of HIV-1 virions. Instead, these cells maintain a low-level of HIV-1 
transcription and protein production allowing them to remain undetected by the 
immune system and mostly unaffected by antiretroviral therapy (282). If 
antiretroviral therapy is interrupted, these latently infected cells are responsible 
for the viremic rebound that occurs in the following two weeks to two months 
(280, 283). One current cure strategy being investigated attempts to 
pharmacologically reactivate these latently infected cells, making them 
increasingly susceptible to antiretroviral therapy and subsequent clearance by 
the adaptive immune response (102). This strategy, referred to as “shock and 
kill”, has thus far failed to completely eliminate latently infected cells, potentially 
in part due to the immune evasion strategies mentioned above that HIV-1 
employs (284-287). Indeed, if reactivated cells are actively producing viral 
proteins, HIV-1 Nef will downregulate MHC-I and CD4 from the cell surface, 
preventing clearance by CTLs or ADCC, respectively (288). In addition, the 
effectiveness of shock and kill strategies is hard to assess as the exact 
anatomical locations and extent of the latent reservoir remain unknown (289).  
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1.12 The burden of HIV-1 
With the devastating impact HIV-1 has had on human populations, and the 
subsequent decades of research that it fueled, we have learned a great deal 
about the virus and how we can limit its pathogenesis. This has resulted in some 
significant progress in the management of HIV/AIDS. Global HIV-1 incidence 
rates peaked in 1997 with 3.2 million new infections while HIV-1 mortality 
reached its highest point in 2004 with 2.1 million deaths. As of 2016, there were 
1.8 million new HIV-1 infections and 1.0 million deaths. The greatest burden of 
HIV-1 and AIDS is found in eastern and southern Africa where there are 19.7 
million people living with HIV-1, accounting for 53% of all infections globally (98). 
As a result, it is in these regions where the most progress on controlling the 
epidemic has been made with eastern and southern Africa experiencing a 64% 
decrease in incidence and a 70% decrease in mortality since 2001. In most 
regions of the world, there have been similar, but less dramatic decreases due to 
the implementation of improved screening and antiretroviral therapy. There has 
been an intense scale-up of antiretroviral therapy in recent years with the number 
of people receiving treatment increasing from 7.5 million in 2010 to 17.0 million in 
2015, representing a coverage rate of 46% (98).   
However, the clinical response to HIV-1 is not uniform and may be stagnating in 
certain regions. In the Middle East and northern Africa, only 24% of those 
infected with HIV-1 have access to treatment and in eastern Europe and central 
Asia, the HIV-1 incidence rate has increased by 60% from 2010 to 2016 (98) 
(Figure 7A, B). Furthermore, even regions that are seeing overall decreases in 
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infection rates have subsets of populations that are not benefitting equally. In 
Canada, Indigenous peoples have a 2.7 times higher incidence of HIV and 
people who inject drugs have a 59 times higher incidence than those who do not 
inject drugs (62). Globally, transgender people are 49 times more likely to be 
infected with HIV-1 and young women and girls are twice as likely as young men 
and boys to be infected with HIV-1 (98). These stark differences in incidence 
rates highlight how the HIV/AIDS pandemic is significantly influenced by the 
social and political culture.  
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Figure 1.7 Global trends in HIV-1 incidence and access to antiretroviral 
therapy. 
(A) HIV-1 incidence rates from 1990-2016 in the 8 WHO geographic regions. (B) 
Antiretroviral therapy coverage in the 8 WHO geographic regions. (A and B 
modified from (98)) 
Controlling this complicated epidemic comes at a cost. It is estimated that in 
2016 there was US$19 billion spent on the AIDS response in LMICs and 
maintaining an adequate response will require well over US$ 20 billion each year 
in LMICs until at least 2030 (290). More efficient and effective strategies at 
preventing or treating HIV-1 will be valuable assets in ending an epidemic that 
has ravaged many generations. There have been very promising clinical trial 
results from long-acting antiretroviral therapies that may increase adherence 
rates (291, 292). Monoclonal antibodies against host proteins may offer 
treatments that avoid the issue of HIV-1 resistance (293-295). Numerous HIV-1 
vaccine trials are underway that are informed by the success of RV144 or are 
attempting new strategies to induce immunity (235). Finally, novel antiretroviral 
targets such as Nef have shown promise in vitro and could be used in 
combination with reactivation agents to clear latently infected cells (215, 288, 
296, 297). These strategies all take different approaches to fight HIV-1, but they 
all require a comprehensive understanding of the virus, how it differs from one 
region to the next and how it thwarts our immune system.  
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1.13 Rationale, Hypothesis and Thesis Objectives 
The HIV-1 genome is just 9 kb, but uses its limited coding capacity to carry the 
genetic information required to devastate the human body (33, 34). A low-fidelity 
reverse transcriptase allows HIV-1 to rapidly evolve to evade the immune 
response, an exquisite example of viral adaptation (72, 73). This lack of genetic 
stability also makes HIV-1 one of the most diverse viruses known (77, 298). The 
impact of genetic diversity on the molecular mechanisms involved in an HIV-1 
infection is not completely understood, leading to unexplained differences in 
disease progression between viral subtypes (120, 121, 124). Throughout this 
dissertation, I will explore the hypothesis that the genetic diversity that defines 
HIV-1 has a pronounced effect on the HIV-1 protein Nef, altering its function 
between and within group M subtypes.  
Nef is a key pathogenic protein, allowing HIV-1 to evade the immune system by 
downregulating MHC-I (171) and CD4 (155). Furthermore, it was recently 
discovered that Nef counteracts the host factor SERINC5 to increase HIV-1 
infectivity (188, 189), but the mechanistic details of the Nef:SERINC5 interaction 
still need to be explored. To address this hypothesis I investigated how MHC-I 
and CD4 downregulation differ among all non-recombinant group M subtypes. 
These studies revealed subtype-specific differences in Nef function that were 
associated with differences in Nef stability between subtypes. Further 
investigation revealed unique subcellular distribution of the rarely studied 
subtypes G and H. A low expressing Nef isolate of the globally predominant 
subtype C was then analyzed using mutational and stability studies, identifying a 
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previously undefined region in an alpha helix of Nef that is essential for protein 
expression and function (299). These findings are found in chapter 2. In chapter 
3, the molecular details of the recently defined Nef-meditated SERINC5 
downregulation are elucidated. The microscopy technique BiFC was used to 
demonstrate an in cellulo Nef:SERINC5 interaction, implicating key Nef protein 
interaction motifs. The Nef:SERINC5 complex was then mapped throughout the 
cell, highlighting the ability of Nef to hijack protein trafficking machinery, shuttling 
SERINC5 to degradative compartments to favour HIV-1 replication. Mutational 
analysis of SERINC5 shed light on the genetic determinants of the anti-infectivity 
activity of this poorly understood HIV-1 restriction factor. From there, these 
findings were placed in the context of the HIV-1 epidemic, investigating the 
conservation and variation in SERINC5 downregulation among Nef isolates from 
subtype C and A endemic regions.  
1.14 Importance 
HIV-1 Nef acts as a key pathogenic factor in disease progression. As such, it is 
essential that we have a detailed understanding of the functions of Nef and how 
they are influenced by genetic diversity. As HIV/AIDS decreases in prevalence 
and incidence in North America, it is important that our understanding of the virus 
takes into account the diversity of the epidemic and how it differs from the 
subtype B-dominated infections in high-income countries. Furthermore, the 
recent discovery of SERINC5 as an HIV-1 restriction factor and the role of Nef in 
its antagonism opens novel avenues of research that need to be explored to fully 
understand the pathogenic properties of Nef.  
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Chapter 2  
2 Impact of HIV-1 genetic diversity on Nef function and 
expression from group M subtypes 
2.1 Introduction 
Despite vast improvements in our ability to prevent, detect and treat HIV/AIDS, 
this chronic disease remains a major global health concern with over 36 million 
infected individuals globally by the end of 2016 (1). One of the reasons a vaccine 
and/or cure for HIV-1 has been so elusive is the extensive genetic diversity of the 
virus (2, 3). Specifically, HIV-1 is divided into 4 groups that represent 
independent zoonotic transmission of simian immunodeficiency virus (SIV) to 
humans and share >70% nucleotide homology (4). The most globally prevalent 
group is the HIV-1 Major group or group M, which accounts for approximately 
90% of global infections. The three other groups, Non-M and Non-O or group N, 
outlier group or group O and group P, which was named to conform to the 
alphabetical nomenclature used previously, are responsible for the remaining 
10% of HIV-1 infections, almost exclusively in central Africa. HIV-1 group M can 
be further subdivided into subtypes named alphabetically A through K, with the 
exception of E and I (5). Intersubtype variation can range up to 10-15% 
difference in amino acid sequence when measured at the 3’ end of the HIV-1 
genome (4). The prevalence rates of HIV-1 group M subtypes also vary, with 
subtype B responsible for approximately 10% of the epidemic, whereas subtype 
C was responsible for close to 50% or global infections in 2007 (6).  
The identification of HIV-1 as the causative agent of AIDS in 1983 was confirmed 
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by isolation of the virus from AIDS patients from France and the United States. 
The virus isolated from these patients belonged to HIV-1 group M subtype B, 
which is most prevalent in North America and Western Europe (7, 8). This virus, 
or variants of it, has served as the model virus in much of the subsequent HIV-1 
research, and as a result, there remains a gap in our understanding of how HIV-1 
genetic diversity affects its biology. This gap in our understanding is particularly 
evident in regards to subtypes that are found almost exclusively in central Africa. 
As the epicenter of the HIV-1 pandemic, central Africa has the greatest diversity 
in subtypes (6); however, there has been very little molecular research 
conducted using these subtypes. Determining if genetic differences influence the 
function of HIV-1 proteins may shed light on the differences in HIV-1 disease 
progression in individuals infected with different subtypes.  
The prominent role HIV-1 Nef plays in disease progression is striking given its 
apparent lack of enzymatic activity (9). However, Nef is a multifunctional protein 
capable of interacting with numerous cellular host proteins (10). Such a wide 
array of protein-protein interactions enables Nef to alter T cell activation (11, 12), 
increase virion infectivity (13, 14), modulate membrane trafficking to 
downregulate cell surface receptors (15), among other functions. The most well 
studied functions of Nef are the downregulation of major histocompatibility 
complex class I (MHC-I) (16-19) and CD4 receptors from the cell surface (20). 
Downregulation of MHC-I by Nef prevents the detection of virally infected cells by 
cytotoxic T-lymphocytes (CTLs) (21), whereas the removal of CD4 from the cell 
surface by Nef limits killing of infected CD4+ T cells by antibody-dependent cell-
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mediated cytotoxicity (ADCC) (22, 23) and unfavorable superinfection, thereby 
increasing viral dissemination (24). 
In order to determine the impact of HIV-1 genetic diversity on the function of Nef, 
we performed a functional analysis of representative reference strains from each 
non-recombinant group M subtype. These proteins were analyzed for MHC-I and 
CD4 downregulation. In addition, the cellular localization of these proteins was 
investigated, as the multifunctional activity of Nef relies on its distinct subcellular 
distribution allowing Nef to partake in protein-protein interactions. 
Taken together, our studies revealed a striking variability in functionality between 
Nef proteins from group M subtypes. Furthermore, defects in expression and 
function appear to be related to aberrant subcellular distribution of Nef proteins. 
These observations led us to focus subsequent investigations on the differences 
in function between a subtype B and a subtype C Nef protein. Extensive 
mutational analysis allowed us to identify three point mutations in the subtype C 
Nef protein at otherwise highly conserved residues. These rare point mutations 
were analyzed for their effects on Nef-mediated MHC-I and CD4 downregulation. 
Interestingly, we were able to attribute a defect in Nef function to the stability of 
Nef protein expression, highlighting the importance of these residues in proper 
function of this key HIV-1 pathogenic factor.  
  
76 
2.2 Methods 
2.2.1 Cell Culture 
CD4+ HeLa (ATCC, Manassas, VA) and HEK 293T cells (Life Technologies, 
Carlsbad, CA) were grown in complete DMEM containing 10% FBS (Wisent, 
Quebec, Canada), 100 U/ml penicillin and 100 µg/ml streptomycin (Hyclone, 
Logan, UT). Jurkat E6.1 T cells (Catalog number 177; National Institutes of 
Health, AIDS Research and Reference Reagent Program) were cultured in RPMI 
1640 supplemented as above with the addition of 1% sodium pyruvate, 1% non-
essential amino acids and 2 mM L-glutamine (Hyclone). All cell lines were grown 
at 37°C in the presence of 5% CO2 and sub-cultured in accordance with 
supplier’s recommendations. 
2.2.2 Proviral plasmids and cloning strategy  
The pNL4.3 ΔGag/Pol EGFP replication-incompetent HIV-1 proviral vector (25, 
26) was used as the base template for modification into the viral expression 
vector system. Primer overlap extension mutagenesis (27) was used to amplify 
two fragments flanking the nef coding sequence in order to remove nef and insert 
XmaI and NotI restriction sites, as described previously (26). Various nef coding 
sequences were amplified from expression plasmids generously provided by Dr. 
Thomas Smithgall (University of Pittsburgh School of Medicine) or synthetically 
generated using Invitrogen GeneArt™ Synthesis (Thermo Fisher Scientific, 
Waltham, MA). Subtype specific primers were used to introduce XmaI and NotI 
sites on the 5’ and 3’ end of nef, respectively, enabling the insertion of nef 
sequences into the pNL4.3 ΔGag/Pol EGFP vector. Nef Silent B was designed 
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by introducing all synonymous mutations from Nef C.BR92025 into Nef B.JRFL 
and matching the codon usage for all non-synonymous mutations between the 
two proteins. Nef Silent C was designed similarly, but by introducing all 
synonymous mutations from Nef B.JRFL into Nef C.BR92025 and matching 
codon usage for all non-synonymous mutations.  
The pNL4.3 ΔGag/Pol EGFP dVpu plasmids were constructed by inserting a vpu 
gene that was mutated to contain a premature stop codon into the pNL4.3 
ΔGag/Pol EGFP proviral vectors containing various nef sequences. Preexisting 
EcoRI and BamHI restriction sites were used to transfer the mutated vpu 
sequence from HIV-1NL4-3 vpu/nef/UD Deletion mutant (p230; NIH-AIDS reagents 
catalog number 2535) vector into pNL4.3 ΔGag/Pol EGFP.  
Nef-EGFP fusion protein plasmids were generated by inserting various nef 
sequences into the pN1-EGFP (Takara, Mountain View, CA) expression plasmid. 
pN1-EGFP was digested with AgeI and NotI and nef coding sequences were 
introduced using subtype specific primers that added AgeI and NotI sites to the 5’ 
and 3’ ends of nef, respectively. pN1 RFP-KDEL was designed using PCR 
subcloning to replace EGFP with RFP in a pN1 EGFP-KDEL plasmid kindly 
provided by Dr. Ron Flannagan (Western University, London, ON). 
Site-directed mutagenesis (28) was performed to generate point mutations in nef. 
Mutagenic primers were designed using Agilent Technologies Primer Design 
software and Agilent Technologies protocols (29) were used to introduce point 
  
78 
mutations. Sequencing was performed at the Robarts Research Institute 
Genomics Center to confirm all point mutations. 
2.2.3 Nef Chimeras 
Chimeric Nef proteins were constructed using a yeast recombination system 
described previously (30). Briefly, PCR products from Nef B.JRFL and 
C.BR92025 were amplified using one forward or reverse primer that bound 
externally to the Nef open reading frame and an additional forward or reverse 
primer that bound within the Nef open reading frame. Internal primers were 
designed within the Nef coding sequence based on regions of high homology 
between Nef from subtype B.JRFL and C.BR92025 to allow for recombination in 
yeast. External primers remained unchanged, however, multiple sets of primers 
within Nef were designed to allow for multiple junction points between the Nef 
sequences form subtype B.JRFL and C.BR92025. These sets of primers were 
used to produce various pairs of PCR products, one N-terminal fragment from 
Nef B.JRFL and a corresponding C-terminal fragment form Nef C.BR92025, or 
vice versa. A modified HIV-1 vector that had the Nef open reading frame 
replaced with the selectable marker URA3 was used as the receiving vector. 
Following transformation and recombination, yeast colonies were selected based 
on growth on 5-Fluoroorotic acid containing media. Yeast DNA was purified and 
used to electroporate competent bacteria to harvest DNA for downstream cloning 
and assays. Triple and quadruple chimeric proteins (eg. Nef BCB and Nef CBCB) 
were constructed using the same methodology, but with chimeric proteins used 
as the template for PCR reactions.  
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2.2.4 Lentiviral production and processing 
Lentiviral vectors were produced in HEK 293T cells. Cells were triple transfected 
using PolyJet (FroggaBio, Toronto, ON) with pNL4.3 ΔGag/Pol EGFP Nef NL4.3 
or the modified plasmids, as well as pdR8.2 and pMD2.G (pdR8.2 and pMD2.G 
were provided by Didier Trono (Addgene plasmid #12263 and #12259, 
respectively)) as previously described (31). Lentiviral vectors were harvested 48 
hours post-transfection. Briefly, virus-containing media was centrifuged at 3 000 
×g for 5 min to remove cellular debris and subsequently passed through a 0.2 µm 
filter. Filtered supernatant was supplemented with an additional 20% FBS prior to 
storage at -80°C. 
2.2.5 Flow Cytometry 
To quantify cell surface expression levels of MHC-I, Jurkat E6.1 cells were 
infected with indicated viruses and fixed 48 hours later in 2% paraformaldehyde 
(PFA). Cells were surface-stained for MHC-I using W6/32 (anti-MHC-I; pan-
selective, provided by D. Johnson, Oregon Health and Sciences University). 
Background fluorescence was verified using a no primary control, which revealed 
a nil value. Cell surface MHC-I expression was quantified by flow cytometry (BD 
FACSCanto II) and the data analyzed using FlowJo software (version 9.6.4, 
Treestar, Ashland, OR). Infected cells were first gated by selecting for EGFP 
positive cells and then MHC-I downregulation efficiency was calculated as 
follows: 
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MHC-I downregulation efficiency was reported as a percent relative to NL4.3, 
where 100% represents MHC-I downregulation efficiency equivalent to NL4.3 
and 0% is equivalent to infection with a virus lacking Nef (dNef). MFIexp 
represents the mean fluorescence intensity (MFI) of surface MHC-I in cells 
infected with our experimental samples; MFIdNef represents surface MHC-I MFI in 
cells infected with a virus that does not express Nef; and MFINL4.3 represents the 
MFI of cells infected with our virus expressing NL4.3 Nef. For reference, NL4.3 
Nef removed a median of 62±7% of MHC-I found on the cell surface when 
compared to dNef.  
Cell surface CD4 on Jurkat E6.1 cells was detected using the same protocol and 
an allophycocyanin (APC)-conjugated anti-CD4 monoclonal antibody (clone, 
OKT4, BioLegend, San Diego, CA). For reference, NL4.3 Nef removed a median 
of 51±9% of CD4 found on the cell surface when compared to dVpu dNef.  
To quantify cell surface CD4 on CD4+ HeLa cells, cells were collected 24 hours 
post-transfection by washing with PBS and trypsinizing followed by fixation in 2% 
PFA. Fixed cells were stained with an APC-conjugated OKT4 and analyzed by 
flow cytometry (BD FACSCanto II) and the FlowJo software. Transfected cells 
were first gated on EGFP positive cells and then CD4 downregulation efficiency 
was calculated as follows: 
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CD4 downregulation efficiency is reported as a percent relative to NL4.3, where 
100% represents CD4 downregulation efficiency equivalent to NL4.3 and 0% is 
equivalent to transfection with a plasmid expressing EGFP alone. MFIexp 
represents the mean fluorescence intensity of surface CD4 in cells transfected 
with our experimental samples. MFIEGFP represents mean fluorescence intensity 
of surface CD4 in cells transfected with a plasmid expressing EGFP alone. 
MFINL4.3 represents the mean fluorescence intensity of cells transfected with a 
plasmid expressing Nef NL4.3-EGFP. For reference, NL4.3 Nef-EGFP removed 
89±2% of CD4 found on the cell surface when compared to EGFP alone.  
2.2.6 Western Blots 
Infected Jurkat E6.1 cells or transfected CD4+ HeLa cells were collected at 48 or 
24 hours, respectively, and lysed in lysis buffer (25 mM HEPES, 300 mM NaCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100 and 1× complete Protease 
inhibitor Tablets (Roche, Indianapolis, IN)). Cells were lysed at 4°C while rotating 
for 20 min before insoluble cellular debris was removed by centrifugation at 20 
000 ×g for 20 min. Lysates were boiled at 98°C in 5× SDS-PAGE sample buffer 
(0.312 M Tris pH 6.8, 25% 2-mercaptoethanol, 50% glycerol, 10% SDS) and 
proteins were separated on 12% SDS-PAGE gels and subsequently transferred 
to nitrocellulose membranes. Membranes were blocked in 5% non-fat skimmed 
milk (Bioshop, Burlington, Ontario, Canada) in TBS containing 0.1% Triton X-100 
for 45 min, then incubated overnight at 4°C with various primary antibodies: 
rabbit anti-Nef polyclonal antibody (1:2500; catalog number 2949, NIH AIDS 
Research and Reference Reagent Program, USA), rabbit anti-GFP polyclonal 
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antibody (1:3000; Clontech; Takara), or mouse anti-β-actin monoclonal IgG 
(1:3000; Thermo Fisher Scientific, Waltham, MA).  Membranes were washed 3 
times in TBS containing 0.1% Triton X-100 and incubated for 2 hours at room 
temperature with the appropriate species-specific HRP-conjugated antibodies 
(1:3000; Thermo Fisher Scientific, Waltham, MA). Blots were developed using 
ECL substrates (Millipore Inc., Billerica, MA) and a C-DiGit chemiluminescence 
western blot scanner (LI-COR Biosciences, Lincoln, NE). 
2.2.7 Quantitative Reverse Transcriptase PCR (qRT-PCR) 
Jurkat E6.1 cells were infected with various lentiviral vectors at equivalent 
infection rates based on EGFP fluorescence. RNA was collected from infected 
Jurkat E6.1 cells 48 hours post-infection using PureLink® RNA Mini Kit (Thermo 
Fisher Scientific, Waltham, MA) and stored at -80°C. Purified RNA was reverse 
transcribed into bulk cDNA using SuperScript® III First-Strand Synthesis System. 
cDNA was used as a template for qRT-PCR with SensiFAST™ SYBR No-ROX 
Kit (FroggaBio, Toronto, ON) to amplify Env and Nef specific amplicons using the 
following primers: common Env and Nef fwd 5’ – GGCGGCGACTGAAGAAG, 
Env rev 5’ – ACTATGGACCACACAACTATTGCT, Nef rev 5’ – 
GATTGGGAGGTGGGTTGCT. qRT-PCR runs were run on a Rotor-Gene 6000 
(Qiagen, Valencia, CA) with the following conditions: 1 cycle at 95°C for 2 min for 
polyermase activation, 40 cycles at 95°C for 5 s for denaturation, 60°C for 10 s 
for annealing, 72°C for 15 s for extension. Relative levels of Nef and Env mRNA 
were calculated from standard curves generated from plasmids encoding the 
respective genes at known concentrations.  
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2.2.8 Transfections and Microscopy 
CD4+ HeLa cells were seeded onto coverslips at 5×105 cells/coverslip 24 hours 
prior to transfection. The respective plasmids were transfected into CD4+ HeLa 
cells at a concentration of 400 ng/µL using PolyJet (FroggaBio, Toronto, ON). 
Cells were washed three times with PBS 24 hours post-transfection before 
fixation in 4% PFA for 20 minutes at room temperature. Cells were blocked in 5% 
Bovine Serum Albumin/PBS containing 0.01% Triton X-100 for 1 hour prior to 
immunostaining.  Cells were washed twice with PBS before immunostaining (if 
required). Primary antibodies were diluted in 5% Bovine Serum Albumin/PBS 
containing 0.01% Triton X-100 and cells were stained with respective antibodies 
for 2 hours. Primary antibodies include mouse anti-TGN46 (1:100; Sigma Aldrich. 
Clone TGN46-8), mouse anti-CD63 (1:200, Developmental Studies Hybridoma 
Bank. Clone H5C6), mouse anti-LAMP1 (1:200, Developmental Studies 
Hybridoma Bank. Clone H4A3). Secondary antibodies were diluted (1:400) in 5% 
Bovine Serum Albumin/PBS containing 0.01% Triton X-100 and cells were 
stained for 2 hours. Secondary antibodies include Alexa Fluor® 647 goat-anti-
mouse (Jackson ImmunoResearch, West Grove, PA) and Alexa Fluor® 647 
donkey anti-rabbit (Jackson ImmunoResearch West Grove, PA). Mitochondria 
were stained using 100 nM of MitoTracker® Deep Red FM (Thermo Fisher 
Scientific, Waltham, MA) for 30 minutes prior to washing with PBS and fixation as 
above. After immunostaining, coverslips were mounted on slides using 
Fluormount-G or DAPI-Fluoromount-G (Southern Biotech, Birmingham, AL). 
Cells were imaged on a Leica DMI6000 B at 100× objective settings using the 
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Hamamatsu Orcaflash 4.0 Camera. Images were deconvolved using the Leica 
Application Suite software. Co-localization analysis was conducted using the 
Pearson Correlation from the Image J plugin (32).  
2.2.9 Proteasome Inhibition 
Proteasomal inhibition was performed on infected Jurkat E6.1 T cells. MG132 
(Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO to a stock concentration 
of 10 mM and diluted in RPMI to the desired working concentrations. Cells were 
pelleted and washed with PBS prior to resuspension and incubation with MG132-
containing media or media containing DMSO as the vehicle control. Cells were 
incubated for the indicated times and lysed at 48 hours post-infection.  
2.2.10 Pulse-chase 
Jurkat E6.1 cells were infected with specific lentiviruses for 48 hours post-
infection and subsequently incubated in starvation media (DMEM lacking L-
cysteine and L-methionine supplemented with 5% Gibco® Dialyzed Fetal Bovine 
Serum (Thermo Fisher Scientific, Waltham, MA) and Gibco® GlutaMAX™) for 30 
min. Starvation media was removed and cells were pulsed with pulse media 
(starvation media supplemented with EXPRE35S35 Protein Labeling Mix [35S] 
(Perkin Elmer, Guelph, Ontario, Canada) at 55µCi/mL) for 30 min. Cells were 
washed with complete RPMI supplemented with 20% FBS and then chased with 
the same media for 0, 30, 120 or 240 min at 37ºC. After the chase period, cells 
were lysed in 800 µL of RIPA-Doc buffer (140 mM NaCl, 10 mM NaH2PO4, 1% 
Triton X-100, 0.05% sodium dodecyl sulfate, 0.5% sodium deoxycholate) by 
rocking at 4°C for 10 min followed by centrifugation at 20 000 ×g at 4°C for 10 
  
 
 
85 
 
min. Following centrifugation the supernatant was removed and 
immunoprecipitated by incubation with anti-Nef (cat: 2949; NIH AIDS Reagent 
Program) conjugated Protein-A agarose beads (Sigma-Aldrich, St. Louis, MO) 
overnight at 4°C while rocking. Agarose beads were then washed twice with 1 
mL of RIPA-Doc and resuspended in 20 µL of 5× SDS loading buffer prior to 
boiling for 5-10 min at 95°C. Proteins were separated by SDS-PAGE on a 12% 
gel followed by fixation (50% methanol, 10% acetic acid in water) for 5-10 min. 
Gels were dried for 2 hours onto whatman paper using a Model 583 Gel Dryer 
(BioRad, Hercules, CA) and the autoradiography signal was captured by placing 
the dried gel in a phosphor storage cassette for 48 hours and developing on a 
Storm 820 Phosphoimager (GE Healthcare, Chicago, IL). ImageQuant 5.2 (GE 
Healthcare) software was used to quantify band intensity.      
2.2.11 Sequence Logo Generation 
Sequence logos were generated using WebLogo software 
(http://weblogo.berkeley.edu/logo.cgi) with the input sequences collected from 
the NIH Los Alamos Database. Sequences were selected from each country that 
contained a given subtype, with a maximum of 10 sequences selected from each 
country. Sequences were then screened for any large deletions or incomplete 
sequences. Residues in the sequence logos were colored based on Clustal 
Omega (33, 34) sequence alignments; residues in blue are acidic amino acids, 
residues in pink are basic amino acids, residues in red are uncharged non-polar 
amino acids and those in green are uncharged polar amino acids. Frequency of 
polymorphisms at positions 13, 84 and 92 were determined using the 
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AnalyzeAlign tool found at the Los Alamos HIV Database to query 4553 full-
length Nef protein sequences selected using their Filtered Web Search 
(http://www.hiv.lanl.gov/content/index). 
2.2.12 Structural Modeling 
Mac PyMOL 3 software (Schröinger, New York, NY) was used to construct 
structural models depicting Nef residues W13 and A84 (PDB ID: 4EN2) (35).  
2.2.13 Statistical Analysis 
Statistical analysis was conducted using GraphPad Prism software (GraphPad 
Software, Inc., La Jolla, CA). Downregulation and qRT-PCR data was analyzed 
by one-way ANOVA, while pulse-chase data was analyzed by one-phase decay 
non-linear regression.  
2.3 Results 
2.3.1 Known functional motifs in HIV-1 Nef are conserved across 
group M subtypes. 
To investigate potential differences in Nef function among group M subtypes we 
compiled a set of reference strains representing subtypes A1, A2, B, C, F1, F2, 
G, H and K, selected from Los Alamos National Laboratory’s HIV Sequence 
compendium (36) and a subtype D consensus sequence. These proteins were 
compared to the commonly used laboratory strain NL4.3, which is a laboratory 
adapted HIV-1 strain that was generated from intentional recombination of the 
two subtype B isolates, IIIB/LAI and NY5 (37). These subtype reference strains 
were aligned with NL4.3 to identify any differences in known Nef functional motifs 
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(Figure 2.1). We were primarily interested in motifs that have been 
experimentally shown to be involved in the ability of HIV-1 Nef to downregulate 
CD4 and MHC-I, the best described functions of Nef.  
Common to essentially all Nef functions is the need for Nef to be co-
translationally modified at its amino-terminus by the addition of a myristoyl group, 
a fatty acid moiety that allows for membrane association in infected cells. In Nef, 
this myristolyation occurs on a glycine at residue 2 (G2), which is completely 
conserved among the reference strains we analyzed (Figure 2.1). In addition, 
there was a high degree of conservation in most Nef functional motifs, with those 
responsible for the interaction of Nef with the cytoplasmic tail of CD4 (WL57) (38), 
the interaction with SFKs (P72xxP75) (39, 40), and AP-2 interaction (LL165) (41) 
being 100% conserved between the analyzed subtypes. Other motifs known to 
be involved in MHC-I and CD4 downregulation were also highly conserved with 
substitutions that maintain polarity and/or size. These include motifs mediating 
interaction with AP-1 (M20) (35) and PACS-1/2 (EEEE65) (19, 42), which are 
involved in MHC-I downregulation and motifs mediating interaction with Pak2 
kinase (RR105) (43) and the vacuolar ATPase (DD177) (44, 45), which are involved 
in CD4 downregulation. Notably, a tyrosine at position 120, Y120, which is 
required for optimal PACS-1 binding and therefore MHC-I downregulation (19), 
showed the most variability with Nef subtypes D, G and K having a phenylalanine 
in lieu of tyrosine.  
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Figure 2.1 Sequence alignment of Nef proteins from HIV-1 group M 
reference strains. 
 
MGGKWSKSSVIGWPAVRERMRRAE----------PAAD----------GVGAVSRDLEKH 40 
MGSKWSKSSIVGWREVRERLRQTL----------AAARG----------VGAVSQDLEKY 40 
MGGKWSKRTIVGWPEIRERMRRTPPAAEGVRPTPPAAEG----------VGAVSQDLARH 50 
MGGKWSKRSVPGWSTVRERMRRAE----------PAADRVRRTEPAAVGVGAVSRDLEKH 50 
MGNKWSKCSTVGRPAIRERMRRAP-----------AAEG----------VGPASQDSDKY 39 
MGGKWSKSSIVGWPAIRERIRRTE----------PAAD----------GVGAVSRDLEKH 40 
MGGKWSKSSIVGWPAVGERMRQTP----------TAAEG----------VGAVSRDLDRR 40 
MGGKWSKSSIVGWPAIRERIR--------------AAEG----------VGAVSQDLDKR 36 
MGGKWSKR---GWPAVRERIRQTP-----IRQTPPAAEG----------VGAVSQDLARH 42 
           MGGKWSKSSIVGWPAVRERIRRAQ----------PAADG----------VGAVSRDLDRR 40 
MGNKWSKS----WPQVRERMRRAPA---------PAADG----------VGAVSQDLAKH 37 
MGGKWSKSSIVGWSTVRERMRKTP----------PAADG----------VGAVSQDLDKH 40 
                **.****        : **:*              **            **..*:*  :  
 
GAITSSNTAANNAACAWLEAQEE-EEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEG 99 
GAVTSSN--VNHPSCAWLEAQEEEE-VGFPVRPHVPLRPMTYKGALDLSHFLKEKGGLDG 97 
GAVTSSNTAANNPDCAWLEAQEEE-EVGFPVRPQVPLRAMTYKGAVDLSHFLKEKGGLDG 109 
GAITSSNTAATNADCAWLEAQED-EEVGFPVRPQVPLRPMTYKGAVDLSHFLKEKGGLEG 109 
GALTSSSTPANNADCAWLEAQQEEEEVGFPVRPQVPLRPMTYKAVVDLSFFLEEKGGLEG 99 
GAITSSNTAATNADCAWLEAQEEDEEVGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLEG 100 
GAITSSNTRTTNPDLAWLEAQEEEE-VGFPVRPQVPVRPMTYKAAVDLSHFLKEKGGLEG 99 
GAITNSNTGATNADLAWLEAQEEE--VGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLEG 94 
GAITSSNTATNNPDCAWLEAQEEDSEVGFPVRPQVPVRPMTYKAAFDLSFFLKEKGGLDG 102 
GAVTINNTAATNPDVAWLEAQEEAEEVGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLDG 100 
GAITSSNTAATNADCAWLEAQTEE-EVGFPVKPQIPLRPMTYKGAVDLSFFLKEKGGLDG 96 
GAVTSSNTAFNNPDCAWLEAQEDE-DVGFPVRPQVPLRPMTFKGAFDLGFFLKEKGGLDG 99 
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LIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKG 159 
LIYSRRRQEILDLWVYNTQGYFPDWQNYTPGPGVRYPLTFGWCFKLVPVDPDEVEQANEG 157 
LIYSQRRQDILDLWVYNTQGYFPDWQNYTPGPGARFPLTFGWCFKLVPVDPSEVEEATEG 169 
LIHSQKRQDILDLWVYHTQGYFPDWQNYTPGPGIRFPLTFGWCFKLVPVEPEKVEEANEG 169 
LIYSKKRQDILDLWVYNTQGYFPDWQNYTPGPGVRFPLTFGWCFKLVPVDPREVEEANTG 159 
LVWSQKRQEILDLWVYNTQGFFPDWQNYTPGPGIRYPLTFGWCFELVPVDPEEVEEATEG 160 
LIYSKKRGDTLDLWVYHTQGYFPDWQNYTPGPGIRYPLTLGWCFKLVPVDPEEVEKANEG 159 
LIYSRKRQEILDLWVYHTQGYFPDWQNYTPGPGPRFPLTFGWCFKLVPVDPEEVEKANEG 154 
LIYSKKRQDILDLWVYNTQGFFPDWQNYTPGPGTRLPLTFGWCLKLVPVDPAVVEEATTE 162 
LIYSKKRQEILDLWVYNTQGYFPDWQNYTPGPGEGYPLTFGWCFKLIPVDPQEVERANEG 160 
LIYSKKRQEILDLWVHNTQGYFPDWQNYTPGPGIRYPLTFGWCYKLVPVDPSEVEEANEG 156 
LIYSKRRQEILDLWVYHTQGFFPDWQNYTPGPGIRYPLTFGWCYKLVPVDPREVEEATEG 159 
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ENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC- 206  
ENNSLLHPMCQHGMDDEEKETLRWRFDSRLALRHRAQEMHPEFYKDC- 204  
ENNSLLHPICQHGAEDPEREVLKWKFDSRLALRHLAREQHPEFYKDC- 216  
ENNCLLHPMSQHGIEDPEKEVLEWRFDSKLAFHHVARELHPEYYKDCG 217  
ENNSLLHPMSLHGMEDSHREVLQWKFDSLLARRHMARELHPEYYKDC- 206  
ENNCLLHPMCQHGMEDPEREVLMWRFNSRLAFEHKARVLHPEFYKDC- 207  
ENNCLLHPMSQHGMEDEDREVLRWKFDSSLALRHIARERHPEFYQD-- 205  
ENNCLLHPMSLHGMEDDDKEVLKWQFDSRLALRHIARERHPEYYKD-- 200  
ENNSLLHPIWQHGMEDEDREVLIWRFDSSLARRHLARELHPEFYKNC- 209  
ENNCLLYPICQHGMEDEEGEVLMWKFDSRLAFTHTAREKHPEFYKDC- 207  
ENNCLLHPICQHGIEDEEREVLQWKFDSSLARRHIARELHPEFYKDC- 203  
ENNCLLHPVNQHGMEDEHREVLKWKFDSSLARKHVAREMHPEYYKDC- 206  
                **..**:*:  ** :* . *.* *:*:* **  * *:  ***::::   
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Clustal Omega (33, 34) was used to align protein amino acid sequences of Nef 
from the laboratory strain NL4.3, or reference strains from subtypes A1, A2, B, C, 
F1, F2, G, H, J, and K, as well as a consensus sequence of subtype D from the 
NIH AIDS Los Alamos Database. Dotted boxes highlight motifs implicated in both 
CD4 and MHC-I downregulation. Solid boxes highlight motifs implicated in MHC-I 
downregulation. Dashed boxes highlight motifs implicated in CD4 
downregulation. “*” indicates identical residues, “:” indicates conserved residues, 
“.” indicates semiconserved residues. Residues in blue are acidic amino acids, 
residues in pink are basic amino acids, residues in red are uncharged non-polar 
amino acids and those in green are uncharged polar amino acids. 
2.3.2 Group M subtypes differ in their ability to downregulate CD4.  
In order to determine if the genetic variability present between group M subtypes 
impacted the function of HIV-1 Nef, we tested HIV-1 group M reference 
sequences for two key Nef functions.  To test Nef-dependent CD4 
downregulation, we constructed a set of mammalian expression plasmids 
encoding Nef-EGFP fusion proteins to express Nef in CD4+ HeLa cells.  Nef was 
expressed outside the context of other HIV-1 proteins to isolate the effect of Nef 
on surface CD4 levels, as other HIV-1 proteins are also able to downregulate 
CD4 (Figure 2.2A). Accordingly, CD4+ HeLa cells were transfected with Nef-
EGFP plasmids and analyzed for cell surface CD4 levels at 24 hours post-
transfection. CD4 downregulation in cells expressing Nef from the various 
subtypes was normalized to cells expressing the laboratory adapted NL4.3 
subtype B strain. CD4 downregulation was well conserved across group M 
subtypes with the exceptions of subtypes C, G and H, which had significantly 
decreased CD4 downregulation efficiency. Subtype C Nef displayed a CD4 
downregulation efficiency 60% of NL4.3, while subtype G and H had a 
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downregulation efficiency just over 25% of NL4.3 (Figure 2.2B, C).  
To explore potential causes of the decreased CD4 downregulation in subtypes C, 
G and H, we investigated the expression of the various Nef proteins following 
transfections in CD4+ HeLa cells. Surprisingly, subtypes C, G and H showed a 
marked decrease in Nef protein expression by western blot (Figure 2.2D). This 
variable expression occurred despite nef being expressed from identical 
plasmids encoding high expression promoters (Figure 2.2A). In addition, the 
fusion proteins were detected using an anti-GFP antibody ruling out antibody 
binding differences between subtypes.  
 
Figure 2.2 Nef proteins from group M reference strains differ in CD4 
downregulation. 
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(A) Schematic of pN1 Nef-EGFP plasmids that express Nef-EGFP fusion 
proteins from HIV-1 group M subtype reference strains driven by a CMV 
promotor. (B) CD4+ HeLa cells were transfected with plasmids expressing EGFP 
or various Nef-EGFP fusion proteins and stained for cell surface CD4 24 hours 
post-transfection. Cell surface CD4 was measured by flow cytometry. A 
representative histogram is shown. (C) CD4 downregulation was quantified and 
calculated relative to NL4.3 (green) (n≥5, p<0.05). (D) CD4+ HeLa cells were 
transfected with plasmids expressing EGFP or various Nef-EGFP fusion proteins 
and lysed at 24 hours post-transfection. Lysed cells were analyzed for Nef-EGFP 
and actin protein expression by western blot.  
2.3.3 Group M subtypes also differ in their ability to downregulate 
MHC-I.  
We next investigated Nef-mediated downregulation of MHC-I utilizing a modified 
viral vector system to infect the CD4+ T-cell line, Jurkat E6.1. Multiple HIV-1 
proteins, Nef, Env and Vpu, modulate cell surface levels of CD4, whereas 
differences in cell surface MHC-I levels are predominantly determined by the 
actions of Nef upon infection (15). As a result, we were able to use an infection 
model to investigate MHC-I downregulation (Figure 2.3A), rather than the 
transfection model used to test CD4 downregulation (Figure 2.2A). Accordingly, 
HIV-1 group M Nef reference sequences (Figure 2.1) were inserted into an 
NL4.3-based replication incompetent HIV-1 lentiviral vector that expresses EGFP 
(Figure 2.2A) and can be pseudotyped with the envelope protein from vesicular 
stomatitis virus (31). This system allows for us to better recapitulate an HIV-1 
infected cell while measuring MHC-I levels.  
To test Nef-mediated MHC-I downregulation, Jurkat E6.1 cells were infected with 
pseudoviruses expressing Nef from various subtypes for 48 hours and then 
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analyzed for cell surface levels of MHC-I by flow cytometry. In contrast to CD4, 
Nef proteins from different subtypes displayed more variability in their ability to 
downregulate MHC-I (Figure 2.3B, C). As observed, for CD4 downregulation, Nef 
from subtypes C, G and H showed a significantly decreased ability to 
downregulate MHC-I. However, unlike with CD4 downregulation, subtype A2 and 
F1 also had a decreased ability to downregulate MHC-I (Figure 2.3C). Analysis of 
MHC-I downregulation efficiencies revealed that subtypes A2, C, F1, G and H all 
had significantly decreased downregulation efficiency compared to the laboratory 
adapted subtype B strain NL4.3. It should be noted that subtypes A2 and F1 still 
maintained roughly 80% of NL4.3 activity, while subtypes C and G had below 
25% of NL4.3 activity and subtype H had just over 50% (Figure 2.3C).  
We once again explored Nef expression at the protein level as a possible cause 
for the observed differences in MHC-I downregulation across the tested 
subtypes. As expected, we were able to detect robust protein expression for Nef 
NL4.3 while no Nef protein was detected upon infection of Jurkat E6.1 cells with 
a virus that fails to express Nef (Figure 2.3D; NL4.3 and dNef, respectively). 
Moreover, bands corresponding to Nef were also detectable from Jurkat E6.1 T 
cells infected with viruses encoding Nef from subtypes A1, A2, B, D, F1 and F2, 
whereas subtype C, G, H and K infections resulted in little to no detection of Nef 
protein expression (Figure 2.2D). In contrast with the Nef-EGFP fusion proteins 
analyzed for CD4 downregulation (figure 2.3D), a polyclonal anti-Nef antibody 
was used to detect Nef protein expression. Moreover, to control for any possible 
differences in infection rates between viruses encoding the various Nef proteins 
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we also measured EGFP proteins levels by western blot. EGFP is expressed 
from the virus, but from a differentially spliced mRNA, providing an independent 
marker of infection rates. Accordingly, we did not observe any striking differences 
in GFP protein expression across subtypes (Figure 2.3D), suggesting all cells 
were infected at similar rates and differences in Nef levels were intrinsic to the 
protein.  
 
Figure 2.3 Nef proteins from group M reference strains also differ in MHC-I 
downregulation. 
(A) Schematic of pNL4-3 ΔGag/Pol EGFP proviral vector that was used as a 
template to generate pseudovirus expressing group M subtype reference strains. 
(B) Jurkat E6.1 T cells were infected with pseudovirus expressing Nef proteins 
from various group M subtype reference strains. At 48 hours post-infection, cells 
were stained for cell surface MHC-I and analyzed by flow cytometry. A 
representative histogram with an IgG isotype control is shown. (C) MHC-I 
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downregulation was quantified and calculated relative to NL4.3 (green) (n≥5, 
p<0.05). (D) Jurkat E6.1 T cells were infected with pseudoviruses expressing Nef 
proteins from various group M subtype reference strains. At 48 hours post-
infection, cells were lysed and analyzed for Nef, GFP and actin protein 
expression by western blot.  
2.3.4 Nef from Subtype C, G and H reference strains demonstrate 
abnormal expression and subcellular localization. 
Nef proteins from reference strains representing group M subtypes C, G, and H 
consistently showed decreased ability to downregulate CD4 and MHC-I, which 
appeared to be due to decreased steady-state levels of Nef (Figures 2.2 and 
2.3). To further explore the cause of these observed differences, we next 
measured levels of HIV-1 Nef mRNA transcripts from pseudovirus infected cells. 
Jurkat E6.1 T cells infected with HIV-1 pseudovirus encoding Nef from NL4.3 or 
subtype B, C, G or H reference strains were harvested 48 hours post-infection 
and bulk mRNA was collected from cell lysates. Upon qRT-PCR analysis, NL4.3 
and subtypes B, C, G and H all showed equivalent mRNA levels, suggesting 
differences in protein expression occur post-transcription (Figure 2.4A).  
To gain a better understanding of what was leading to the decreased function 
and expression of Nef proteins from subtypes C, G and H, we investigated the 
subtype reference strains for their subcellular localization. Indeed, the proper 
subcellular localization of HIV-1 Nef is essential for its function (46), while 
aberrant localization of Nef to one of various subcellular locales used to degrade 
proteins may provide insight to the cause of decreased Nef protein expression.  
Due to its interaction with the cargo sorting proteins PACS-1 and -2, HIV-1 Nef is 
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known to display a paranuclear distribution when expressed in cells, co-localizing 
with the trans-Golgi network (TGN) (19, 47). To determine if Nef proteins from 
group M subtype reference strains differed in their subcellular localization we 
visualized, by fluorescence microscopy, CD4+ HeLa cells transfected with Nef-
EGFP fusion proteins and co-stained for the trans-Golgi marker TGN46 (Figure 
2.4B) (48). Interestingly, Nef from subtype G and H displayed a distinct 
subcellular distribution when compared to the other Nef proteins analyzed 
(Figure 2.4B; NL4.3, subtype B, C and G shown). Nef from subtype G and H 
were more evenly distributed throughout transfected cells in a somewhat 
reticulated pattern (Figure 2.4B). Nef from the subtype C reference strain, the 
other low expressing Nef protein we identified, appeared to display a more typical 
paranuclear subcellular distribution, albeit at a decreased fluorescence intensity 
(Figure 2.4B).  
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Figure 2.4 Abnormal cellular distribution of Nef proteins from subytpe C, G 
and H reference strains. 
(A) Jurkat E6.1 T cells were uninfected (UI) or infected with lentiviral vectors 
encoding Nef from the laboratory strain NL4.3 or Nef from the subtype reference 
strains B, C, G or H. At 48 hours post-infection, mRNA was isolated from the 
cells and used for quantitative reverse transcriptase PCR (qRT-PCR). Levels of 
Nef specific mRNA are shown relative to levels of HIV-1 Env specific mRNA 
(p<0.05, n=2). (B) CD4+ HeLa cells were transfected with various Nef-EGFP 
fusion plasmids. Cells were fixed in 4% PFA, immunostained for TGN46, and 
imaged on a Leica DMI6000 widefield microscope on the 100X objective; scale 
bar = 10µm, green=Nef-EGFP, red=TGN46. (C) Images were deconvolved and 
co-localization analysis was completed using the Pearson’s Correlation with the 
Image J plugin. 
These visual observations were supported by quantification using Pearson’s 
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correlation coefficient, a measure of the co-localization between two proteins 
(32).  Indeed, Nef proteins from group M subtypes co-localized with TGN46 to 
varying degrees, ranging from a Pearson’s correlation of 0.60 for NL4.3 Nef to 
0.11 for Nef from the subtype H reference strain (Figure 2.4C). Only Nef proteins 
from subtypes F1 and F2 displayed a TGN46 co-localization not significantly 
lower than NL4.3, but strikingly subtype G and H had the lowest Pearson’s 
correlation, 0.15 and 0.11, respectively (Figure 2.4C). Notably, subtypes G and H 
had Pearson’s correlations significantly lower than the next lowest subtype, A1; 
Pearson’s correlation of 0.26, suggesting subtype G and H displayed an 
abnormal subcellular distribution relative to the HIV-1 group M reference strains 
that we analyzed (Figure 2.4B, C). As expected, Nef from subtype C 
demonstrated moderate co-localization with TGN46 (Figure 2.4B, C; Pearson’s 
correlation of 0.36), not significantly different than the functional Nef proteins 
from subtype A2 and K reference strains.  
2.3.5 Low expressing Nef subtype C, G and H do not undergo 
proteasomal degradation.  
Due to the decreased protein levels we observed for Nef proteins from subtype 
C, G and H reference strains (Figure 2.2 and 2.3), we hypothesized that these 
proteins may be being targeted for degradation by cellular cytosolic processes 
that mediate the degradation of proteins (49). To test this hypothesis, we first 
used the proteasomal inhibitor MG132 to potentially rescue Nef proteins from 
subtype C, G and H and delineate if these proteins are degraded via the 
proteasomal pathway. Thus, Jurkat E6.1 T cells were infected with viruses 
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encoding Nef from NL4.3 or subtype C and treated with 10 µM of MG132 for 0, 2, 
4, or 8 hours immediately prior to collection and lysis at 48 hours post-infection. 
Lysed cells were then assayed for Nef expression by western blot (Figure 2.5). 
Inhibition of the proteasomal degradation pathway did not increase detectable 
levels of Nef from the subtype C reference strain, with the most prominent band 
corresponding to Nef occurring in the absence of MG132 (Figure 2.5A; 0 hours). 
Alternatively, Jurkat E6.1 T cells were infected with viruses encoding Nef from 
NL4.3 or subtype G or H and treated with varying concentrations of MG132 for 6 
hours immediately prior to collection and lysis at 48 hours post-infection. 
Intracellular content of the lysed cells was then analyzed by western blot. As with 
previous experiments (Figure 2.2 and 2.3), we were unable to detect robust 
protein expression for Nef proteins from subtype G and H, whereas Nef from 
NL4.3 was readily detectable (Figure 2.5B, C). Upon treatment with 0, 5, 10 or 20 
µM of MG132, there was no observable change in protein levels of any of the Nef 
proteins investigated (Figure 2.5B, C). Taken together, these findings suggest 
that the decreased levels of Nef from subtype C, G and H reference strains are 
not due to degradation of these viral proteins by the proteasome. 
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Figure 2.5 Subtype C, G and H expression is not rescued by proteasomal 
inhibition.  
(A) Uninfected (UI) or Jurkat E6.1 T cells infected with pseudoviruses encoding 
Nef from subtype B or C reference strains were treated with 10 µM of the 
proteasomal inhibitor MG132 for 0, 2, 4, or 8 hours prior to collection and lysis at 
48 hours post-infection. Cell lysates were analyzed for Nef, GFP and actin 
protein expression by western blot. (B) Jurkat E6.1 T cells infected were infected 
with pseudovirus encoding Nef from NL4.3 or subtype G (B) or H (C) reference 
strains. At 42 hours post-infection, infected cells were treated with 0, 5, 10 or 20 
µM of the proteasomal inhibitor MG132 for 6 hours prior to collection and lysis at 
48 hours post-infection. Cell lysates were analyzed for Nef, GFP and actin 
protein expression by western blot.  
2.3.6 Low expressing Nef subtype C, G and H are not targeted to 
a lysosomal or multivesicular bodies compartment. 
In addition to degradation by the proteasome, decreased expression of cytosolic 
proteins can be due to their uptake into the endosomal network within cells (50). 
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Proteins can be internalized and removed from cells either via degradation in 
lysosomal compartments or secreted in exosomes via a CD63 dependent 
mechanism (50). To investigate these potential routes of protein removal as the 
cause of decreased Nef expression, we imaged CD4+ HeLa cells transfected with 
Nef-EGFP fusion proteins from HIV-1 subtype B, C, G and H reference strains. 
Transfected cells were then co-stained with lysosomal-associated membrane 
protein 1 (LAMP-1) or CD63, markers of the lysosome (51) and exosome (52) 
pathways, respectively. As previously observed, Nef proteins from subtype G and 
H displayed a distinct subcellular distribution (Figure 2.4B), however, these 
proteins did not appear to be localized to either LAMP-1 or CD63 positive 
compartments (Figure 2.6A, C). When LAMP-1 co-localization was quantified, all 
subtypes had a Pearson’s correlation less than 0.22 (Figure 2.6B). Nef from 
subtype B and C had increased co-localization relative to subtype G and H, but 
their low absolute co-localization values suggest they only had a weak co-
localization with the lysomsomal compartment (Figure 2.6B). Quantification of 
Nef/CD63 co-localization supported the fluorescence microscopy, with subtypes 
G and H having low Pearson’s correlations of 0.10 and 0.16, respectively. 
Subtype C had an elevated Pearson’s correlation of 0.42. This increased co-
localization was also seen for subtype B (Figure 2.6C, D; Pearson’s correlation of 
0.36), making the exosomal pathway an unlikely explanation of its low protein 
expression.  
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Figure 2.6 Nef subtype C, G, and H are not preferentially removed via the 
endosomal network. 
(A) CD4+ HeLa cells were transfected with various plasmids encoding Nef-EGFP 
fusion proteins from different HIV-1 subtype reference strains, and 
immunostained for LAMP-1. Cells were fixed in 4% paraformaldehyde and 
imaged on a Leica DMI6000 B widefield microscope on the 100× objective; scale 
bar = 10 µm, green=Nef-EGFP, red=LAMP-1. (B) Images were deconvolved and 
co-localization analysis was completed using the Pearson’s correlation with the 
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Image J plugin. (C) CD4+ HeLa cells were transfected with various plasmids 
encoding Nef-EGFP fusion proteins from different HIV-1 subtype reference 
strains, and immunostained for CD63. Cells were fixed in 4% PFA and imaged 
on a Leica DMI6000 B widefield microscope on the 100× objective; scale bar = 
10 µm, green = Nef-EGFP, red = CD63. (D) Images were deconvolved and co-
localization analysis was completed using the Pearson’s correlation with the 
Image J plugin. 
2.3.7 Nef subtype G and H display increased mitochondrial co-
localization. 
As investigation of the canonical proteasomal and lysosomal degradation 
pathways could not explain the decreased expression and distinct subcellular 
localization of Nef from subtype G and H reference strains, we next investigated 
alternate subcellular locales. Nef is a cytosolic protein that is membrane bound 
(46), we therefore investigated other membrane-delineated compartments in the 
cell. We first investigated the localization of Nef proteins from subtypes B, C, G 
and H with the endoplasmic reticulum (ER), as this membrane bound organelle 
can be a site of protein degradation via the endoplasmic-reticulum-associated-
degradation pathway (ERAD). To label the ER, we constructed a red fluorescent 
protein (RFP) that was modified to include the ER target sequence KDEL, RFP-
KDEL. Proteins that contain the KDEL target sequence are retained in the 
endoplasmic reticulum due to recognition by the KDEL receptor (53). CD4+ HeLa 
cells were co-transfected with Nef-EGFP fusion proteins and RFP-KDEL and 
then imaged by fluorescence microscopy. Interestingly, Nef from subtype C did 
appear to co-localize with RFP-KDEL (Figure 2.7A), but this finding was not 
supported when multiple independent experiments were quantified. Indeed, there 
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was minimal co-localization as measured using Pearson’s correlation. Nef 
proteins from subtype B, C, G and H all displayed similar co-localization as the 
cytosolic EGFP, which was used as a negative control (Figure 2.7B). This is in 
contrast to an EGFP protein that was modified with a KDEL target sequence, 
which we used as our positive control, and showed near ubiquitous co-
localization with RFP-KDEL, as seen with a Pearson’s correlation of 0.95 (Figure 
2.7B). Overall, these findings do not support the ER as the subcellular 
destination of low expressing Nef proteins from subtypes C, G and H. 
The final subcellular compartment that we investigated was the mitochondria. 
Although, there has not been any reports of HIV-1 Nef localizing to this organelle, 
the reticulated nature of the distribution of Nef from subtype G and H (Figure 2.4 
and 2.6) was reminiscent of fluorescence imaging of the mitochondria (54). In 
order to label the mitochondria we used the mitochondrial potential-dependent 
fluorescent dye, MitoTracker® Deep Red FM. CD4+ HeLa cells were transfected 
with Nef-EGFP fusion proteins from subtype B, C, G and H and prior to fixation 
were incubated with 100 nM of MitoTracker® Deep Red FM for 30 minutes. 
Strikingly, there was strong co-localization of all Nef proteins with MitoTracker® 
(Figure 2.7C, D), however, it is important to note that even cells transfected with 
unfused EGFP displayed moderate co-localization with MitoTracker® (Figure 
2.7D). We believe this was due to the diffuse nature of the MitoTracker® dye, 
which was particularly evident in the perinuclear region of cells (Figure 2.7C). To 
determine if the strong co-localization of Nef with MitoTracker® was maintained 
outside these heavily labeled regions, we selected peripheral areas of 
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transfected cells and reanalyzed them for Nef/MitoTracker® co-localization. 
Interestingly, when only these peripheral regions were considered, the degree of 
co-localization of Nef proteins from subtype B and C reference strains with 
MitoTracker® decreased to levels not significantly different than cells transfected 
with EGFP alone (Figure 2.7D). However, the strong co-localization of Nef 
proteins from subtype G and H with MitoTracker® was maintained, with both 
subtypes having a Pearson’s correlation of 0.71 (Figure 2.7D). These findings 
support our early observations that Nef proteins from subtype G and H reference 
strains display a unique subcellular distribution (Figure 2.4B, C), even when 
compared to the other low expressing subtype C reference strain (Figure 2.7D). 
They also raise the possibility that these Nef proteins are preferentially localized 
to mitochondrial dense regions of the cells, an as of yet unreported finding for 
HIV-1 Nef.   
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Figure 2.7 Increased co-localization of Nef proteins from subtype G and H 
with mitochondria. 
(A) CD4+ HeLa cells were co-transfected with various Nef-EGFP fusion plasmids 
encoding Nef from different HIV-1 subtype reference strains, and KDEL-RFP. 
Cells were fixed in 4% PFA and imaged on a Leica DMI6000 B widefield 
microscope on the 100× objective; scale bar = 10 µm. (B) Images were 
deconvolved and co-localization analysis was completed using the Pearson’s 
correlation with the Image J plugin. Green bar = positive control, Red bar = 
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negative control. (C) CD4+ HeLa cells were transfected with various Nef-EGFP 
fusion plasmids encoding Nef from different HIV-1 subtypes. Cells were stained 
with 100 nM MitoTracker® DeepRed for 15 min, then fixed in 4% PFA, and 
imaged on a Leica DMI6000 widefield microscope on the 100× objective; scale 
bar = 10 µm, green=Nef-EGFP, red=mitochondria, boxes represent an example 
of the area considered in peripheral co-localization analysis. (D) Total (dark blue 
or red) or peripheral (light blue or red) colocalization of Nef-EGFP and 
MitoTracker® Deep Red. Images were deconvolved and co-localization analysis 
was completed using the Pearson’s correlation with the Image J plugin. 
2.3.8 Differences in Subtype C expression and function are due to 
variations in amino acid sequence.  
Unable to identify the route of degradation for the low expressing Nef proteins 
from subtype C, G and H reference strains, we focused subsequent 
investigations on elucidating the genetic determinants of the low expressing 
subtype C. Our studies contrasted the low expressing subtype C reference strain 
C.BR92025 with the high expressing subtype B reference strain B.JRFL, as it 
displayed the greatest functionality in our earlier tests (Figure 2.2 and 2.3) and 
displayed typical subcellular distribution in our previous investigations (Figure 
2.4). Before altering the protein sequences of Nef B.JRFL and Nef C.BR92025, 
we first wanted to verify that the differences in protein expression were not due to 
differences in codon-usage between these two Nef proteins. To do so, we 
synthesized a Nef B.JRFL protein that contained all possible synonymous 
mutations found in Nef C.BR92025, termed Nef Silent B, ensuring that the only 
differences between Nef C.BR92025 and Nef Silent B were the non-synonymous 
mutations that resulted in amino acid changes (Figure 2.8A). The same process 
was performed to synthesize a Nef Silent C, which contained all the synonymous 
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mutations found in Nef B.JRFL (Figure 2.8A).  
These synthesized protein sequences were inserted into the proviral vectors 
described earlier (Figure 2.3A), which were then used to generate HIV-1 
pseudoviruses expressing Nef Silent C or Nef Silent B. To test these proteins for 
functionality, Jurkat E6.1 T cells were infected with pseudovirus and stained for 
cell surface MHC-I at 48 hours post-infection. Surprisingly, when analyzed for 
MHC-I downregulation by flow cytometry, Nef Silent B demonstrated increased 
efficiency relative to Nef B.JRFL, whereas Nef Silent C was less efficient than 
Nef C.BR92025 at downregulating MHC-I (Figure 2.8). Indeed, cells infected with 
pseudovirus encoding Nef Silent C had more MHC-I on their cell surface than 
cells infected with pseudovirus that does not produce Nef (Figure 2.8B; Silent C 
and dNef, respectively). Furthermore, to determine if different codon usage 
between Nef C.BR92025 and Nef B.JRFL impacted protein expression, 
pseudovirus infected Jurkat E6.1 cells were lysed and analyzed by western blot. 
In line with the functional data above (Figure 2.8B), there were no obvious 
differences in the expression of Nef B.JRFL and Nef Silent B or Nef C.BR92025 
and Nef Silent C (Figure 2.8C). These results suggest that the decreased 
function and expression of Nef C.BR92025 is not due to codon-usage, but rather 
due to differences in the amino acid sequence.  
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Figure 2.8 Decreased expression and function of Nef C.BR92025 is due to 
differences in amino acid sequence. 
(A) Schematic of Nef B.JRFL (Silent B) or Nef C.BR92025 (Silent C) nucleotide 
sequences that were synthesized to mimicked the codon usage Nef C.BR92025 
or Nef B.JRFL, respectively. Nef constructs were inserted into proviral vectors to 
produce pseudovirus. (B) Jurkat E6.1 T cells were infected with the pseudovirus 
lacking Nef expression (dNef; red) or expressing the indicated Nef construct and 
stained for surface MHC-I at 48 hours post-infection. MHC-I downregulation was 
measured by flow cytometry and calculated relative to NL4.3 (green). (n≥3, 
p<0.05) (C) Jurkat E6.1 T cells were infected with pseudovirus expressing the 
indicated Nef constructs and lysed at 48 hours post-infection. Lysates were 
analyzed for Nef, GFP and actin expression by western blot. 
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2.3.9 Subtype C impairments are due to genetic differences in two 
alpha helices.  
To locate the region of the subtype C protein that is responsible for the 
differences in function and expression, we constructed a series of chimeric 
proteins. The C-terminus of Nef B.JRFL was replaced with increasingly larger 
segments of Nef C.BR92025 and the same procedure was repeated for replacing 
the C-terminus of Nef C.BR92025 with increasingly larger segments of B.JRFL 
(Figure 2.9A; BC 3-1 and CB 3-1, respectively). The sequences for these 
chimeric proteins were inserted into the proviral vectors described earlier (Figure 
2.3A), which were then used to generate pseudovirus that express various 
chimeric Nef proteins.  
To test Nef function, Jurkat E6.1 T cells were infected with pseudoviruses 
expressing Nef B.JRFL, Nef C.BR92025 or the various chimeric Nef proteins and 
stained for surface MHC-I at 48 hours post-infection. MHC-I downregulation was 
analyzed by flow cytometry. When the C-terminal 90 amino acids of B.JRFL were 
replaced with the corresponding C-terminal 90 amino acids of C.BR92025 
(Figure 2.9A; BC 3) there was no detectable change in MHC-I downregulation. 
Strikingly, when the next 50 amino acids of Nef B.JRFL (NL4.3 positions 116-67) 
were replaced with the corresponding 50 amino acids of Nef C.BR92025 (Figure 
2.9A; BC 2), there was a significant decrease in MHC-I downregulation to less 
than 50% of NL4.3 (Figure 2.9B). When the next 43 amino acids of Nef B.JRFL 
(NL4.3 position 24-67) were replaced with those of Nef C.BR92025 (Figure 2.9A; 
BC 1), there was no additional decrease in MHC-I downregulation. It is important 
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to note that the function of these chimeric proteins never fell to the level of the full 
length Nef C.BR2025, suggesting that the final N-terminal 24 amino acids that 
were not replaced in our chimeric proteins also played a role in determining 
MHC-I downregulation (Figure 2.9A, B). In addition to MHC-I downregulation, we 
also measured expression of these chimeric proteins by western blot of lysates 
from Jurkat E6.1 T cells infected with the pseudoviruses used above. Strikingly, 
the same segments of Nef C.BR92025 that decreased MHC-I downregulation 
(Figure 2.9A, B) resulted in nearly undetectable levels of protein (Figure 2.9C). 
These findings further suggest that the functional impairment seen in Nef 
C.BR92025 is linked to defects in protein expression.   
Importantly, when the same chimeric experiments were performed with segments 
of Nef C.BR92025 being replaced with Nef B.JRFL (Figure 2.9A; CB 3-1), there 
was an increase in MHC-I downregulation and protein expression when the 
central region Nef B.JRFL (NL4.3 positions 116-67) was introduced into Nef 
C.BR92025 (Figure 2.9B, C). These Nef C.BR92025 chimeric experiments 
corroborate the findings from our Nef B.JRFL chimeric experiments and support 
this region as a major determinant of Nef function and expression. In line with the 
Nef B.JRFL chimeric experiments, the chimeric protein with only 24 N-terminal 
amino acids from Nef C.BR92025 (Figure 2.9A; CB 1) did not show a complete 
rescue of function equivalent to Nef B.JRFL (Figure 2.9B). This suggests that this 
N-terminal region is also important for Nef function, however, these N-terminal 
amino acids do not appear to be required to rescue expression of Nef 
C.BR92025 (Figure 2.9C). 
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Figure 2.9 Decreased function and expression of Nef C.BR92025 is 
determined by an N-terminal and central region. 
(A) Schematic of chimeric proteins of Nef B.JRFL with increasing C-terminal 
portions of Nef C.BR92025 (BC 3-1) or vice versa (CB 3-1). Nef constructs were 
inserted into proviral vectors to produce pseudovirus. (B) Jurkat E6.1 T cells 
were infected with the pseudovirus lacking Nef expression (dNef; red) or 
expressing the indicated Nef construct and stained for surface MHC-I at 48 hours 
post-infection. MHC-I downregulation was measured by flow cytometry and 
calculated relative to NL4.3 (green) (n≥3, p<0.05). (C) Jurkat E6.1 T cells were 
infected with pseudovirus expressing the indicated Nef constructs and lysed at 
48 hours post-infection. Lysates were analyzed for Nef, GFP and actin 
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expression by western blot.  
To confirm the importance of the central region (NL4.3 positions 67-116) and the 
N-terminal region (NL4.3 positions 1-24) in determining the decreased 
expression and function of Nef C.BR92025 we completed additional chimeric 
experiments. Chimeric proteins were constructed to introduce region 67-116 of 
Nef C.BR92025 into Nef B.JRFL (Figure 2.10A; Nef BCB). The introduction of 
these 49 amino acids significantly decreased the ability of Nef BCB to 
downregulate MHC-I in Jurkat E6.1 T cells infected with pseudovirus expressing 
this chimera (Figure 2.10B). This 49 amino acid region was also introduced into 
the BC 1 chimeric protein used in the previous chimeric experiment to construct a 
Nef B.JRFL protein that contained amino acids 1-24 and 67-116 of Nef 
C.BR92025 (Figure 2.10A; CBCB). Strikingly, this Nef CBCB chimera showed a 
further decrease in its ability to downregulate MHC-I in Jurkat E6.1 T cells 
infected with pseudovirus expressing this new chimeric (Figure 2.10B). 
Additionally, both Nef BCB and Nef CBCB chimeric proteins showed decreased 
expression via western blot in infected cells, however, these proteins were still 
detectable (Figure 2.10C).  
Similar chimeric proteins were constructed by inserting amino acids 1-24 and/or 
67-116 of Nef B.JRFL into a Nef C.BR92025 backbone (Figure 2.10A; CBC and 
BCBC). When either region was introduced on its own (Figure 2.10A; CBC or CB 
1), the resulting Nef proteins functioned at about 50% of Nef NL4.3, whereas 
when both regions were introduced (Figure 2.10A; BCBC) the resulting Nef 
protein downregulated MHC-I as efficiently as Nef B.JRFL (Figure 2.10B). In both 
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chimeras that contained amino acids 67-116 from Nef B.JRFL (Figure 2.10A; 
CBC and BCBC), there was a marked increase in protein expression as detected 
by western blot of pseudovirus infected Jurkat E6.1 T cells (Figure 2.10C). 
However, amino acids 1-24 did not appear to increase protein expression (Figure 
2.10C), highlighting the importance of the central region (amino acids 67-116) in 
the expression of Nef.  
 
Figure 2.10 Amino acids 1-24 and 67-116 contain the amino acid 
determinants of altered function and expression of Nef C.BR92025 
!"#$%
&!'(
)
*
*)*)
*)*
)*)
)*)*
*)+,
)*+,
!"
#$%
)*
)
*)
+,
&!
'(
) *)
*)
Į*)3 N'D
ĮȕDFWLQ
Į1HI N'D
N'D
* *)
*
)*
+,
)*
)*
Nef B
!'(+)
Nef B
,  ,,-
1HIDDSRVLWLRQ1/QXPEHULQJ

!"
!'(+*
!'(+)
!'(+)
!'(+*
!'(+)
Nef B
!'(+*
!'(+*
!'(+)
!'(+*
!'(+)
!'(+)
!'(+*
!'(+*(+*
!'(+*
!'(+*!'(+)
!'(+)
!'(+) !'(+)
!'(+)
    



)*)*
)*+,
*)*
*
*)*)
*)+,
)*)
)
&!'(
!"#$%
./*+0+'R1QUHJX2DWLRQ3((LFHQF\+45+R(+!"#$%+
!
'(
+*
RQ
VW
UX
FW
#"
$"
6666
QV QV
6666
  
114 
(A) Schematic of chimeric proteins of Nef B.JRFL with amino acids 67-116 
(BCB), 1-24 (CB 1) or both (CBCB) of Nef C.BR92025. Schematic of chimeric 
proteins of Nef C.BR92025 with amino acids 67-116 (CBC), 1-24 (BC 1) or both 
(BCBC) of Nef B.JRFL. Nef constructs were inserted into proviral vectors to 
produce pseudovirus. (B) Jurkat E6.1 T cells were infected with the pseudovirus 
lacking Nef expression (dNef; red) or expressing the indicated Nef construct and 
stained for surface MHC-I at 48 hours post-infection. MHC-I downregulation was 
measured by flow cytometry and calculated relative to NL4.3 (green) (n≥3, 
p<0.05). (C) Jurkat E6.1 T cells were infected with pseudovirus expressing the 
indicated Nef constructs and lysed at 48 hours post-infection. Lysates were 
analyzed for Nef, GFP and actin expression by western blot.  
2.3.10 Point mutations in C.BR92025 are located in highly 
conserved regions in HIV-1 Nef.  
Having identified the N-terminal 24 amino acids and central region 67-116 as 
containing the determinants of decreased function and expression of Nef 
C.BR92025, we next analyzed the amino acid sequence of these regions. Nef 
protein sequence alignments revealed point mutations in Nef C.BR92025 at 
positions 13 (W13R), 84 (A84V) and 92 (E92K) that were absent in the laboratory 
adapted subtype B strain NL4.3 (Figure 2.11A) and in all other subtype reference 
strains analyzed (Figure 2.1). To determine the prevalence of these point 
mutations across prominent HIV-1 group M subtypes, we constructed amino acid 
sequence logos of Nef for regions spanning residues 13, 84 and 92 from 
subtypes A1, B, C and D (Figure 2.11). These subtypes were selected due to 
their high global prevalence compared to other Group M subtypes (6). Sequence 
logos were constructed by selecting up to 10 sequences from each country that 
had Nef sequences available in the NIH Los Alamos HIV database (55). These 
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sequence logos revealed a high level of conservation of W13, A84, and K92 in 
other subtype C Nef sequences (Figure 2.11A) and across other prominent HIV-1 
subtypes (Figure 2.11B). When 4553 full-length Nef protein sequences from the 
NIH Los Alamos HIV database were queried W13, and A84 occurred at >99% 
frequency and K92 occurred at a frequency of 92.75%. However, the frequency 
for a basic residue at position 92 (K92 or R92) was 99.52%. 
 
NL4.3  MGGKWSKSSVIGWPAVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTAANNAACAWLEA 60
Consensus_C MGGKWSKSSIVGWPAVRERIRRTEPAAEGVGAASQDLDKHGALTSSNTATNNADCAWLEA 60
C.BR92025 MGNKWSKCSTVGRPAIRERMRR-APAAEGVGPASQDSDKYGALTSSSTPANNADCAWLEA 59
** ****.* :* **:***:**  ***:*** .*:* :*:**:***.* :*** ******
NL4.3 QE-EEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQG 119
Consensus_C QEEEEEVGFPVRPQVPLRPMTYKAAFDLSFFLKEKGGLEGLIYSKKRQEILDLWVYHTQG 120
C.BR92025 QQEEEEVGFPVRPQVPLRPMTYKAVVDLSFFLEEKGGLEGLIYSKKRQDILDLWVYNTQG 119
*: ******** ************..***.**:*********:*::**:*****:*.*** 
NL4.3 YFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPERE 179
Consensus_C  YFPDWQNYTPGPGVRYPLTFGWCFKLVPVDPREVEEANEGENNCLLHPMSQHGMEDEDRE 180
C.BR92025 YFPDWQNYTPGPGVRFPLTFGWCFKLVPVDPREVEEANTGENNSLLHPMSLHGMEDSHRE 179
***************:*******:*****:* :***** ***..****:* ***:* .**
NL4.3   VLEWRFDSRLAFHHVARELHPEYFKNC* 206
Consensus_C  VLKWKFDSHLARRHMARELHPEYYKDC* 207
C.BR92025 VLQWKFDSLLARRHMARELHPEYYKDC* 206
**:*:*** ** :*:********:*:**!
!"
#" !"#$%&'()* !"#$%&'(+ !"#$%&'(,
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Figure 2.11 Rare point mutations identified in the Nef protein of subtype C 
reference strain C.BR92025. 
(A) Clustal Omega was used to align protein amino acid sequences of Nef from 
the laboratory strain NL4.3, a subtype C consensus sequence from the NIH AIDS 
Los Alamos Database and the subtype C reference strain C.BR92025. Inset 
boxes show sequence logos with the size of the one letter amino acid code 
proportional to the frequency at which that amino acid is found at a given 
position. Black arrows indicate rare point mutations found in the subtype C 
reference strain C.BR92025. (B) Sequence logos from globally prevalent HIV-1 
subtypes A1, B and D. Black arrows indicate Nef amino positions 13, 84, and 92. 
“*” indicates identical residues, “:” indicates conserved residues, “.” indicates 
semiconserved residues. Residues in blue are acidic amino acids, residues in 
pink are basic amino acids, residues in red are uncharged non-polar amino acids 
and those in green are uncharged polar amino acids. 
2.3.11 Decreased expression and function of Nef C.BR92025 is 
specific to this HIV-1 reference strain.  
Due to the rare nature of the W13R, A84V and K92E mutations identified in Nef 
C.BR92025 we wanted to see if the decreased function and expression we 
observed (Figure 2.2 and 2.3) was unique to this reference strain. To do so, we 
replicated our assays of Nef-mediated CD4 (Figure 2.2) and MHC-I (Figure 2.3) 
downregulation, but this time included a subtype C consensus Nef sequence 
obtained from the NIH Los Alamos HIV database (sequence can be seen in 
Figure 2.11A). As before, we analyzed CD4 downregulation in CD4+ HeLa cells 
transfected with plasmids encoding Nef-EGFP fusion proteins with Nef from 
NL4.3, consensus C, C.BR92025 or B.JRFL. As mentioned above, these 
constructs allowed us to analyze CD4 downregulation independent of HIV-1 Env 
and Vpu, which can also downregulate CD4 (24). In accordance with our initial 
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test of CD4 downregulation (Figure 2.2), CD4+ HeLa cells transfected with Nef 
C.BR92025-EGFP showed a significant decrease in CD4 downregulation relative 
to NL4.3 (Figure 2.12A). However, we now demonstrate that this decrease in 
function is specific to this subtype C reference strain as Nef Consensus C-EGFP 
displayed equivalent CD4 downregulation relative to NL4.3 (Figure 2.12A). As 
before, CD4 was efficiently downregulated from CD4+ HeLa cells transfected with 
Nef B.JRFL-EGFP (Figure 2.12A). Furthermore, when transfected cells were 
analyzed for protein expression by western blot, we once again observed 
reduced Nef protein levels in cells expressing Nef C.BR92025-EGFP, but not in 
cells transfected with Nef Consensus C-EGFP (Figure 2.12B). These findings 
suggest that the impaired function and expression of Nef C.BR92025 is specific 
to this reference strain. 
We next investigated Nef-mediated CD4 downregulation in a T cell line to verify 
that the impairment of Nef C.BR29025 in this key function occurs in the 
physiological host cells of HIV-1. In order to delineate the effects of HIV-1 Vpu, 
we inserted the various Nef proteins into NL4.3-based lentiviral vectors that 
lacked expression of Vpu (dVpu). Jurkat E6.1 T cells infected with pseudovirus 
made from these vectors demonstrated a similar pattern of CD4 downregulation 
to that in CD4+ HeLa cells, with Nef C.BR92025 unable to effectively 
downregulate CD4 (Figure 2.12C). Strikingly, this impairment in CD4 
downregulation is much more evident when Nef C.BR92025 is expressed in the 
absence of NL4.3 Vpu, suggesting Vpu partially masks this defect in Nef 
C.BR9025 function. As with the results from CD4+ HeLa cells (Figure 2.12A), 
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CD4 was efficiently downregulated from the cell surface of Jurkat E6.1 T cells 
infected with pseudovirus expressing Nef Consensus C and Nef B.JRFL in the 
presence or absence of Vpu (Figure 2.12C). This once again highlights the 
functional impairment of Nef C.BR92025 in contrast to a subtype C consensus 
Nef.   
To test Nef-mediated MHC-I downregulation we used the NL4.3-based, 
replication incompetent lentiviral vectors described earlier (Figure 2.3A). As 
observed prior (Figure 2.3), Nef C.BR92025 demonstrated impaired MHC-I 
downregulation in pseudovirus infected Jurkat E6.1 T cells, barely above the 
levels of a lentiviral vector lacking the Nef protein (dNef), which served as our 
negative control (Figure 2.12D). Jurkat E6.1 T cells infected with lentiviral vectors 
expressing consensus C Nef showed levels of MHC-I downregulation equivalent 
to NL4.3 and Nef B.JRFL (Figure 2.12D) further demonstrating the observed 
defects in Nef C.BR92025 function are specific to this reference strain. Indeed, 
when pseudovirus infected Jurkat E6.1 T cells were analyzed for Nef expression 
by western blot, consensus C Nef was readily detectable, whereas we were once 
again unable to detect a strong band corresponding to Nef C.BR92025  (Figure 
2.12E). To independently confirm the reduced expression of Nef C.BR92025, we 
constructed alternative vectors that encoded Nef C.BR92025 and Nef B.JRFL 
fused to EGFP. When Jurkat E6.1 T cells infected with these vectors were 
analyzed by flow cytometry, those expressing Nef C.BR92025 had a clear 
reduction in EGFP fluorescence, indicative of reduced Nef-EGFP protein levels 
(Figure 2.12F).  
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Figure 2.12 Impaired function and expression of Nef C.BR92025 is unique 
to this reference strain. 
(A) CD4+ HeLa cells were transfected with plasmids encoding EGFP fusion 
proteins from the laboratory strain NL4.3, Consensus C Nef, or Nef from the 
reference strains B.JRFL or C.BR92025 as well as a non-fused EGFP as a 
negative control. Cell surface levels of CD4 were measured using flow cytometry 
with an APC conjugated anti-CD4 antibody 24 hours post-transfection. 
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Downregulation efficiency relative to NL4.3 was calculated using mean 
fluorescence intensity (p<0.05, n=3). (B) Cell lysates from transfected CD4+ 
HeLa cells were collected and lysed 24 hours post-infection. Lysates were 
analyzed for fusion protein expression by western blot using an anti-GFP 
antibody. (C) Jurkat E6.1 T cells were infected using lentiviral vectors either 
expressing NL4.3 Vpu or not (dVpu) in addition to expressing Nef from the 
laboratory strain NL4.3, lacking Nef expression (dNef), Consensus C Nef, or Nef 
from the reference strains B.JRFL or C.BR92025. Cell surface levels of CD4 
were measured using flow cytometry with an APC conjugated anti-CD4 antibody 
48 hours post-infection. Downregulation efficiency relative to NL4.3 was 
calculated using mean fluorescence intensity (p<0.05, n=3). (D) Jurkat E6.1 T 
cells were infected with lentiviral vectors expressing Nef from the laboratory 
strain NL4.3, lacking Nef expression (dNef), Consensus C Nef, or Nef from the 
reference strains B.JRFL or C.BR92025. Cell surface levels of MHC-I were 
measured by flow cytometry 48 hours post-infection with a pan-specific anti-
MHC-I primary antibody (W6/32) and an Alexa Fluor® 647 conjugated secondary 
antibody. Downregulation efficiency relative to NL4.3 calculated using mean 
fluorescence intensity (p<0.05, n=4). (E) Uninfected Jurkat E6.1 cells (UI) or cells 
infected with the lentiviral vectors described above expressing non-fusion Nef 
proteins were collected and lysed 48 hours post-infection. Lysates were analyzed 
for Nef, EGFP and actin protein levels by western blot. (F) Jurkat E6.1 cells were 
infected with lentiviral vectors encoding EGFP fused to the Nef proteins from the 
reference strains B.JRFL and C.BR92025. A representative histogram from three 
independent experiments is shown 
2.3.12 C.BR2025 undergoes increased protein turnover.  
As we were previously unable to demonstrate Nef C.BR92025 being 
preferentially targeted for a cellular degradation pathway (Figure 2.5 and 2.6) we 
posited that Nef C.BR92025 was undergoing accelerated degradation relative to 
Nef NL4.3 and Nef B.JRFL. In order to investigate the rate of Nef protein turnover 
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we performed a pulse-chase experiment with Jurkat E6.1 cells infected with 
lentiviral vectors expressing the high-expressing Nef B.JRFL or the low-
expressing Nef C.BR92025. Infected cells were labeled with 35S-
Methionine/Cysteine for 30 min (pulse) and then chased in unlabeled media for 
up to 240 min. Subsequently, Nef protein was purified by immunoprecipitation 
using anti-Nef coated agarose beads and Nef protein levels were analyzed by 
autoradiography. Interestingly, the amount of Nef C.BR92025 protein remaining 
after a 240 min chase period was significantly lower than Nef B.JRFL (Figure 
2.13A). The data from the pulse-chase experiments were fitted with a one-phase 
decay non-linear regression, whose slope was used to calculate the half-life of 
the Nef proteins (Figure 2.13B). The regression analysis revealed that Nef 
C.BR92025 was removed from infected cells almost 4 times faster than Nef 
B.JRFL (half-life of 2.2 hours vs. 8.0 hours).  
 
Figure 2.13 Nef C.BR92025 undergoes increased protein turnover. 
(A) Jurkat E6.1 T cells were infected with lentiviral vectors encoding Nef from the 
reference strains B.JRFL or C.BR92025. At 48 hours post-infection a 35S pulse-
chase was performed. Cells were lysed and immunoprecipitated using an anti-
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Nef antibody. Immunoprecipitated proteins were separated by SDS-PAGE and 
imaged by autoradiography. A representative image from three independent 
experiments is shown. (B) The intensities of bands corresponding to 
immunoprecipitated Nef were determined using ImageQuant 5.2 software and 
used to calculate the amount of protein remaining relative to time point 0. One-
phase non-linear regression was used to calculate protein half-life. Dotted black 
line represents 50% of the initial protein remaining (p<0.05, n=3). 
2.3.13 Rare point mutations in Nef C.BR92025 affect protein 
expression and decreased function.  
To determine the role rare point mutations identified in Nef C.BR92025 play in 
the observed decrease in function and protein expression, we carried out a 
mutational analysis of Nef C.BR92025. Introduction of single point mutations in 
Nef C.BR92025 that revert the amino acids at positions 13, 84, and 92 to the 
conserved residues normally found in Nef (R13W, V84A and K92E) each 
resulted in significant, but incomplete rescue of Nef-mediated MHC-I 
downregulation in pseudovirus infected Jurkat E6.1 T cells (Figure 2.14A). In 
addition to MHC-I downregulation, we analyzed the mutants for Nef expression 
by western blot. Interestingly, reversion of position 84 from a valine, as found in 
C.BR92025, to the conserved alanine was sufficient to rescue expression of Nef 
C.BR92025 despite not fully restoring Nef function (Figure 2.14B). To fully 
restore the function of Nef C.BR92025 to the levels of Nef NL4.3, a combination 
of mutations at position 13 and either position 84 (CR13W V84A) or 92 (CR13W E92K) 
were required (Figure 2.14A).  
In addition to the effects of these rare point mutations on the function of Nef 
C.BR92025, we were also interested in determining if mutations at residues 13, 
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84 and 92 were sufficient to disrupt function and expression of our high 
expressing subtype B reference strain, Nef B.JRFL. To achieve this we 
performed a reciprocal mutational analysis, where we mutated residues 13, 84 
and 92 to the amino acids found in Nef C.BR92025, W13R, A84V, and K92E, 
respectively. Similar to our results with Nef C.BR92025, introduction of single 
point mutations at positions 13 and 84 only partially disrupted the function of Nef 
B.JRFL in pseudovirus infected E6.1 T cells, however, mutation at position 92 did 
not affect function in Nef B.JRFL (Figure 2.14C). Interestingly, a single point 
mutation at position 84 from alanine to valine was sufficient to markedly decrease 
the amount of Nef protein detected by western blot (Figure 2.14D; BA84V), 
mirroring the results from our mutational analysis of Nef C.BR92025 (Figure 
2.14B; CV84A). A combination of mutations at positions 13 and 84 were required 
to fully disrupt expression and function of Nef B.JRFL (Figure 2.14C, D; BW13R 
A84V). A combination of mutations at position 13 and 92 only partially disrupted 
expression and function (Figure 2.14C, D; BW13R K92E), which is in agreement with 
our results that showed the single K92E mutation in Nef B.JRFL did not impair 
function or expression (Figure 2.14C, D; BK92E). These results suggest a critical 
role of residues W13 and A84 (and to a lesser extent E92) in the function of the 
HIV-1 Nef protein, with residue A84 being responsible for controlling protein 
expression (Figure 2.14E).  
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Figure 2.14 Residues 13, 84 and 92 are important for expression and 
function of HIV-1 Nef. 
(A) Jurkat E6.1 T cells were infected using lentiviral vectors expressing Nef from 
the laboratory strain NL4.3, lacking Nef expression (dNef), Nef from the 
reference strain C.BR92025 as well as various C.BR92025 mutants. Cell surface 
levels of MHC-I were measured by flow cytometry 48 hours post-infection with a 
pan-specific anti-MHC-I primary antibody (W6/32) and an Alexa Fluor® 647 
conjugated secondary antibody. Downregulation efficiency relative to NL4.3 was 
calculated using mean fluorescence intensity (p<0.05, n=4). (B) Cell lysates from 
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Jurkat E6.1 T cells infected with the lentiviral vectors described above were 
collected and lysed 48 hours post-infection. Lysates were analyzed for Nef, 
EGFP and actin protein levels by western blot. (C) and (D) The same 
experiments described in (A) and (B) were conducted using lentiviral vectors 
expressing Nef from the reference strain B.JRFL as well as various B.JRFL 
mutants. (E) A summary of results from experiments with lentiviral vectors 
harboring combination mutants in C.BR92025 (CR13W V84A) and B.JRFL (BW13R 
A84V K92E) from (A) and (C), respectively.  
2.3.14 A point mutation at residue 84 results in a rapid decrease in 
Nef C.BR92025 protein levels.  
Our mutational analysis suggests that proper and sustained expression of the 
HIV-1 Nef protein requires an alanine at position 84. In order to support these 
findings we conducted additional pulse-chase experiments in Jurkat E6.1 T cells 
using lentiviral vectors encoding Nef B.JRFL, Nef C.BR92025 or those Nef 
proteins harboring point mutations at position 84. As described above, Nef 
C.BR92025 protein levels decrease at a faster rate than Nef B.JRFL (Figure 
2.13). Mutation of the valine at position 84 in Nef C.BR92025 to an alanine 
rescues the protein from rapid removal, more than doubling its half-life (Figure 
2.15A, B; 2.2 hours to 4.6 hours). Similarly, mutation of the alanine at position 84 
in Nef B.JRFL to a valine is sufficient to dramatically increase the rate at which 
the protein is removed from cells, shortening its half-life to almost a quarter of the 
wild-type Nef B.JRFL (Figure 2.15A, B; 8.0 hours to 2.1 hours). The importance 
of residue 84 is further highlighted by the complete disruption of MHC-I 
downregulation through the introduction of a large bulky tryptophan residue into 
the otherwise highly functional Nef B.JRFL (Figure 2.15C). These findings 
  
126 
support the importance of residue 84 of HIV-1 Nef, suggesting that mutating Nef 
A84 away from the highly conserved alanine is sufficient to disrupt expression of 
HIV-1 Nef. 
 
Figure 2.15 Alanine at position 84 in HIV-1 Nef is critical for sustained 
expression. 
(A) Jurkat E6.1 T cells were infected with lentiviral vectors encoding Nef from the 
reference strains B.JRFL or C.BR92025 as well as mutants at position 84 
(B.JRFLA84V and C.BR92025V84A). At 48 hours post-infection a 35S pulse-chase 
was performed. Cells were lysed and immunoprecipitated using an anti-Nef 
antibody. Immunoprecipitated proteins were separated by SDS-PAGE and 
imaged by autoradiography. A representative image of three independent 
experiments is shown. (B) The intensities of bands corresponding to 
immunoprecipitated Nef were determined using ImageQuant 5.2 software and 
used to calculate the amount of protein remaining relative to time point 0. One-
phase non-linear regression was used to calculate protein half-life. Dotted black 
line represents 50% of the initial protein remaining (p<0.05, n=3). (C) Jurkat E6.1 
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T cells were infected using lentiviral vectors expressing Nef from the laboratory 
strain NL4.3, lacking Nef expression (dNef), Nef from the reference strains 
B.JRFL or C.BR92025 as well as B.JRFL mutants at residue 84 (BA84V and 
BA84W). Cell surface levels of MHC-I were measured by flow cytometry 48 hours 
post-infection with a pan-specific anti-MHC-I primary antibody (W6/32) and an 
Alexa Fluor® 647 conjugated secondary antibody. Downregulation efficiency 
relative to NL4.3 calculated using mean fluorescence intensity (p<0.05, n=4).    
2.4 Discussion 
In the early years of the HIV/AIDS epidemic, the viral isolates used for research 
studies were predominantly from group M subtype B due to the very high 
prevalence of subtype B in North America and Western Europe, where much of 
the early research was taking place (7, 8). As the extensive genetic diversity of 
HIV-1 became apparent, there was a need to develop a panel of full-length 
reference strains for the various HIV-1 subtypes (36, 56). These reference strains 
were selected based on availability of full-length molecular clones and no 
obvious history of recombination. As such, they were thought to be pure subtype 
strains and could serve as representative of the various group M subtypes. 
Despite the existence of these panels, there still remains very little information on 
the function of HIV-1 proteins from group M subtypes that have lower global 
prevalence.  
We aimed to determine if the genetic variability inherent in HIV-1 impacted the 
function of Nef, an HIV-1 accessory protein that plays a major role in 
pathogenesis (57). Our functional analysis revealed three reference strains, 
C.BR92025, G.FI93HH8793 and H.BE93VI997 that had decreased levels of 
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expression and consequently displayed significantly impaired function, as 
measured by CD4 (Figure 2.2) and MHC-I (Figure 2.3) downregulation efficiency. 
This decreased expression was confirmed to be at the protein level (Figure 2.4) 
and was not reversible by chemical inhibition of the proteasome (Figure 2.5).   
As HIV-1 Nef exerts its function through establishing a network for protein:protein 
interactions with host proteins throughout infected cells, proper subcellular 
localization of this accessory protein is vital (58). Indeed, when the N-terminal 
myristoylation site on Nef, which targets it to lipid membranes, is mutated, Nef is 
rendered essentially useless (59). Therefore, we investigated the subcellular 
localization of the low expressing reference strains to determine if we could 
identify the source of their functional and expression impairment. Strikingly, Nef 
proteins from subtype G and H reference strains displayed a unique subcellular 
distribution that was markedly different from all other Nef proteins analyzed 
(Figure 2.4). Upon further investigation, these atypically distributed Nef proteins 
appeared to co-localize with mitochondria (Figure 2.7). To the best of our 
knowledge, there have been no previous reports of HIV-1 Nef interacting with 
mitochondria, however viral proteins from human cytomegalovirus and hepatitis 
C have been shown to localize to mitochondrial membranes (60). Interestingly, it 
has been documented that mitochondria are able to respond to external stresses, 
such as viral infection, and initiate mitophagy (self degradation of mitochondria 
through autophagy) (61). This process could explain the decreased levels of Nef 
from subtype G and H, but this is just speculation, with many more investigations 
needed to support such a mechanism. Indeed, the increased co-localization with 
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mitochondria of Nef from subtype G and H reference strains was only observed 
when isolating the periphery of transfected cells for image quantification (Figure 
2.7C, D). Furthermore, mitophagy results in degradation via the lysosome, which 
we were unable to detect in our assays. A more objective method would be 
needed to confirm this unique finding.  
Our further investigations focused on the other low expressing reference strain 
C.BR92025. The reference strain C.BR29025 was isolated from a 23-year-old 
male hemophilic patient from Brazil in 1992 and later deposited into the NIH Los 
Alamos HIV database (62). Upon phylogenic analysis, the full-length C.BR92025 
clustered with other subtype C reference strains, suggesting that it was not 
dramatically different from other subtype C viruses (56, 62, 63). These reference 
strains were selected to allow for intersubtype comparison of HIV-1 proteins, 
specifically the lesser-studied regulatory proteins; however, they were selected 
based on availability of full-length sequences without verification that all proteins 
functioned properly (56).  
The clinical progression of this patient is not well documented, but at the time of 
sampling he had active viral replication with detectable viral titers and p24 levels 
(62). In addition, C.BR92025 has been used as a reference strain and is 
replication-competent in vitro (64, 65). However, given the importance of HIV-1 
Nef for disease progression, decreased expression of this key accessory protein 
should result in decreased viral replication. Indeed, when C.BR92025 has been 
used as a reference strain, it has demonstrated decreased fitness compared to 
the laboratory strain HIV-1 BaL (65). Interestingly, in competition assays to 
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determine viral fitness, C.BR92025 was outcompeted by viral isolates from long-
term survivors (65). These findings demonstrate that C.BR92025 has decreased 
replicative capacity, but the authors did not explore these differences further, so it 
is not possible to attribute defects in replication directly to Nef. Analysis of Nef 
sequences from a separate cohort comparing elite controllers to chronic 
progressors showed no increased prevalence of mutations at residues 13, 84 or 
92 between the two groups (66). However, as this cohort was limited to 45 
viruses from each group, a much larger database is needed to make definitive 
conclusions on the role of these mutations in disease progression.  
Given the high mutation rate of HIV-1 and the strong immunogenicity of the Nef 
protein (67), highly conserved residues suggest functional and/or structural 
importance. As a result, we were intrigued to discover the subtype C reference 
strain C.BR92025 contained three rare residues at positions 13, 84 and 92 
(NL4.3 numbering), which we identified through extensive chimeric protein 
analysis (Figure 2.9 and 2.10). Across every group M subtype found in the NIH 
Los Alamos HIV Database, these residues exist almost exclusively as a 
tryptophan (W13), alanine, (A84) and a basic amino acid (K/R92), whereas in the 
subtype C reference strain C.BR92025, these residues are an arginine (R13), 
valine (V84) and glutamic acid (E92) (Figure 2.11). To determine if the functional 
impairment of Nef C.BR92025 was unique to this reference strain, we once again 
focused on Nef-mediated MHC-I and CD4 downregulation, two well-documented 
Nef functions (16-20). The impairments in both MHC-I and CD4 downregulation 
were not found in a consensus subtype C protein (Figure 2.11A, D), nor Nef 
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NL4.3 and a Nef protein the subtype B reference strain B.JRFL, as documented 
earlier (Figure 2.2 and 2.3). Furthermore, decreased protein expression was not 
seen in cells infected or transfected with Nef from consensus subtype C (Figure 
2.11B, E). These findings further support the hypothesis that the rare point 
mutations identified in Nef C.BR92025 were the source of its decreased function 
and expression. This was of interest because the affected residues lie outside 
the well-described motifs in Nef known to be required for proper receptor 
downregulation. Of the three residues, only W13 has been implicated in MHC-I 
downregulation (35). The importance of CD4 downregulation for HIV-1 replication 
is highlighted by the redundant functions of the viral proteins Nef, Vpu and Env, 
all of which can decrease cell surface levels of CD4 in infected cells (15, 24). 
This functional redundancy may have been enough to compensate for the 
defects in Nef that we have identified and allow this strain to establish an initial 
infection despite its decreased replication efficiency (65). 
Minimal literature exists on naturally occurring residues altering expression of 
HIV-1 Nef. Therefore we decided to explore the low expressing Nef C.BR92025 
further. Pulse chase analysis revealed that Nef C.BR92025 has a half-life that is 
little over a quarter of the high expressing Nef B.JRFL (2.2 hours vs. 8.0 hours) 
(Figure 2.13). This rapid rate of protein turnover explains why Nef C.BR92025 is 
barely detectable by western blot despite mRNA levels equal to Nef B.JRFL 
(Figure 2.4). Interestingly, at the 0 min chase time point, the intensity of the band 
corresponding to Nef C.BR92025 exceeds that of Nef B.JRFL. This increased 
intensity may be due to the presence of two additional sulfur containing 
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methionine residues in Nef C.BR92025 relative to Nef B.JRFL, allowing for 
increased incorporation of [35S]. Regardless, this time point should capture all 
newly synthesized protein produced during the 30 min pulse, with no time for 
protein turnover, suggesting that Nef C.BR92025 is being continually produced at 
a high level, but is removed from cells very efficiently. This efficient removal of 
Nef from infected cells results in increased surface levels of MHC-I and CD4.   
To confirm the role of the rare point mutations in the observed decreases in Nef 
function and protein levels we conducted a mutational study in both subtype B 
and C reference strains B.JRFL and C.BR92025, respectively. Although our 
findings were not completely complementary between the high expressing Nef 
B.JRFL and the low expressing Nef C.BR92025, both sets of experiments found 
an important role for W13 and A84 for expression and function of HIV-1 Nef. 
Specifically, W13 appears to be required for efficient MHC-I downregulation as a 
W13R mutation significantly reduces MHC-I downregulation efficiency of Nef 
B.JRFL, whereas a R13W mutation rescues the MHC-I downregulation efficiency 
of Nef C.BR92025. It is important to note that the role of W13 appears to be 
independent of protein expression levels as these mutations do not alter 
detection of the respective proteins by western blot (Figure 2.14B, D).  However, 
an A84V mutation was sufficient to markedly decrease Nef protein levels in the 
high expressing Nef B.JRFL, while a V84A mutation was sufficient to restore Nef 
to detectable levels in the low expressing Nef C.BR92025. These changes in 
protein levels were accompanied by corresponding changes in MHC-I 
downregulation, suggesting altered protein levels played a role in the impairment 
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in Nef function. The role of the third rare point mutation, E92, is less clear. Our 
mutational studies in Nef C.BR92025 suggest an important role for K92 in 
function and expression of Nef as the restorative E92K mutation partially rescues 
function and expression of Nef C.BR92025. However, in the context of Nef 
B.JRFL, the K92E mutation does not significantly impact function and 
expression.  
Our findings that W13 plays an important role in MHC-I downregulation are in 
agreement with a previous structural study of Nef in complex with MHC-I and AP-
1 (35). This model suggests an intramolecular interaction of W13, located in the 
N-terminal alpha helix, with a hydrophobic pocket in the core of Nef (Figure 
2.16A). This docking of the N-terminal helix is thought to be required for proper 
positioning of Nef at membranes allowing for the formation of the Nef, MHC-I and 
AP-1 complex. This was supported by a W13A mutation that disrupted MHC-I 
downregulation and the ability of Nef to pull-down AP-1 in vitro (35). The 
presence of the charged arginine residue at positions 13 in Nef C.BR92025 
would presumably disrupt this intramolecular interaction (Figure 2.16A), 
explaining the observed decrease in MHC-I downregulation.  
To our knowledge, this is the first report of a role for A84 in proper expression of 
HIV-1 Nef and therefore we wondered if the altered rate of protein turnover we 
observed were attributable to this residue. Pulse-chase analysis of cells infected 
with lentiviral vectors encoding Nef B.JRFL, C.BR92025 and their corresponding 
mutants at position 84 revealed that these single amino acid mutations were 
sufficient to alter the rate of protein turnover. When an A84V mutation was 
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introduced into Nef B.JRFL, its pulse-chase profile shifted to resemble Nef 
C.BR92025, whereas a V84A mutation introduced into Nef C.BR92025 shifted its 
pulse-chase profile to resemble Nef B.JRFL (Figure 2.15A, B).  
These findings were particularly interesting as alanine and valine are quite similar 
in structure, with their side chains differing by just two methyl groups. Analysis of 
previously reported structural models of HIV-1 Nef indicate residue 84 is located 
within alpha helix-2 and is orientated towards the protein core (Figure 2.16B) 
(35). As such the increased size of the valine side chain may cause 
intramolecular steric hindrances that could affect Nef C.BR92025 structure. This 
hypothesis is supported by a tryptophan mutant (A84W), which introduces a 
large bulky residue and more severely disrupted Nef receptor downregulation 
(Figure 2.15C). Accumulated Nef C.BR92025 could be targeted for removal from 
the cell by the various protein degradation pathways (49, 68), resulting in the 
observed increase in protein turnover.  
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Figure 2.16 Potential intramolecular interactions of Nef W13 and A84. 
Structural model of HIV-1 Nef (PDB ID: 4EN2). (A) The N-terminal alpha helix of 
HIV-1 Nef is depicted as a cartoon structure in green with the side chain of W13 
shown in orange. The remaining Nef structure is shown using surface 
representation with electrostatic potentials depicted in red (negative charge) and 
blue (positive charge). Zoomed in image showing W13 (top right) and W13R 
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mutant (bottom right). (B) Nef alpha helix-2 is depicted as a cartoon structure in 
green with the side chain of A84 shown in orange. The remaining Nef structure is 
shown using surface representation with electrostatic potentials depicted in red 
(negative charge) and blue (positive charge). Zoomed in image showing A84 (top 
right) and A84V mutant (bottom right). (C) The amino acid sequence of NL4.3 
Nef is shown with the N-terminal alpha helix and alpha helix-2 depicted using the 
colors described in (A) and (B). 
The conflicting results from the mutational studies in regard to residue 92 
preclude conclusions on its role in Nef function. The findings from our Nef 
B.JRFL mutational studies that residue 92 did not affect MHC-I downregulation is 
in agreement with a recent report that mutation of the KEK94 motif failed to 
disrupt MHC-I downregulation (69). In addition, an earlier study demonstrated 
that K92 was dispensable for Nef-mediated CD4 downregulation (70), further 
suggesting a limited role in Nef function.  
Interestingly, there are a number of MHC-I epitopes that span residue 84, 
suggesting strong immune pressure against consensus protein sequences in that 
region (67, 71-73). Despite increased immune pressure, the presence of an 
alanine at position 84 appears to be under positive selection, further supporting 
its importance in function and/or expression of Nef (71, 72). This study adds to 
other protein-wide screens of polymorphisms to assess genetic robustness of 
HIV-1 proteins such as integrase (74) and capsid (75). Identification of highly 
conserved residues that appear to have strict structural constraints may be useful 
for the development of T cell based vaccines that include Nef as a target for CTL 
responses.  
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In conclusion, we have identified a subtype C reference strain deposited in the 
NIH Los Alamos HIV Database that contains three point mutations at otherwise 
highly conserved residues in HIV-1 Nef. We have shown that the presence of 
these point mutations is responsible for decreased function and expression of the 
viral protein. Of note, an alanine at residue 84 located in Nef alpha helix-2 
appears to be essential for proper expression of HIV-1 Nef. The importance of 
residue 84 in Nef biology provides an additional molecular target for disrupting 
Nef function, an anti-HIV-1 approach that has gained interest in both cure and 
treatment fields (76, 77).     
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Chapter 3  
3 Elucidating the mechanistic details of SERINC5 
antagonism by HIV-1 Nef 
3.1 Introduction 
In order for HIV-1 to successfully replicate in host cells, it must not only 
overcome the adaptive immune response, but also a collection of anti-viral host 
proteins known as restriction factors (1, 2). Examples of restriction factors include 
apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G 
(APOBEC3G) and bone marrow stromal cell antigen 2 (BST2), also termed 
tetherin. APOBEC3G is a cytidine deaminase that is packaged into HIV-1 virions 
and results in cytidine to uracil mutations in newly reverse transcribed viral DNA, 
rendering the encoded HIV-1 proteins non-functional (3, 4). By binding to the 
HIV-1 RNA genome, APOBEC3G also inhibits the binding of reverse 
transcriptase, decreasing the subsequent production of viral DNA (5). Tetherin is 
a cell surface protein that has an N-terminal transmembrane domain and a C-
terminal glycosylphosphatidylinositol (GPI) membrane anchor. In HIV-1 infected 
cells, the N-terminus of tetherin is embedded in the cellular lipid bilayer, while the 
C-terminus is anchored in the lipid bilayer of budding virions through the GPI 
domain. By simultaneously anchoring itself in both the host cell and virion, 
tetherin acts to tether budding virions to the infected cell, preventing their release 
and limiting the intercellular spread of HIV-1 (6). HIV-1 is able to replicate in the 
presence of these restriction factors due to the activity of the viral accessory 
proteins Vif and Vpu. Indeed, Vif counteracts the anti-HIV-1 activity of 
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APOBEC3G by inducing ubiquitination and subsequent proteasomal degradation 
of APOBEC3G, preventing its packaging in virions (4). Similar to Vif, Vpu targets 
tetherin for degradation by inducing its ubiquitination. Furthermore, Vpu hijacks 
the trafficking of tetherin, rerouting it from the cell surface to the trans-Golgi 
network (TGN). Both degradation and rerouting of tetherin deplete the amount of 
this restriction factor on the cell surface, allowing budding virions to be released 
and increasing the spread of HIV-1 (6).  
The anti-restriction factor activity of Vif and Vpu highlights the ability of HIV-1 to 
utilize the functional flexibility of its accessory proteins to evolve mechanisms to 
overcome host cell barriers to replication. The lentiviral accessory protein Nef is 
known to counteract host restriction factors in the closely related simian 
immunodeficiency virus (SIV), but HIV-1 Nef had not been shown to counteract a 
host restriction factor until very recently (7).  
Nef has long been known to increase the infectivity of HIV-1 virions in vivo, but 
the mechanism used by Nef to achieve this increased infectivity has eluded 
researchers for decades (8, 9). However, the recent discovery of the restriction 
factor serine incorporator 5 (SERINC5) and its reported antagonism by Nef has 
established the key player involved in this novel Nef function. Indeed, when cells 
are infected with HIV-1 that is mutated such that it does not express Nef, 
SERINC5 is located at the cell surface and incorporated into the viral membrane 
during the viral budding process. Through an as of yet undetermined mechanism, 
virion-resident SERINC5 molecules interfere with the fusion of virions with host 
cells and the subsequent release of viral contents into the cytoplasm. By 
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downregulating SERINC5 from the cell surface, Nef limits the incorporation of 
SERINC5 in HIV-1 virions, increasing their infectivity and the spread of HIV-1 in 
infected patients (10, 11).   
Prior to the identification of SERINC5 as a novel HIV-1 restriction factor there 
was limited research on the physiological role of SERINC5. SERINC5, also 
referred to as C5orf12, is a multipass transmembrane protein with 10 
transmembrane domains (12). Studies of the rat orthologue of SERINC5 have 
implicated this protein in the biosynthesis of the serine containing lipids 
phosphatidylserine and sphingolipids. SERINC5 may act as a scaffold protein at 
the plasma membrane, allowing for the assembly of lipid synthesizing protein 
complexes (13).  
Following the identification of SERINC5 as an HIV-1 restriction factor, there have 
been studies into the evolution of SERINC5 antagonism by Nef (14, 15), the 
mechanism of SERINC5 viral restriction (16-20) and the mechanism by which 
Nef antagonizes SERINC5 (21, 22). These studies have increased our 
understanding of the implications of this function of Nef, however, there remains 
multiple aspects of this interaction that remain unknown. Mutational studies have 
implicated the trafficking protein AP-2 in the downregulation of SERINC5 (10, 11, 
16), however the direct interaction motifs involved in Nef-mediated SERINC5 
downregulation have not been fully described. Most studies have focused on the 
impact of these mutations on HIV-1 infectivity rather than investigating the 
Nef:SERINC5 interaction directly. Indeed, only recently was it demonstrated that 
Nef forms a complex with SERINC5 in cells (22). Additionally, domain-swapping 
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studies have shown that the fourth intracellular loop in SERINC5 is required for 
its anti-infectivity effects, however, it is not known if this intracellular loop is 
involved in a Nef:SERINC5 interaction (21).  
In addition to elucidating details of Nef-mediated SERINC5 downregulation, 
these recent studies have also created some confusion. Of particular interest is 
the ultimate fate of downregulated SERINC5 in infected cells. There is 
compelling evidence suggesting that SERINC5 downregulation is mechanistically 
similar to Nef-mediated CD4 downregulation with both Nef functions involving an 
AP-2 mediated trafficking pathway (10, 14, 16). Nef-mediated CD4 
downregulation relies on interactions with AP-2 and the beta subunit of the 
coatomer COPI to traffic CD4 to lysosomes for degradation (23). Initial studies 
demonstrating the requirement for AP-2 in Nef-mediated SERINC5 
downregulation would suggest a similar fate to CD4. However, earlier studies 
concluded that SERINC5 is not degraded following its downregulation and 
instead cell surface levels of SERINC5 are decreased while total cellular levels 
remain unchanged (10, 11, 16). This is contrary to the recent findings of Shi, J. et 
al., who investigated the trafficking pathway that SERINC5 undertakes following 
its downregulation and demonstrated sorting of SERINC5 into the 
aforementioned degradative lysosomal compartments (22).  
Furthermore, these initial studies have largely focused on laboratory strains of 
HIV-1 Nef or have used well described reference sequences. This approach is 
valuable to establish the breadth of this Nef function and potential differences 
between HIV-1 subtypes. This has allowed researchers to demonstrate that 
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SERINC5 downregulation is a conserved function of Nef and may play a role in 
the interspecies spread of SIVs (14). However, these previous findings do not 
provide a clear picture of the variability of Nef-mediated SERINC5 
downregulation and the importance of this function in the pathogenicity of Nef.   
HIV-1 Nef has evolved to be a highly multifunctional protein, capable of 
mediating numerous protein-protein interactions. The recent discovery of 
SERINC5 is just the latest example of how Nef modifies the cellular architecture 
of infected cells to best suit HIV-1 replication. The significant role Nef plays in 
HIV-1 disease progression necessitates a comprehensive understanding of the 
interactions mediated by Nef and their consequences. Herein, we have utilized 
the biochemical technique bimolecular fluorescence complementation (BiFC) to 
confirm the interaction of HIV-1 Nef with the restriction factor SERINC5 and used 
mutational analysis to identify genetic determinants of this interaction in both 
proteins. We also used BiFC to outline a detailed trafficking pathway used by Nef 
to downregulate SERINC5 and support the findings that SERINC5 is ultimately 
sorted into a degradative compartment. Finally, we analyzed the downregulation 
of SERINC5 by 15 patient derived nef sequences and demonstrate that 
SERINC5 downregulation is highly variable and more sensitive than CD4 
downregulation to differences in Nef expression. These findings enhance our 
understanding of how Nef is able to antagonize the restriction factor SERINC5, 
allowing for optimal HIV-1 infectivity.     
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3.2 Methods 
3.2.1 Cell Culture  
CD4+ HeLa cells (ATCC, Manassas, VA) were grown in complete DMEM 
containing 10% FBS (Wisent, Quebec, Canada), 100 U/ml penicillin and 100 
µg/ml streptomycin (Hyclone, Logan, UT). All cells were grown at 37°C in the 
presence of 5% CO2 and sub-cultured in accordance with supplier’s 
recommendations. 
3.2.2 Expression vectors 
The pBJ5 plasmid encoding SERINC5 was kindly provided by Dr. Heinrich 
Gottlinger (University of Massachusetts Medical School, Boston, MA). An XbaI 
site within SERINC5 was used to insert an internal hemagglutinin (HA) epitope 
tag between residues 290-291 (SERINC5 int.HA), as described previously (10). 
N- and C-terminal deletion mutants were constructed using primers that 
introduced a XhoI restriction enzyme (RE) site and an upstream start codon or a 
NotI site and an early stop codon, respectively. Mutants were inserted into a 
XhoI/NotI digested pBJ5 vector. 
BiFC vectors were constructed by inserting Nef NL4.3 or the various Nef mutants 
into a pVC-N1 plasmid (24). Inserts were PCR amplified with primers encoding 
EcoRI and AgeI restriction enzyme (RE) sites and inserted into an EcoRI/AgeI 
digested pVC-N1 vector. SERINC5-VN WT or the various SERINC5-VN mutants 
were constructed in a similar fashion, but inserted into a XhoI/NotI digested pVN-
N1 vector.   
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Nef-EGFP fusion plasmids were generated by inserting patient-derived Nef 
sequences into the pEGFP-N1 (Takara, Mountain View, CA) expression plasmid. 
pEGFP-N1 was digested with EcoRI and BamHI and Nef coding sequences were 
introduced using isolate specific primers that added an EcoRI and BamHI site 
with no stop codon to the 5’ and 3’ ends of Nef, respectively. The SERINC5-GFP 
fusion plasmid was constructed using the same methods as above, but with 
SERINC5 specific primers. 
Sequencing was performed at the Robarts Research Institute Genomics Center 
to confirm all constructs. 
3.2.3 Bimolecular Fluorescence Complementation (BiFC) 
For BiFC studies, CD4+ HeLa cells were seeded onto coverslips. Twenty-four 
hours later, cells were transfected with VN and/or VC containing plasmids at 
equal molar ratios with PolyJet transfection reagent (FroggaBio, Toronto, 
Canada). Twenty-four hours post-transfection, cells were incubated for one hour 
at room temperature to allow for fluorophore maturation (24). This maturation 
period is needed to allow for the chemical reactions required to form the cyclic 
fluorophore from the two non-fluorescent VN and VC fragments (25). Once 
matured, cells were fixed in 4% PFA and prepared for immunofluorescence or 
flow cytometry. 
3.2.4 Immunofluorescence  
The staining protocol used for immunofluorescence has been described 
elsewhere (26).  Briefly, all cells used in BiFC or localization studies were fixed 
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24 hours post-transfection by washing twice with PBS, incubating for 20 minutes 
in 4% PFA and subsequently washing three times in PBS. Intracellular 
compartments were stained by first permeabilizing cells (5% BSA in PBS and 
0.2% Triton X-100) for 1 hour and subsequently incubating with the appropriate 
antibodies diluted in blocking buffer for 2 hours (anti-Rab5, Cell Signaling; 1:200, 
anti-Rab7, Cell Signaling; 1:100, anti-LAMP-1, Developmental Studies 
Hybridoma Bank; 1:200, anti-TGN46, Sigma Aldrich; 1:200, anti-CD63, 
Developmental Studies Hybridoma Bank; 1:200, anti-HA, Thermo Fisher 
Scientific; 1:400). Cells were washed three times in blocking buffer and incubated 
with a secondary antibody diluted in blocking buffer (donkey anti-rabbit Alexa 
Fluor® 647 or donkey anti-mouse Alexa Fluor® 647 (1:1000; Jackson 
ImmunoResearch, West Grove, PA)) for 2 hours at room temperature. Finally, 
cells were washed three times in PBS (3 minutes each) and mounted onto glass 
slides using Fluoromount-G or DAPI-Fluoromount-G (Southern Biotech, 
Birmingham, AL).  
Once stained, cells were observed using a Leica DMI6000 B with 63× or 100× 
objectives using the FITC, Cy3, Cy5 and DAPI filter settings and imaged with a 
Hamamatsu Photometrics Delta Evolve camera. Images were deconvolved using 
the Advanced Fluorescence Deconvolution (Leica, Wetzlar, Germany) 
application on the Leica Application Suite software. Co-localization analysis was 
conducted using Pearson’s Correlation from the Image J plugin JACoP, as 
described previously (27). 
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3.2.5 Flow Cytometry 
For BiFC experiments, CD4+ HeLa cells were prepared for flow cytometry 
following fluorophore maturation (24). Cells were washed twice with PBS and 
trypsinized for 3-5 minutes at 37°C and 5% CO2. Cells were then washed twice in 
PBS and fixed in 2% PFA for 15 minutes at 4 degrees. Cells were finally washed 
twice with PBS and read using the GFP channel on a BD FACSCanto II flow 
cytometer. Data was analyzed using FlowJo software (version 9.6.4; TreeStar, 
Ashland, OR) and the BiFC signal was determined by measuring the mean 
fluorescence intensity (MFI) of GFP. 
For receptor downregulation studies, CD4+ HeLa cells were transfected with Nef-
EGFP and/or SERINC5 int.HA plasmids according to the manufacture’s 
instructions. Twenty-four hours post-transfection cells were washed twice with 
PBS and trypsinized for 3-5 minutes at 37°C and 5% CO2. Cells were then 
washed twice in PBS and fixed in 2% PFA for 15 minutes at 4 degrees. Following 
fixation, cells were washed twice with PBS and incubated with the appropriate 
fluorophore-conjugated antibody (APC-conjugated mouse anti-human CD4, 
1:250, clone OKT4, BioLegend, San Diego, CA; Alexa Fluor® 647 mouse anti-
HA.11, 1:250, BioLegend, San Diego, CA) while rocking at room temperature for 
1 hour. Cells were washed twice with PBS and read using the GFP and APC 
channels on the BD FACSCanto II flow cytometer. Data was analyzed using 
FlowJo software (version 9.6.4; TreeStar, Ashland, OR). 
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3.2.6 Western Blots  
Transfected CD4+ HeLa cells were collected at 24 hours by lysis in SDS-PAGE 
sample buffer (0.062 M Tris pH 6.8, 5% 2-mercaptoethanol, 10% glycerol, 2% 
SDS). Cells were lysed at 4°C while rotating for 20 min before insoluble cellular 
debris was removed by centrifugation at 20 000 ×g for 20 min. Lysates were 
sonicated at 30% max power (Sonic Dismembrator Model 300, Thermo Fisher 
Scientific, Waltham, MA) and proteins were separated on 12% SDS-PAGE gels 
and subsequently transferred to nitrocellulose membranes. Membranes were 
blocked in 5% non-fat skimmed milk (Bioshop, Burlington, Ontario, Canada) in 
TBS containing 0.1% Triton X-100 for 45 min, then incubated overnight at 4°C 
with various primary antibodies: rabbit anti-Nef polyclonal antibody (1:2500; 
catalog number 2949, NIH AIDS Research and Reference Reagent Program, 
USA), rabbit anti-GFP polyclonal antibody (1:3000, Clontech, Takara), rabbit anti-
SERINC5 polyclonal antibody (1:1000, Abcam PLC, Cambridge, UK, mouse anti-
HA monoclonal antibody (1:2500, Thermo Fisher Scientific, Waltham, MA), or 
mouse anti-β-actin monoclonal IgG (1:3000, Thermo Fisher Scientific, Waltham, 
MA).  Membranes were washed 3 times in TBS containing 0.1% Triton X-100 
and incubated for 2 hours at room temperature with the appropriate species-
specific HRP-conjugated antibodies (1:3000, Thermo Fisher Scientific, Waltham, 
MA). Blots were developed using ECL substrates (Millipore Inc., Billerica, MA) 
and a C-DiGit chemiluminescence western blot scanner (LI-COR Biosciences, 
Lincoln, NE). 
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3.2.7 Patient Cohort Information 
Patient-derived Nef proteins were isolated from PBMCs collected from treatment-
naïve, HIV-1 infected women from Zimbabwe or Uganda. The details of this 
cohort have been described previously (28-30). Briefly, women from Zimbabwe 
or Uganda were enrolled in a study looking at the effects of hormonal 
contraception on HIV-1 acquisition. Participants were eligible if they were 
between the ages of 18 and 35, HIV-negative, sexually active, not pregnant, and 
had no history of injection drug use or blood transfusion in the past 3 months 
(30). Participants were ineligible if they had a hysterectomy or used an 
intrauterine device or had an abortion in the last 30 days (30). Women were 
monitored and those who contracted HIV-1 were enrolled in the Hormonal 
Contraception and HIV-1 Genital Shedding and Disease Progression among 
Women with Primary HIV Infection study. HIV-1 infected women were followed 
longitudinally, with CD4 cell counts and viral load measurements taken 
approximately every 3 months. For this study, patients were selected if they had 
samples taken within 150 days post sero-conversion to avoid isolating 
sequences from women with extensive quasispecies. Patient nef sequences 
were isolated with a nested-PCR protocol using primers that bind upstream of nef 
in the env open reading frame and downstream of nef in the HIV-1 3’ LTR (Table 
3.1). Sequences were obtained from 45 patients, 15 of those sequences were 
successfully cloned into expression vectors. Sequences denoted with a four digit 
isolate number were from HIV-1 infected women from Zimbabwe and represent 
HIV-1 group M subtype C. Sequences denoted with a hyphenated isolate number 
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were from HIV-1 infected women from Uganda and represent HIV-1 group M 
subtype A. Subtyping was performed based on protease (PR), reverse 
transcriptase (RT) and env sequences, as described previously (31). Access to 
this cohort was kindly provided by Dr. Eric Arts (University of Western Ontario, 
London, ON). All human ethics protocols have been approved by Case Western 
University and/or Western University (Project title – In vitro analysis of HIV fitness 
and evolution in newly HIV infected women; Project ID – 105737). 
Table 3.1 Primers used for patient-derived nef sequencing. 
Primer PCR Round Direction Sequence 
JD-352 I Sense AGGAAGCACTATGGGCGC 
 JD-617 I Sense GCTGACGGTACAGGCCA 
 JD-616 I Sense TTCCTTGGGTTCTTGGGA 
 JD-355 I Anti-Sense GCACTCAAGGCAAGCTTTAT 
 JD-354 I Anti-Sense GAGGCTTAAGCAGTGGGTTC 
 JD-310 II Sense AGCTACCACCGCTTGAGAGAC 
 JD-618 II Sense GAAGAAGGTGGAGAGAGAG 
 JD-619 II Sense TGTGGAACTTCTGGGAC 
 JD-621 II Anti-Sense CCAGGCTCAGATCTGGTC 
 JD-620 II Anti-Sense ACCAGAGAGACCCAGTACA 
 3.2.8 Sequence alignments  
Clustal Omega was used to generate amino acid sequence alignments of Nef 
NL4.3 and Nef 2130 (32, 33). 
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3.2.9 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism software (GraphPad 
Software, Inc., La Jolla, CA). All results were analyzed by one-way analysis of 
variance except the correlation of receptor downregulation and Nef expression 
(Figure 3.7D), which was analyzed by linear regression.  
3.3 Results 
3.3.1 Cellular interaction of SERINC5 and Nef requires a diacidic 
motif in Nef.  
Initially, we sought to explore the mechanistic details of Nef-mediated SERINC5 
downregulation. To do so, we first wanted to demonstrate a Nef:SERINC5 
interaction in cells using the technique of bimolecular fluorescence 
complementation (BiFC). BiFC employs a split fluorophore to visualize the close 
association of two proteins. The N- and C-terminal portions of the Venus 
fluorophore, VN and VC, respectively, are fused to two proteins of interest, which 
are then co-expressed. If the two proteins of interest come within 20 angstroms 
the split fluorophore is able to reconstitute and can be detected by fluorescence 
microscopy or flow cytometry (25). Accordingly, we constructed plasmids 
encoding the fusion proteins SERINC5-VN (S5-VN in Figure 3.1) and Nef-VC 
and co-transfected them in CD4+ HeLa cells. Cells were imaged after a 24 hour 
incubation and a 1 hour reconstitution at room temperature. Strikingly, there was 
a strong fluorescent signal in cells co-expressing both protein fragments 
suggesting that Nef and SERINC5 are in close proximity within cells (Figure 
3.1A, B). 
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We next sought to determine what motifs in HIV-1 Nef were involved in the 
Nef:SERINC5 interaction. Previous reports had implicated the Nef dileucine motif 
at position 164/165 (LL165) and the diacidic motif at positions 174/175 (DD175) as 
important for Nef-mediated SERINC5 downregulation (16), but it remained 
unknown if these motifs were involved in a Nef:SERINC5 interaction. To test this, 
we co-transfected CD4+ HeLa cells with SERINC5-VN and Nef-VC proteins that 
were mutated at either the dileucine motif (Nef-VC LL/AA165) or at the diacidic 
motif (Nef-VC DD/GA175) and visualized for potential reconstitution of the Venus 
fluorophore using fluorescence microscopy. When compared to cells expressing 
wild-type Nef (Nef-VC WT), cells expressing Nef-VC LL/AA165 or Nef-VC 
DD/GA175 showed a significant decrease in BiFC signal, however, the effect of 
the Nef LL/AA165 mutation was less severe and highly variable when compared to 
the Nef DD/GA175 mutation (Figure 3.1A, B). These findings suggest that the 
Nef:SERINC5 interaction is dependent on the aspartic acid residues at positions 
174 and 175 and to a lesser extent on the leucine residues at positions 164 and 
165.  
In order to corroborate the BiFC readout using an alternative method, we also 
measured the BiFC signal between Nef and SERINC5 by flow cytometry. 
Accordingly, we co-expressed Nef-VC WT, LL/AA165 or DD/GA175 and SERINC5-
VN fusion proteins and measured the BiFC signal on the GFP channel. 
Importantly, when the fusion proteins were expressed on their own, there was no 
detectable fluorescence (Figure 3.1C, D). As in our fluorescence microscopy 
experiments (Figure 3.1A, B), robust fluorescence was detected upon the co-
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expression of Nef-VC WT and SERINC5-VN (Figure 3.1C, D). However, when 
Nef was mutated at the diacidic motif, Nef-VC DD/GA175, there was a significant 
decrease in the Nef:SERINC5 BiFC signal (Figure 3.1C, D). Interestingly, when 
measured by flow cytometry, the Nef-VC LL/AA175 mutant did not disrupt the 
Nef:SERINC5 BiFC signal (Figure 3.1C, D). These findings support the role of 
the Nef diacidic motif, Nef DD175, in the Nef:SERINC5 interaction, but suggest 
that the Nef LL165 motif does not play a major role in mediating the Nef:SERINC5 
interaction.  
 
Figure 3.1 Nef and SERINC5 interact in cells.   
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(A) CD4+ HeLa cells were co-transfected with SERINC5-VN and one of Nef-VC 
WT, Nef-VC LL/AA165, or Nef-VC DD/GA175. Twenty-four hours post-transfection 
cells were imaged on the FITC channel. Imaged cells were manually outlined to 
aid visualization. (B) The mean fluorescence intensity (MFI) of the BiFC signal 
was measured using ImageJ software and quantified relative to the signal from 
SERINC5-VN/Nef-VC WT co-transfected cells. (n≥31, **** p<0.0001) (C) CD4+ 
HeLa cells were co-transfected as in (A) and then prepared for flow cytometry 
and read using the GFP channel. A representative histogram is shown. (D) GFP 
MFI, representing BiFC signal, was quantified from 3 independent experiments. 
(*** p<0.001) 
3.3.2 SERINC5 with intracellular loop four deletion maintains a 
BiFC fluorescent signal with Nef. 
Upon identifying the diacidic motif of Nef (Nef DD175) as important for the 
Nef:SERINC5 interaction (Figure 3.1), we next mapped the regions of SERINC5 
that were required for this interaction. Since SERINC5 has only recently begun to 
be studied, there is limited information available on amino acid motifs involved in 
its function. As a result, instead of introducing point mutations in SERINC5, we 
made larger deletions of regions we suspected may be involved in its interaction 
with Nef (Figure 3.2A). SERINC5 is a multi-pass transmembrane protein with 10 
transmembrane domains. We used topology predicting software (TMHMM Server 
v. 2.0, DTU Bioinformatics) to identify potential regions in SERINC5 with which 
Nef could interact (34, 35). We focused on the 3 largest intracellular regions as 
they would be the putative interaction domains with the cytosolic Nef protein. 
These intracellular SERINC5 domains are: the N-terminal and C-terminal tails as 
well as the fourth and largest intracellular loop. An 8 amino acid section of the N-
terminal tail, SERINC5 int.HA d24-32, was targeted for deletion as it preserved a 
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predicted signal peptide sequence in the N-terminal 23 amino acids required for 
sorting SERINC5 to the cell surface. A large portion of the fourth intracellular 
loop, SERINC5 int.HA d339-384, was also deleted to try and maximise the 
likelihood of including any potential binding motifs. In addition, two C-terminal 
deletions were made resulting in SERINC5 int.HA 1-449 and SERINC5 int.HA 1-
451 (Figure 3.2A). These two separate C-terminal deletions were made as 
transmembrane predicting software differed in their estimation of where the final 
transmembrane segment of SERINC5 became intracellular. All mutated 
SERINC5 proteins were designed with an internal HA epitope tag to facilitate 
subsequent experiments (Figure 3.2A). 
We first determined if our engineered SERINC5 deletions or truncations affected 
SERINC5 protein expression. Plasmids encoding the SERINC5 int.HA (referred 
to as S5 WT in Figure 3.2) and the various SERINC5 mutants (S5 d24-32, d339-
384, 1-449 and 1-451 in Figure 3.2) were transfected in CD4+ HeLa cells and 
stained with an Alexa Fluor® 647 conjugated anti-HA antibody to detect cell 
surface SERINC5 protein levels. Transfected and stained cells were analyzed by 
fluorescent microscopy and MFI of Alexa Fluor® 647 was quantified for each 
condition (Figure 3.2B, C). When compared to non-transfected cells, all truncated 
proteins could be visualized suggesting the truncated proteins were expressed. 
However, when compared to wild-type, SERINC5 int.HA d24-32, 1-449 and 1-
451 had a decreased Alexa Fluor® 647 MFI, suggesting these deletions may 
interfere with trafficking of SERINC5 (Figure 3.2A, B). In addition to testing cell 
surface levels of the SERINC5 mutants by microscopy, we utilized western 
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blotting to detect total expression of the mutants in transfected cells. CD4+ HeLa 
cells were transfected as above, and lysates were collected at 24 hours. The 
various SERINC5 proteins were detected using both an anti-HA and anti-
SERINC5 antibody (Figure 3.2F). The only commercially available antibody 
against SERINC5 was raised against an epitope contained in the d339-384 
deletion, thus SERINC5 int.HA d339-384 was only detectable using the anti-HA 
antibody. Interestingly, all truncated SERINC5 proteins were readily detectable 
by western blot. Indeed, staining with the anti-HA antibody produced a similar 
pattern to that observed with fluorescent microscopy (Figure 3.2A, B), but 
staining with anti-SERINC5 resulted in the detection of strong signals for the C-
terminal deletion mutants SERINC5 int.HA 1-449 and 1-451 (Figure 3.2F). 
Together, these findings suggest that the SERINC5 deletions did not completely 
disrupt the folding or stability of SERINC5, but impaired cell surface levels of all 
but the SERINC5 variant with the deletion of the fourth intracellular loop 
(SERINC5 int.HA d339-384). 
In order to determine if the SERINC5 deletion mutants had an impact on the 
Nef:SERINC5 interaction, we next used these SERINC5 mutations (Figure 3.2A) 
in BiFC experiments. Accordingly, the SERINC5 mutants were fused to the N-
terminal portion of the Venus fluorophore to make them compatible with Nef-VC 
for BiFC experiments. CD4+ HeLa cells were co-transfected with Nef-VC and 
SERINC5 int.HA-VN (S5-VN WT in Figure 3.2) or the various SERINC5 int.HA-
VN deletion mutants (S5-VN d24-32, d339-384, 1-449 and 1-451 in Figure 3.2) 
and analyzed by fluorescence microscopy to determine the BiFC MFI. As with 
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our previous BiFC experiments, we were only able to detect a fluorescent signal 
when both Nef-VC and SERINC5 int.HA-VN were co-transfected and not when 
unfused VN and VC fragments were co-transfected (Figure 3.2C, D). A BiFC 
signal was also detectable for all mutants, but only SERINC5 int.HA-VN, 
SERINC5 int.HA-VN d339-384 and SERINC5 int.HA-VN 1-449 had a BiFC signal 
significantly increased from the negative control, VC:VN (Figure 3.2D). Whereas 
Nef-VC:SERINC5 int.HA-VN 1-449 had a BiFC signal significantly less than Nef-
VC:SERINC5 int.HA-VN, the deletion of the fourth intracellular loop (SERINC5 
int.HA-VN d339-384), did not decrease the BiFC signal (Figure 3.2D). Nef-
VC:SERINC5 int.HA-VN d339-384 showed a strong fluorescent signal not 
significantly different than Nef-VC:SERINC5 int.HA-VN, suggesting that upon 
deletion of this intracellular region Nef-VC and SERINC5 int.HA-VN d339-384 are 
still able to reconstitute an active fluorophore. The remaining mutants did have 
decreased BiFC signals when co-transfected with Nef-VC, but when compared 
relative to their total expression (Figure 3.2C), these mutants did not appear to 
further disrupt the Nef:SERINC5 interaction. 
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Figure 3.2 Characterizing SERINC5 deletion mutants for expression and 
BiFC potential. 
(A) Schematic of SERINC5 int.HA (S5 WT) deletion mutants showing regions 
deleted (red boxes) and location of HA epitope tag. (B) CD4+ HeLa cells were 
transfected with the indicated SERINC5 (S5) constructs and at 24 hours post-
transfection were surface stained with an anti-HA antibody conjugated to Alexa 
Fluor® 647. Scale bar represents 20 µm. (C) CD4+ HeLa cells were co-
transfected with Nef-VC and a VN-tagged version of the indicated SERINC5 
constructs (S5-VN). At 24 hours post-transfection cells were imaged for BiFC. 
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Scale bar represents 20 µm. (D) ImageJ software was used to quantify surface 
Alexa Fluor® 647 MFI of cells from (B), (n≥17). (E) The MFI of the BiFC signal 
from (C) was measured using ImageJ software, (n≥14, * are compared to VC:VN, 
* p<0.05, **** p<0.0001). (F) CD4+ HeLa cells were transfected with the 
SERINC5 constructs shown in (A) and collected and lysed at 24 hours post-
transfection. Proteins were detected by western blot using an anti-SERINC5, 
anti-HA or anti-actin antibody. (Note: the epitope that is detected by anti-
SERINC5 is deleted in SERINC5 int.HA d339-384 (S5 d339-384)) 
3.3.3 SERINC5 lacking intracellular loop 4 is susceptible to 
NefNL4.3-mediated downregulation. 
Our findings that deletion of the fourth intracellular loop (SERINC5 int.HA d339-
384) did not disrupt the Nef:SERINC5 BiFC signal (Figure 3.2C, D) was 
surprising given that this region had recently been implicated in the anti-infectivity 
activity of SERINC5 (21). However, that study did not explore the interaction 
between Nef and SERINC5. Given that the Nef-VC:SERINC int.HA-VN d339-384 
interaction gave a robust BiFC signal (Figure 3.2), we next wanted to determine if 
Nef could remove this mutant SERINC5 from the cell surface. Before measuring 
Nef-mediated SERINC5 downregulation efficiency, we first wanted to determine if 
the deletions introduced into SERINC5 impaired its ability to reach the cell 
surface. CD4+ HeLa cells were transfected with SERINC5 int.HA, d24-32, d339-
384, 1-449 or 1-451 (S5 WT, d24-32, d339-384, 1-449 or 1-451 in Figure 3.3), 
stained with anti-HA Alexa Fluor® 647 and then cell surface levels were 
quantified by flow cytometry. We observed that compared to SERINC5 int.HA, 
when cells were transfected with SERINC5 int.HA d24-32 and 1-449, very few 
cells expressed these mutant SERINC5 variants on their surface. This is in 
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contrast to SERINC5 int.HA d339-384 and 1-451, which both had a similar size 
of SERINC5 positive population compared to SERINC5 int.HA (Figure 3.3A, B). 
We also were able to measure the density of SERINC5 on the surface of cells by 
measuring Alexa Fluor® 647 MFI. Whereas the d24-32 and 1-449 deletions 
decreased the number of cells expressing SERINC5 on their surface, none of the 
SERINC5 deletions completely abrogated the MFI of SERINC5 on the cell 
surface. However, SERINC5 int.HA d24-32 and 1-451 had significantly 
decreased cell surface SERINC5, suggesting that these mutations may affect the 
ability of SERINC5 to reach the cell surface (Figure 3.3A, B).   
For our analysis of Nef-mediated SERINC5 downregulation we focused on 
SERINC5 int.HA d339-384 and 1-451, as the other two deletion mutants had 
minimal SERINC5 positive populations. Accordingly, CD4+ HeLa cells were co-
transfected with EGFP or Nef-EGFP and SERINC5 int.HA, d339-384 or 1-451 
and stained with anti-HA Alexa Fluor® 647. Cells were analyzed using flow 
cytometry by first gating on GFP positive cells and then measuring Alexa Fluor® 
647 MFI (SERINC5 expression) (Figure 3.3C). The fold decrease in SERINC5 
downregulation was calculated by taking the ratio of Alexa Fluor® 647 MFI in 
cells transfected with EGFP and SERINC5 int.HA, d339-384 or 1-451 compared 
to cells transfected with Nef-EGFP and SERINC5 int.HA, d339-384 or 1-451. 
Surprisingly, deletion of the fourth intracellular loop (S5 d339-384) or the C-
terminal deletion in 1-451 (S5 1-451) did not impair the ability of NefNL4.3 to 
downregulate SERINC5 (Figure 3.3D). These findings suggest that SERINC5 
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with an intracellular loop 4 deletion is still susceptible to NefNL4.3-mediated 
downregulation. 
 
Figure 3.3 SERINC5 with deletion of intracellular loop 4 is susceptible to 
NefNL4.3-mediated downregulation. 
(A) Cell surface expression of SERINC5 deletion mutants. CD4+ HeLa cells were 
transfected with the indicated SERINC5 constructs and stained with Alexa Fluor® 
647 anti-HA 24 hours post-transfection. Cells were analyzed by flow cytometry 
and gated based on a non-transfected control. (B) Cell surface expression of 
SERINC5 deletion mutants were quantified based on either the % of SERINC5 
positive cells (teal) or the Alexa Fluor® 647 MFI of SERINC5 positive cells (red). 
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(C) SERINC5 downregulation was measured in CD4+ HeLa cells transfected with 
SERINC5 int.HA WT, SERINC5 int.HA d339-384 or SERINC5 int.HA 1-451 and 
EGFP or Nef-EGFP. Cells were gated based on non-transfected cells and cells 
transfected with EGFP alone. (D) Fold decrease in cell surface SERINC5 
expression was quantified based on 3 independent experiments. Fold decreases 
were calculated by taking the ratio of Alexa Fluor® 647 MFI in Nef-EGFP vs. 
EGFP co-transfected cells 
3.3.4 HIV-1 Nef traffics SERINC5 to LAMP-1 and CD63 positive 
compartments. 
After demonstrating that Nef and SERINC5 interact in cells, and defining the 
genetic determinants of this interaction, we next wanted to elucidate where in the 
cell Nef was trafficking SERINC5 in order to determine the functional significance 
of this interaction. To do this, we once again employed the technique of BiFC, 
this time in conjunction with counter staining for various intracellular 
compartments. We first focused on the endosomal trafficking pathway that can 
be visualized by staining for the trafficking proteins Rab5 and Rab7. Rab5 and 
Rab7 mark early and late endosomes, respectively, and represent a common 
pathway used by Nef to traffic cellular proteins, most notably MHC-I and CD4, 
away from the cell surface (26, 36). To define how Nef alters the subcellular 
localization of SERINC5 we first transfected CD4+ HeLa cells with SERINC5-
EGFP (S5-EGFP in Figure 3.4) alone to observe where SERINC5 localized in the 
absence of Nef (Figure 3.4A). We then compared this subcellular distribution with 
that of the Nef:SERINC5 BiFC signal in CD4+ HeLa cells co-transfected with Nef-
VC and SERINC5-VN (S5-VN in Figure 3.4B). Neither SERINC5-EGFP or the 
Nef:SERINC5 signal showed a strong co-localization with the early endosomal 
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marker Rab5, both with Pearson’s correlation below 0.3 (Figure 3.4C; 0.27 v. 
0.29). There was a slightly increased co-localization with the late endosomal 
marker Rab7, with the Nef:SERINC5 BiFC signal co-localizing significantly more 
than SERINC5-EGFP, however, both had Pearson’s correlation less than 0.5 
(Figure 3.4C; 0.39 v. 0.46). These findings suggest that Nef:SERINC5 complexes 
have increased trafficking to late endosomal compartments, but that this 
localization does not represent grossly abnormal trafficking of SERINC5 (Figure 
3.4D). The presence of SERINC5-EGFP and the Nef:SERINC5 BiFC complex in 
late endosomes is not surprising given that endocytosed cargo often traffics 
through the late endosome to its final destination. 
The next compartment we investigated was that of multivesicular bodies (MVBs). 
It is well documented that Nef expression leads to the accumulation of MVBs and 
that Nef traffics cargo, such as CD4, through MVBs en route to lysosomes (23, 
37, 38). MVBs contain intraluminal vesicles, the contents of which are degraded 
by fusion of MVBs with lysosomes or released extracellularly as exosomes when 
MVBs fuse with the plasma membrane (39). Indeed, the routing of Nef within 
MVBs is essential for the release of Nef in exosomes . MVBs can be labelled with 
antibodies against the membrane protein CD63, a heavily glycosylated 
tetraspanin protein that is enriched in MVBs and used as a marker for exosomes 
(39). Strikingly, SERINC5-EGFP displayed little co-localization with CD63 
positive compartments, with a Pearson’s correlation of 0.21, but the 
Nef:SERINC5 BiFC complex showed a significantly increased co-localization, 
0.52, with the marker for MVBs (Figure 4C). This discrepancy suggests that Nef 
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alters the physiologic subcellular distribution of SERINC5 by trafficking it to a 
CD63 positive compartment (Figure 3.4D).  
In order to determine where SERINC5 is ultimately trafficked inside cells, we 
explored two terminal trafficking compartments. The TGN, where Nef sequesters 
MHC-I following its downregulation (26, 40), can be labelled using TGN46, which 
recognizes an integral trans-Golgi membrane protein. Similar to the late 
endosomes, we observed that there was co-localization of both SERINC5-EGFP 
and Nef:SERINC5 BiFC with the TGN, but significantly more SERINC5-GFP 
localized to the TGN (Figure 3.4C; 0.52 v. 0.41). The other terminal trafficking 
compartment we explored was the lysosome, which can be labelled using 
antibodies that target lysosomal-associated membrane protein-1 (LAMP-1) (41). 
Nef is known to target internalized CD4 to lysosomes, resulting in its degradation 
(23). Interestingly, we saw a distinct difference in the co-localization patterns of 
SERINC5-EGFP and the Nef:SERINC5 BiFC complex (Figure 3.4A, B). As with 
the MVBs, we observed that SERINC5-EGFP did not co-localize strongly with 
LAMP-1, whereas the Nef:SERINC5 BiFC complex had a significantly increased 
co-localization with the lysosomal marker (Figure 3.4C; 0.19 v. 0.59). Taken 
together, our findings suggest HIV-1 Nef is able to hijack normal SERINC5 
trafficking and ultimately shuttle this restriction factor to a degradative 
compartment, via MVBs (Figure 3.4D).   
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Figure 3.4 HIV-1 Nef reroutes SERINC5 to CD63 and LAMP-1 positive 
compartments. 
(A) CD4+ HeLa cells were transfected with SERINC5-EGFP (S5-EGFP) and at 
24 hours post-transfection were permeablized and stained for markers of 
subcellular compartments. Representative images are shown. Scale bar 
represents 20 µm. (B) CD4+ HeLa cells were co-transfected with Nef-VC and 
SERINC5-VN (S5-VN) and at 24 hours post-transfection were permeablized and 
stained for markers of subcellular compartments. Representative images are 
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shown. Merged images from cells transfected with VC and VN not attached to 
target proteins are included to show specificity of BiFC signal. Scale bar 
represents 20 µm. (C) Quantification of co-localization between subcellular 
markers and SERINC5-EGFP (green) or Nef:SERINC5 BiFC (red). Co-
localization was determined using Pearson’s Correlation of at least 30 cells for 
each condition. (* p<0.05, ** p<0.01, **** p<0.0001) (D) Schematic showing the 
BiFC interaction of Nef and SERINC5 and the trafficking route taken by 
SERINC5 in the presence or absence of Nef. 
3.3.5 Altered trafficking of SERINC5 requires the Nef diacidic and 
dileucine motifs.  
To confirm the altered trafficking of SERINC5 and investigate the Nef motifs 
involved, we next conducted BiFC experiments using Nef proteins mutated at the 
dileucine (Nef-VC LL/AA165) or diacidic motifs (Nef-VC DD/GA175). We focused 
on how these mutants affected the trafficking of SERINC5 to CD63 and LAMP-1 
positive compartments, as these were the prominent differences observed 
between SERINC5-EGFP and Nef:SERINC5 (Figure 3.4) and these motifs are 
important in the Nef:SERINC5 interaction (Figure 3.1). CD4+ HeLa cells were co-
transfected with SERINC5-VN and Nef-VC WT, LL/AA165 or DD/GA175 and then 
counter stained with antibodies against CD63 or LAMP-1 (Figure 3.5A, C). As 
anticipated due to its role in the Nef:SERINC5 interaction, mutation of the diacidic 
motif significantly decreased the ability of Nef to shuttle SERINC5 to CD63 and 
LAMP-1 positive vesicles (Figure 3.5B, D; p<0.0001). Interestingly, despite 
inconclusive findings on its role in the Nef:SERINC5 interaction (Figure 3.1), 
mutation of the dileucine motif decreased the ability of Nef to shuttle SERINC5 to 
the same extent as mutation of the diacidic motif (Figure 3.5B; p=0.24, Figure 
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5D; p=0.68). These findings suggest that the although the Nef LL165 motif plays a 
minor role in the Nef:SERINC5 interaction, this motif, along with Nef DD175, is 
required for the diversion of SERINC5 to MVBs and lysosomes. 
 
Figure 3.5 Diacidic and dileucine motifs in Nef are required for altered 
trafficking of SERINC5. 
CD4+ HeLa cells were transfected with SERINC5-VN and Nef-VC LL/AA165 or 
Nef-VC DD/GA175. Twenty-four hours post-transfection cells were stained for 
CD63 (A) or LAMP-1 (C). Representative images are shown. Scale bars 
represent 20 µm. Co-localization of the BiFC signal with CD63 (B) or LAMP-1 (D) 
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was quantified based on Pearson’s Correlation for cells co-transfected with 
SERINC5-VN and Nef-VC WT (green), LL/AA165 (yellow) or DD/GA175 (orange). 
(n≥16 cells; **** p<0.0001) 
3.3.6 Steady state levels of SERINC5 are reduced upon Nef 
expression.  
Given that Nef is shuttling SERINC5 through MVBs to lysosomes (Figure 3.4), 
we hypothesized that the levels of SERINC5 in Nef expressing cells would be 
decreased. To test this, we analyzed SERINC5 protein levels in CD4+ HeLa cells 
co-transfected with SERINC5 int.HA (S5 in Figure 3.6) and EGFP, Nef-EGFP or 
Nef-EGFP DD/GA175. SERINC5 int.HA was readily detectable in cells co-
transfected with SERINC5 int.HA and EGFP, however, when SERINC5 int.HA 
was expressed with Nef-EGFP there was a marked decrease in SERINC5 int.HA 
levels by western blot (Figure 3.6). Interestingly, when SERINC5 int.HA was co-
transfected with Nef mutated at its diacidic motif, Nef-EGFP DD/GA175, we no 
longer observed a decrease in SERINC5 int.HA levels. These findings support 
the trafficking of SERINC5 to MVBs and subsequent trafficking to a degradative 
compartment or release through extracellular vesicles. Furthermore, these 
findings also support the role of the diacidic motif in the downregulation and 
decrease of cellular SERINC5 levels.  
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Figure 3.6 HIV-1 Nef decreases SERINC5 protein levels. 
CD4+ HeLa cells were either transfected individually with SERINC5 int.HA (S5), 
EGFP, Nef-EGFP or Nef-EGFP DD/GA175, or co-transfected with SERINC5 
int.HA (S5) and EGFP, Nef-EGFP or Nef-EGFP DD/GA175. At 24 hours post-
transfection cells were lysed and analyzed for SERINC5 expression by western 
blot using an anti-SERINC5 antibody.  
3.3.7 SERINC5 downregulation is highly variable among patient 
derived Nef isolates.  
Nef appears to use a similar mechanistic pathway to downregulate CD4 and 
SERINC5 (11, 42, 43). It is well documented that CD4 downregulation is highly 
conserved among HIV-1 Nef proteins (44). Therefore, we were interested if 
SERINC5 downregulation displayed this same level of conservation. To do so, 
we used 15 Nef patient isolates from a cohort of treatment-naïve, HIV-1 infected 
women from Uganda and Zimbabwe. Sequences from Uganda were HIV-1 group 
M subtype A, whereas those from Zimbabwe were HIV-1 group M subtype C. 
These women were enrolled in a study to determine the effect of hormonal 
contraception on HIV-1 transmission. Participants were routinely tested for HIV-1 
infection by serology and once they sero-converted they had CD4 cell counts and 
viral loads measured throughout their follow-up (28-30). nef sequences were 
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isolated from purified PBMCs by PCR and cloned into an mammalian expression 
vector to generate EGFP fusion proteins for flow cytometry analysis. To test the 
functionality of these patient Nef isolates, CD4+ HeLa cells were transfected with 
the various Nef-EGFP plasmids, stained with an anti-CD4 antibody and CD4 
downregulation was measured by flow cytometry. As expected, CD4 
downregulation was conserved among the HIV-1 Nef proteins (Figure 3.7A). All 
isolates except 2130 showed significantly enhanced CD4 downregulation 
efficiency compared to our negative control, cells transfected with EGFP alone, 
but not significantly different than our positive control, cells transfected with Nef 
NL4.3-EGFP. In addition to analyzing Nef function, these EGFP-fused Nef 
proteins enabled the examination of protein expression by measuring the EGFP 
MFI levels in transfected cells. Unlike CD4 downregulation, we observed a high 
level of variability in regards to Nef expression among isolates. With isolates 
showing significantly increased or decreased EGFP MFI compared to Nef NL4.3-
EGFP (Figure 3.7A). These results suggest that the Nef isolates retrieved from 
this cohort are functionally active, despite varying expression levels. The 
variability in Nef expression was confirmed by western blot of CD4+ HeLa cells 
transfected with the Nef-EGFP fusion proteins (Figure 3.7B). 
After establishing the functionality of the Nef isolates, we next investigated the 
ability of these proteins to downregulate SERINC5. CD4+ HeLa cells were co-
transfected with SERINC5 int.HA and the various Nef isolates, stained with an 
anti-HA antibody conjugated to Alexa Fluor® 647 and SERINC5 downregulation 
was determined by flow cytometry. Interestingly, in contrast to CD4 
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downregulation, SERINC5 downregulation varied greatly among Nef isolates 
(Figure 3.7C). As with the above experiments, we observed a wide range of Nef 
expression as measured by EGFP MFI. Unlike CD4, these differences in protein 
expression greatly influenced  SERINC5 downregulation, with more highly 
expressed Nef proteins tending to downregulate SERINC5 to a larger degree 
(Figure 3.7D). However, there were a number of isolates including 2005, 2391 
and 2634 that displayed high Nef expression by EGFP MFI, but presented 
minimal SERINC5 downregulation. Of note, as with CD4 downregulation, Nef 
isolate 2130 failed to downregulate SERINC5 any more than cells transfected 
with EGFP alone. Interestingly, when comparing 14 Nef isolates, we observed a 
significant positive correlation between isolate expression and SERINC5 
downregulation, but not with CD4 downregulation (Figure 3.7D). This correlation 
was seen when Nef 2130 was removed due to mutations that disrupted its 
expression (Figure 3.8). These results demonstrate that Nef-mediated SERINC5 
downregulation is more variable than CD4 downregulation among HIV-1 infected 
individuals and is more sensitive to differences in Nef expression. 
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Figure 3.7 SERINC5 downregulation is highly variable among patient 
derived Nef proteins. 
Nef protein sequences were isolated from a cohort of treatment-naïve, HIV-1 
infected women. (A) CD4+ HeLa cells were transfected with EGFP or one of the 
indicated Nef-EGFP fusion proteins. At 24 hours post-transfection EGFP positive 
cells were analyzed for CD4 expression by flow cytometry using an APC anti-
CD4 antibody. FlowJo software was used to quantify fold decrease in surface 
CD4 levels (purple) and Nef expression (green) based on EGFP MFI from 3 
independent experiments. (B) CD4+ HeLa cells were tansfected as in (A) and at 
24 four hours post-transfection analyzed for Nef-EGFP fusion protein and 
GAPDH expression using an anti-GFP antibody. (C) CD4+ HeLa cells were co-
transfected with SERINC5 int.HA and EGFP or one of the indicated Nef-EGFP 
fusion proteins. At 24 hours post-transfection EGFP positive cells were analyzed 
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for surface SERINC5 int.HA expression by flow cytometry using an anti-HA 
antibody conjugated to Alexa Fluor® 647 . FlowJo software was used to quantify 
fold decrease in surface SERINC5 levels (purple) and Nef expression (green) 
based on EGFP MFI from 3 independent experiments. (D) The correlation 
between receptor downregulation and Nef expression for CD4 (green) and 
SERINC5 (red) was determined using Prism software. (* refers to a slope 
significantly not zero, * p<0.05). Note: isolate 2130 was removed from the 
analysis for (D) due to the identification of mutations that disrupt its expression.   
3.3.8 Functionally impaired Nef isolate 2130 was retrieved from a 
slow-progressor.  
As noted above, Nef isolate 2130 was unable to downregulate CD4 and 
SERINC5 (Figure 3.7A, B). In addition, based on GFP MFI, Nef isolate 2130 was 
very weakly expressed (Figure 3.7A, B). To explore possible mechanisms for 
these abnormalities we analyzed the amino acid sequence of 2130. Interestingly, 
we found that Nef isolate 2130 uses a non-canonical isoleucine as a start codon, 
and contains two premature stop codons at NL4.3 position 113 and 141 (Figure 
3.8A). Together, these mutations explain why Nef isolate 2130 was undetectable 
by western blot (Figure 3.7C) and not functional (Figure 3.7A, B). After identifying 
these mutations we next investigated their impact on the disease progression of 
the patient this isolate was recovered from. To do so, we analyzed the CD4 cell 
counts and viral load measurements from this patient as well as 44 other patients 
from the cohort. Strikingly, the patient from which isolate 2130 was retrieved had 
high CD4 cell counts and low viral loads that were sustained for close to 5 years 
after sero-conversion (Figure 3.8B, C). These findings add to the documented 
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phenomena of individuals infected with Nef-defective viruses experiencing 
delayed disease progression. 
 
Figure 3.8 Non-functional Nef 2130 isolated from a patient with delayed HIV-
1 disease progression. 
(A) Clustal Omega was used to compile an amino acid sequence alignment of 
Nef 2130 and Nef NL4.3. Nucleotide polymorphisms of note are outlined in black 
boxes. Red residues are uncharged non-polar, green are uncharged polar, pink 
residues are basic, blue residues are acidic, • indicates stop codon; * below 
residues indicates identical residues, : indicates conserved residues. Scatter plot 
showing CD4 cell counts (B) or viral load (C) vs. days post-infection for 45 
patients from which Nef sequences were retrieved.  
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3.4 Discussion 
Initial studies demonstrating the anti-infectivity role of SERINC5 and its 
antagonism by HIV-1 Nef clearly showed the ability of Nef to limit the 
incorporation of  SERINC5 into budding virions (10, 11). However, these studies 
focused primarily on the infectivity of the resulting viruses, rather than on the 
mechanistic details of how Nef downregulates SERINC5. We used bimolecular 
fluorescence complementation (BiFC) to demonstrate that HIV-1 Nef interacts 
with SERINC5 in cells (Figure 3.1A). This is in agreement with a recent report 
from Shi, J. et al (22), but in contrast to that study, we demonstrated that 
mutation of the diacidic motif at Nef positions 174/175 (Nef DD/GA175) 
significantly decreases the ability of Nef and SERINC5 to interact. This diacidic 
motif has been shown to be required for the Nef-mediated antagonism of 
SERINC5, as mutations of the two aspartic acid residues results in similar virion 
infectivity as cells infected with Nef deleted viruses (16). Surprisingly, mutation of 
the Nef dileucine motif, Nef LL165, which has also been shown to be required for 
SERINC5 antagonism, did not conclusively decrease the Nef:SERINC5 BiFC 
signal. There was a significant, but highly variable decrease when measured by 
fluorescent microscopy, but no significant change when measured by flow 
cytometry (Figure 3.1). Nef DD175 is a motif required for the interaction of Nef with 
subunit H of the vacuolar ATPase, which acts as a connector protein between 
Nef and AP-2 (45). Additionally, structural studies have demonstrated that Nef 
DD175 stabilizes the central loop region of Nef (149-179), which interacts directly 
with the α-σ2 ‘hemicomplex’ of AP-2 (46). The Nef dileucine motif is the primary 
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motif responsible for the Nef:AP-2 interaction and binds directly to the α-σ2 
‘hemicomplex’ (14, 47, 48). Our findings suggest that the interaction of  Nef with 
subunit H of the vacuolar ATPase is required for the initial interaction of Nef and 
SERINC5, but that this interaction can occur in the absence of the Nef:AP-2 
interaction.  
We next explored what regions of SERINC5 may be involved in the 
Nef:SERINC5 interaction (Figure 3.2). As there is limited knowledge on the 
structure and function of SERINC5 we constructed a series of deletion mutants 
that targeted different intracellular regions of SERINC5 (Figure 3.2A). Deletions 
that targeted the N- or C-terminal tails of SERINC5 impaired the proper cell 
surface expression of SERINC5 and not surprisingly also disrupted the 
Nef:SERINC5 BiFC interaction. However, deletion of intracellular loop 4 of 
SERINC5 did not affect the cell surface expression of SERINC5 or the strength 
of the BiFC signal (Figure 3.2B, C, D). Western blotting showed that all deletion 
mutants were expressed, but that the N- and C-terminal deletions decreased 
expression more than deletion of intracellular loop 4 of SERINC5 (Figure 3.2E). 
These findings are intriguing in light of a recent study that used domain swapping 
experiments to show that intracellular loop 4 is responsible for the anti-infectivity 
activity of SERINC5 (21). This suggests that the structural determinants for the 
Nef:SERINC5 interaction may be distinct from those required for the anti-viral 
affects of SERINC5. Further supporting this distinction was the fact that deletion 
of intracellular loop 4 did not impair the trafficking of SERINC5 to the cell surface 
or the ability of NefNL4.3 to downregulate SERINC5 from the cell surface. This 
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raises the possibility that additional smaller intracellular loops in SERINC5 
contribute to the interaction with Nef, akin to the distinct functional roles of 
intracellular domains of G-coupled protein receptors (49). However, additional 
studies will be required to determine if our intracellular loop deletion impacts the 
anti-infectivity activity of SERINC5. 
We also employed BiFC to elucidate the molecular pathway used by Nef to 
remove SERINC5 from the cell surface (Figure 3.3). Our data suggests that the 
Nef:SERINC5 complex is trafficked through early and late endosomes to a 
lysosomal compartment, via MVBs (Figure 3.3D). This is in contrast to SERINC5 
expressed in the absence of Nef, which is localized predominantly at the TGN. 
The molecular pathway we demonstrated by BiFC is the same pathway used by 
Nef to downregulate and degrade CD4 (23). Even prior to the discovery of 
SERINC5, there have been a number of studies that suggest the pro-infectivity of 
HIV-1 Nef is related to its ability to hijack the clathrin-dependent endocytic 
machinery (45, 50, 51). This function has been well documented as the means 
by which Nef downregulates CD4, suggesting SERINC5 antagonism is 
mechanistically similar to CD4 downregulation.  
The mechanistic similarities between CD4 and SERINC5 downregulation are 
further supported by BiFC experiments that demonstrate the requirement of the 
dileucine (Nef LL165) and diacidic (Nef DD175) motifs in Nef for transport of 
SERINC5 to CD63 positive MVBs and LAMP-1 positive lysosomes (Figure 3.5). 
The trafficking defect observed with the diacidic motif mutation is in agreement 
with our earlier findings that this mutation disrupts the interaction of Nef and 
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SERINC5. The disrupted trafficking of SERINC5 in the presence of Nef LL/AA165 
supports the involvement of AP-2 in SERINC5 downregulation, even if this motif 
is not essential for the interaction of Nef and SERINC5. AP-2 has been widely 
implicated in SERINC5 downregulation by mutational and gene knock-out 
experiments (10, 14, 16), but here we visually demonstrate the altered trafficking 
of SERINC5 when the motifs involved in the Nef:AP-2 interaction are mutated. 
The localization of the Nef:SERINC5 complex to a lysosomal compartment 
suggests that Nef is mediating the degradation of SERINC5. We demonstrate 
through western blot that SERINC5 levels are decreased upon expression of Nef 
and that this decrease in SERINC5 expression is rescued by mutation of the 
diacidic motif in Nef (Nef DD/GA175). This is in agreement with a recent report 
showing that chemical blockade of lysosomal acidification increased the levels of 
SERINC5 in cells (22), but in contrast with earlier reports that suggested Nef 
does not affect steady state levels of SERINC5 (16). Given the similar endocytic 
pathway used by Nef to downregulate CD4 and SERINC5 shown here, and 
elsewhere, one would suspect a similar degradative fate of these two targets of 
HIV-1 Nef. Further studies investigating the kinetics of SERINC5 protein turnover 
in the presence or absence of Nef could provide more conclusive evidence of the 
fate of SERINC5. Unfortunately, the multiple transmembrane domains within 
SERINC5 increases the difficulty of many of the biochemical assays of protein 
turnover. 
We also demonstrated that the ability of patient-derived Nef proteins to 
downregulate SERINC5 is highly variable (Figure 3.7). This is in contrast to Nef-
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mediated CD4 downregulation, which is conserved across various Nef proteins 
(44). Interestingly, we show that there is a significant correlation between Nef 
protein expression and SERINC5 downregulation, but not CD4 downregulation. 
This suggests that SERINC5 downregulation is more sensitive to differences in 
Nef protein expression, potentially due to differences in the affinity of Nef for CD4 
versus SERINC5. Alternatively, there may be as of yet underdetermined motifs in 
HIV-1 Nef that influence SERINC5, but not CD4 downregulation. One of the 
characteristics of Nef-mediated SERINC5 downregulation that has recently 
emerged is the variable nature of SERINC5 antagonism by Nef (10, 11, 14). The 
first reports of SERINC5 antagonism by Nef demonstrated that the lab adapted 
strain NefSF2 and the primary isolates Nef97ZA012 and Nef93BR020 potently inhibited 
SERINC5 incorporation into HIV-1 virions, whereas the primary isolates 
Nef94UG114 and Nef90CF056 either weakly inhibited or failed to inhibit SERINC5 
incorporation (10). SERINC5 was initially discovered based on screening assays 
that utilized the laboratory strain NefNL4.3, however this strain shows a relatively 
mild inhibition of SERINC5 (10, 11). Indeed, in our study we observed that 
NefNL4.3 resulted in anywhere from a 1.1 (Figure 3.7) to 1.5 (Figure 3.3) fold 
decrease in cell surface levels of SERINC5. This mild inhibition is in contrast to 
some of the patient-derived Nef proteins that we studied, such as the 7.9 fold 
decrease in cell surface SERINC5 levels seen by Nef 2410 (Figure 3.7). Given 
this variability, it raises the possibility that differences in SERINC5 antagonism 
may influence HIV-1 spread and pathogenesis. This is supported by a study 
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showing the prevalence of SIV in various primate species correlates with the 
ability of their respective Nef proteins to antagonize SERINC5 (14). 
Finally, while investigating SERINC5 downregulation from patient-derived Nef 
proteins we identified a non-functional Nef protein that contained a non-canonical 
start codon and 2 premature stop codons (Figure 3.8). When the patient data 
from which this protein was isolated from was analyzed, we observed elevated 
CD4 levels and sustained low viral loads for close to 5 years post-infection. This 
finding adds to the large body of evidence demonstrating the role of Nef in 
disease progression.  
In this report we demonstrate that Nef and SERINC5 interact within cells and 
begin to outline the amino acid motifs in each protein that are required for this 
interaction. In addition, we have used BiFC to visualize the molecular pathway 
used by Nef to downregulate SERINC5, supporting the prevailing hypothesis that 
Nef uses a similar mechanism to downregulate both CD4 and SERINC5. Finally, 
we provide further support for the highly variable nature of Nef-mediated 
SERINC5 downregulation by investigating this function in patient-derived Nef 
proteins.   
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Chapter 4  
4 Overview, discussion and future directions 
4.1 Discussion 
4.1.1 General Discussion 
As HIV-1 Nef lacks enzymatic or structural activity, it must carry out its functions 
by interacting with a large network of host proteins (1). Nef harbours a number of 
protein-interacting motifs throughout its 206 amino acid sequence that it utilizes 
to modify the intracellular architecture of HIV-1-infected cells to favour viral 
replication (2). These modifications include, but are not limited to, the 
downregulation of cell surface proteins that in one way or another interfere with 
HIV-1 replication. Nef-mediated downregulation of the HIV-1 entry receptor CD4 
(3) and the adaptive immune surveillance molecule MHC-1 (4) are well 
established and extensively characterised in the current literature. However, the 
recent discovery of the host restriction factor SERINC5 (5, 6) and its antagonism 
by HIV-1 Nef highlights the fact that even after more than three decades of HIV-1 
research, we still do not have a complete understanding of this devastating 
pathogen. Indeed, one of the areas of HIV-1 research that still requires 
elucidation is the impact of the genetic flexibility of HIV-1 on the molecular 
mechanisms of the virus.  
4.1.2 Summary of findings  
In chapter 2 of this dissertation, HIV-1 group M subtypes were investigated for 
how they differ in the key Nef functions of CD4 and MHC-I downregulation. This 
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investigation led to the identification of three Nef proteins from subtype C, G and 
H reference strains that displayed atypical function and expression (Figure 2.2 
and 2.3). Furthermore, fluorescence imaging of Nef proteins from subtype G and 
H demonstrated that these proteins were abnormally distributed (Figure 2.4), 
potentially localizing to mitochondria (Figure 2.7). A more in-depth analysis of Nef 
from the subtype C reference strain C.BR92025 led to the discovery of a key 
alanine residue at amino acid position 84, that when mutated, accelerated the 
rate of Nef protein turnover (Figure 2.15) (7).  
In chapter 3, the molecular mechanisms of how Nef antagonizes SERINC5 were 
investigated. HIV-1 Nef was shown to interact with SERINC5 as revealed by 
BiFC (Figure 3.1). This powerful imaging technique was then used to map the 
interaction motifs on Nef and SERINC5 and to elucidate how Nef removed 
SERINC5 from the cell membrane. These studies identified Nef LL165 and Nef 
DD175 as essential for the rerouting of SERINC5 to a lysosomal and/or 
multivesicular body compartment (Figure 3.4 and 3.5), supporting the hypothesis 
that Nef utilizes a similar mechanism to downregulate CD4 and SERINC5. Nef 
DD175 was also shown to be required for the Nef:SERINC5 interaction (Figure 
3.1) and the Nef-dependent decrease of cellular SERINC5 protein levels (Figure 
3.6). Finally, analysis of SERINC5 downregulation by a number of patient-derived 
Nef proteins demonstrated that this recently identified function of Nef is highly 
variable, and more sensitive to changes in Nef expression than CD4 
downregulation (Figure 3.7). 
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4.1.3 Genetic diversity and Nef function 
Our initial interest in investigating the impact of HIV-1 genetic diversity on Nef 
function stems from the key role Nef plays in HIV-1 pathogenesis (8) and the 
observed differences in disease progression between HIV-1 group M subtypes 
(9-11). We hypothesized that if group M subtypes differed in Nef-mediated 
receptor downregulation, that may explain some of the differences in disease 
progression between subtypes. Indeed, transgenic mouse models that express 
HIV-1 Nef in CD4+ cells and develop an AIDS-like phenotype (12), have been 
used to demonstrate decreased pathogenicity of Nef proteins unable to 
downregulate CD4 (13). The same animal model was used to show that the 
Nef:SFK interaction, which is required for MHC-I downregulation, is also required 
for Nef pathogenicity (14). In addition, analysis of Nef proteins from cohorts of 
HIV-1 infected individuals has repeatedly shown a correlation between impaired 
receptor downregulation and disease progression (15-18). However, these cohort 
analyses predominantly focus on differences in Nef function within a specific 
subtype, rather than between subtypes.  
The largest and most conclusive study looking at Nef function between subtypes 
only investigated HIV-1 group M subtypes A, B, C, and D (19), leaving the less 
prevalent subtypes that are found almost exclusively in central and west Africa 
understudied. Indeed, there exists very little literature characterizing the function 
of HIV-1 proteins from subtypes F1, F2, G, H, J and K. This is not all that 
surprising given that when the Los Alamos National Library HIV database is 
queried, there are only 86 complete HIV-1 genome sequences available for 
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subtype G, compared to 3104 for subtype B alone (20). That is a 36-fold 
difference despite that fact that globally subtype B is only responsible for twice as 
many infections as subtype G (21).  
Admittedly, given current estimates, subtypes F, H, J and K are relatively rare, 
but they still account for over a quarter of a million infections globally (21). 
Regardless, their relatively low prevalence does not preclude the study of these 
subtypes from revealing novel and potential useful information about the 
molecular details of HIV-1 infection. Indeed, our analysis of Nef proteins from 
subtype G and H reference strains suggests these proteins have impaired 
function and expression (Figure 2.2 and 2.3) that may be related to their unique 
subcellular distribution to mitochondria (Figure 2.7). Additional studies need to be 
done to determine what is leading to this altered localization and if cells 
expressing these Nef proteins undergo changes in oxidative phosphorylation. 
Furthermore, a more extensive analysis of Nef function in low prevalence group 
M subtypes is required to determine if the findings from the subtype G and H 
reference strains used here occurs elsewhere.   
Interestingly, when, as mentioned above, subtypes A, B, C and D were analyzed 
for Nef-mediated receptor downregulation, the authors of that study also noted 
variations in Nef expression between subtypes (19). On average, Nef proteins 
from subtype C infected individuals displayed decreased expression relative to 
subtypes A, B and D. Differences in Nef expression has also been noted in other 
studies, and some have hypothesized that these differences arise due to immune 
escape mutations that come at a fitness cost (17). Conventionally, it is assumed 
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that there is rapid and abundant Nef production from the first mRNA transcripts 
made during HIV-1 infection (2). Given the heterogeneous nature of HIV-1, it 
would not be surprising if some proportion of viruses did not follow this 
convention. Considering the key role Nef plays in HIV-1 pathogenesis (8) and the 
influence early viremic control has on disease progression (22), these variations 
in Nef expression may have profound effects on the clinical course of HIV-1. 
Therefore, understanding the molecular determinants of variations in Nef 
expression, and how they may be influenced, holds great value. Our identification 
of an alanine residue at position 84 as critical for optimal Nef expression 
highlights how susceptible Nef can be to amino acid variation, even with its 
significant genetic flexibility (Figure 2.15). If regions such as this can be targeted, 
either through induced immune responses, or through chemical interference, it 
could add another therapeutic option to the arsenal against HIV-1.  
We used mammalian expression plasmids (Figure 2.2A) or replication-
incompetent viruses (Figure 2.3A) throughout our studies, and as such, there 
was little to no opportunity for viruses encoding Nef with a mutation at position 84 
to revert back to an alanine or for compensatory mutations to occur that could 
restore expression of the protein. Longer term studies passaging live virus could 
determine if Nef C.BR92025 is able to revert to a more functional form. 
Furthermore, in our infection model we expressed Nef C.BR92025 in the context 
of the a laboratory adapted subtype B virus, NL4.3. Thus, there is a possibility 
that Nef C.BR92025 expressed from its parental viral genome may function 
differently. However, the equal mRNA transcript levels (Figure 2.4A) and 
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impairment in a transfection model (Figure 2.2 and 2.12) make that unlikely in our 
opinion.  
4.1.4 SERINC5 antagonism by HIV-1 Nef 
The past two decades have seen the discovery of a number of host proteins that 
act to restrict HIV-1 infection (23). In order to successfully infect and replicate 
within cells, HIV-1 accessory proteins are able to antagonize these host 
restriction factors. In addition to expanding our understanding of the intricacies of 
HIV-1 infection, the discovery of these virus-host interactions present novel 
therapeutic targets. If the accessory proteins that antagonize host restriction 
factors can be inhibited, the immune system may be able to more effectively 
control HIV-1. In addition, restriction factors have piqued interest as therapeutic 
targets as they do not mutate as freely as viral proteins, one of the major barriers 
of many current treatment strategies (24). Regardless of the approach taken, a 
complete understanding of the mechanistic details of these virus-host 
interactions is required if they are to be exploited for therapeutic use. 
While much of the present research on Nef antagonism of SERINC5 has focused 
on infectivity as a readout, we chose to measure SERINC5 downregulation 
(Figure 3.3 and 3.7) and subcellular trafficking (Figure 3.4 and 3.5) to try and 
elucidate mechanistically how Nef counteracts SERINC5. Our use of BiFC 
allowed us to demonstrate that Nef and SERINC5 interact within cells (Figure 
3.1), a finding that was only recently reported during the preparation of this work 
(25). This finding is significant as it supports a directed targeting of SERINC5 by 
Nef, rather than SERINC5 downregulation being a by-product of global 
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alterations in endocytic trafficking in the presence of Nef. The Nef:SERINC5 
interaction is just one of many that the viral accessory protein is able to mediate, 
and demonstrates how targeting key cellular pathways is an efficient method of 
viral adaptation (1). HIV-1 Nef hijacks the host adaptor protein 2 (AP-2) to insert 
itself in the endocytic network, thereby dramatically altering the cellular 
environment. The interaction with AP-2 is essential for Nef to mediate the 
clathrin-dependent downregulation of CD4, allowing for its subsequent shuttling 
through the endosomal network to a lysosomal compartment, where it is 
degraded (26). Our mutational analysis and subcellular tracking of internalized 
SERINC5 support the hypothesis that the Nef:AP-2 interaction is also key to Nef, 
ultimately targeting SERINC5 for lysosomal degradation.  
We also demonstrated that SERINC5 downregulation is variable among patient-
derived Nef proteins, in contrast to CD4 downregulation, which is highly 
conserved (Figure 3.7). Interestingly, SERINC5 was more sensitive than CD4 to 
differences in Nef protein expression. Given the mechanistic similarities between 
SERINC5 and CD4 downregulation, these differences are intriguing and may 
suggest that SERINC5 downregulation is distinct from that of CD4, in an as of yet 
undetermined manner. Furthermore, whatever differences that exist between 
Nef-mediated SERINC5 and CD4 downregulation may not face as strong of an 
evolutionary selection pressure as there is growing evidence that HIV-1 Env also 
plays a critical role in SERINC5 antagonism (27, 28). Virions containing 
SERINC5-resistant Env proteins do not display impaired infectivity, even in the 
absence of Nef. Therefore, there may be a functional interplay between HIV-1 
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Nef and Env, where SERINC5-sensitive Env proteins require a more functional 
Nef protein. This relationship still needs to be borne out in larger studies of Nef 
and Env proteins.  
In future studies we would like to investigate if the variability in SERINC5 
antagonism by HIV-1 Nef plays a role in disease progression. With the cohort 
available to use, we are in a good position to investigate this. Indeed, this had 
been our original intention, however, inefficient retrieval of Nef isolates from 
patient PBMCs limited the statistical power with which we could analyze the 
effect of SERINC5 downregulation on disease progression. Interestingly, disease 
progression within this cohort has been previously shown to differ between 
infecting subtype (9). If enough Nef proteins can be retrieved, a thorough 
investigation of CD4, MHC-I and SERINC5 downregulation could determine if 
differences in Nef function between subtypes plays a role in disease progression.  
4.1.5 Exploring Nef:host protein interactions 
The study of viruses and how they interact with host cells has been a fruitful area 
of research for those wishing to better understand basic cell biology. The minimal 
coding capacity of most viral genomes necessitates they evolve highly 
multifunctional proteins. These multifunctional proteins, of which HIV-1 Nef is an 
example, can serve as tools for probing the inner workings of cells. Indeed, the 
search for how Nef is able to increase HIV-1 infectivity instigated the study of the 
novel host restriction factor SERINC5 (5, 6). The physiological role of SERINC5 
is still to be fully determined, but its antagonism by HIV-1 Nef will surely expedite 
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our understanding of this host protein, both in the context of HIV-1 infection and 
in healthy cells. 
In our future work we hope to use this approach to investigate other key host 
proteins that Nef hijacks during HIV-1 infection. As a first step we have 
performed a mass spectrometry analysis to characterize the interactome of the 
cargo sorting proteins PACS-1 and -2 (Appendix 1). Nef interacts with these host 
proteins to downregulate MHC-I (29, 30), and in the same vein as the similarities 
in CD4 and SERINC5 downregulation, we hypothesize that this interaction may 
result in other alterations in infected cells. Using the methods outlined in this 
dissertation, we hope to elucidate and describe novel Nef:host interactions that 
can illustrate more about the function of his key HIV-1 protein and the cells it 
inhabits.       
4.1.6 Concluding remarks 
HIV-1 has long been at the forefront of biomedical research and we now know a 
great deal about how and why this virus has reached pandemic proportions. 
However, we have been continually humbled by our inability to prevent or cure 
individuals of their infections. Perhaps there still remain key aspects of HIV-1 and 
how it interacts with host cells that we do not fully understand. We have explored 
the mechanistic details of HIV-1 Nef functions and how this pathogenic protein is 
impacted by the genetic diversity that characterizes HIV-1. We hope that by 
aiding in our basic understanding of this virus, we have strengthened the 
knowledge base from which new and exciting discoveries can emerge. 
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Appendix 
Appendix 1 PACS-1 and PACS-2 interactome 
Appendix 1.1 
Proper cell homeostasis is dependent on the compartmentalization of molecules 
to discrete subcellular locales. This spatial separation was paramount to the 
emergence of multicellular organisms composed of genetically identical cells 
serving distinct functions. To achieve this, eukaryotic cells have evolved a 
network of trafficking proteins that function to target proteins to specific regions 
within the cell (1). One such family of proteins is the Phosphofurin Acidic Cluster 
Sorting or PACS proteins. As their name suggests, PACS proteins were 
identified through the investigation of how the proprotein convertase furin was 
trafficked throughout cells (2, 3). Also contained in their name is the mechanism 
used by PACS proteins to sort their target proteins. Indeed, PACS proteins 
primarily bind to cargo proteins that contain stretches of acidic amino acids and 
connect these proteins with the endomembrane trafficking machinery (4). The 
binding of PACS proteins to cargo proteins can be regulated by the 
phophorylation status of serine residues located in proxmity to acidic clusters 
which are often modulated by cellular kinases and phosphatases such as casein 
kinase 2 (CK2) and protein phosphatase 2A (PP2A), respectively (reviewed in 
(5)).  
The human genome encodes two PACS proteins, PACS-1 and PACS-2, that 
share 54% homology and both primarily function through binding of acidic 
clusters on cargo proteins (6). However, whereas PACS-1 links cargo proteins to 
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the endomembrane network by forming a ternary complex with adaptor proteins 
1 and 3 (AP-1 and -3) (4), PACS-2 forms a ternary complex with the vesicle 
coatmer COPI (6).  
The essential role PACS proteins play in maintaining cellular homeostasis is 
beginning to emerge and is highlighted by various siRNA knockdown 
experiments (reviewed in (7)). Knockdown of PACS-1 demonstrates its 
importance in cellular events such as the TGN localization of furin (2), while 
knockdown of PACS-2 has revealed, amongst other functions, a role in TNF 
(tumour necrosis factor)-related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis (8). Moreover, recent studies have implicated point mutations in both 
PACS-1 (9) and PACS-2 (10) in neurodevelopmental diseases. Interestingly, 
these mutations lie within the Furin Binding Region (FBR) of PACS-1 or PACS-2. 
The FBR is specifically implicated in PACS interactions with cargo proteins (2). 
Given the important and multifunctional role PACS proteins play in organizing 
cellular architecture, it is not surprising that a number of viruses have evolved 
mechanisms to hijack these sorting proteins to assist in their replication 
(reviewed in (11)). For example, as described elsewhere in this thesis, the HIV-1 
accessory protein Nef contains an acidic cluster that allows it to interact with 
PACS-1 and -2 and usurp their roles in membrane trafficking to downregulate 
MHC-I (12, 13).  
The relationship between HIV-1 Nef and the PACS proteins led us to investigate 
other potential virus:host interactions that Nef may be able to establish through 
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its hijacking of the PACS proteins. To do so, we aimed to study the interactome 
of PACS-1 and PACS-2 upon their overexpression. Accordingly, CD4+ HeLa cells 
were transfected with pN1 PACS-1-FLAG and pN1 PACS-2-FLAG plasmids and 
immunoprecipitated with an anti-DYKDDDDK antibody, which recognizes FLAG, 
after lysis at 24 hours post-transfection. Proteins were separated on a 12% gel 
by SDS-PAGE and silver stained using the Pierce® Silver Stain for Mass 
Spectrometry kit (Appendix 1.1.1A and 1.1.2A). The gel was subsequently 
analyzed by liquid chromatography mass spectrometry at the Southern Alberta 
Mass Spectrometry Centre at the University of Calgary. Peptide hits from the 
liquid chromatography mass spectrometry analysis were compiled by the 
Southern Alberta Mass Spectrometry Centre and investigated for enriched 
biological processes using highest confidence interaction scores on STRING 
v10.5 (14).  
Numerous interaction networks were overrepresented in the mass spectrometry 
results compared to what would be expected from a random collection of proteins 
(Appendix 1.1.1B and 1.1.2B). Of note, proteins involved in establishing protein 
localization and response to viruses were enriched in the mass spectrometry 
results. Proteins involved in establishing protein localization include the nuclear 
transport proteins importin 5, 7, 8 and 9, (IPO5, 7, 8 and 9), which were 
immunoprecipitated with PACS-1 and -2 (Appendix 1.1.1D and 1.1.2C) or 
numerous members of adaptor protein family 14-3-3 (YWHAB, YWHAE, 
YWHAH, YWHAG and YWHAZ), which were immunoprecipitated exclusively by 
PACS-2 (Appendix 1.1.2C). Encouragingly, more specific biochemical 
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experiments have previously shown that PACS-2, but not PACS-1 interacts with 
members of the 14-3-3 family (8), supporting the findings from the mass 
spectrometry analysis. The proteins involved in responding to viruses included 
interferon induced proteins (HERC5, IFIT1, 2, and 3) or innate immune 
molecules that sense viral nucleic acids (DDX58 and OASL) (Appendix 1.1.1E 
and Appendix 1.1.2D). 
Our preliminary analysis provides a framework for future investigations of PACS-
1 and -2 interactions that may be co-opted by HIV-1 Nef to aid in viral replication. 
Indeed, we are in the process of validating a number of these hits and 
determining if these interactions are altered in the presence of Nef. These 
studies will hopefully increase our understanding of the multifunctional nature of 
HIV-1 Nef and how it exerts its pathogenic effects.  
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Appendix 1.1. 1 Mass spectrometry analysis of the PACS-1 interactome. 
(A) CD4+ HeLa cells were left untransfected (NT) or transfected with pN1-PACS-
1-FLAG or pN1-PACS-2-FLAG. Cell lysates were immunoprecipitated with anti-
DYKDDDDK agarose beads and washed 5 times in PBS. Immunoprecipitated 
proteins were separated by SDS-PAGE using a 12% gel. The gel was 
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subsequently silver stained using the Pierce® Silver Stain for Mass Spectrometry 
kit (product number 24600; Pierce Biotechnology, Rockford IL) and imaged as 
shown in (A). The lane corresponding to cells transfected with pN1-PACS-1-Flag 
was excised and sent for liquid chromatography mass spectrometry analysis at 
the Southern Alberta Mass Spectrometry Centre at the University of Calgary. 
STRING v10.5 was used generate a protein interaction map (B) and to analyze 
mass spectrometry hits for enriched biological functional groups. Proteins 
involved in establishing protein localization are highlighted in red and a subset of 
these proteins are shown in (C) and (D). Proteins involved in response to viruses 
are highlighted in green and these proteins are shown in (E). 
 
  
208 
 
Appendix 1.1. 2 Mass spectrometry analysis of the PACS-2 interactome. 
(A) CD4+ HeLa cells were left untransfected (NT) or transfected with pN1-PACS-
1-FLAG or pN1-PACS-2-FLAG. Cell lysates were immunoprecipitated with anti-
DYKDDDDK agarose beads and washed 5 times in PBS. Immunoprecipitated 
proteins were separated by SDS-PAGE using a 12% gel. The gel was 
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subsequently silver stained using the Pierce® Silver Stain for Mass Spectrometry 
kit (product number 24600; Pierce Biotechnology, Rockford IL) and imaged as 
shown in (A). The lane corresponding to cells transfected with pN1-PACS-2-Flag 
was excised and sent for liquid chromatography mass spectrometry analysis at 
the Southern Alberta Mass Spectrometry Centre at the University of Calgary. 
Results of the liquid chromatography mass spectrometry analysis were compiled 
by the Southern Alberta Mass Spectrometry Centre. STRING v10.5 was used 
generate a protein interaction map (B) and to analyze mass spectrometry hits for 
enriched biological functional groups. Proteins involved in establishing protein 
localization are highlighted in red and a subset of these proteins are shown in 
(C). Proteins involved in response to viruses are highlighted in green and these 
proteins are shown in (D). 
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